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methyltransferase  1  (Dnmt1)  is  the  most  ubiquitously  expressed  DNA  methyltransferase  and 
responsible for maintenance of DNA methylation patterns during semi‐conservative DNA replication. 
The  fidelity  of  this  process  is  crucial  for  genome  stability  and  is  based  on  the  recognition  of 
hemimethylated CpG sites emerging at the replication fork. Indeed, it is well established that Dnmt1 
has  a preference  for  substrates  containing hemimethylated over unmethylated CpG  sites  in  vitro. 
However,  it remained elusive how and at which step of  the methyl  transfer reaction  the substrate 
discrimination occurs, and also if or how intrinsic or interacting factors regulate Dnmt1 activity.  
To investigate the mechanistic basis of Dnmt1’s maintenance function we developed a versatile non‐
radioactive  assay  for methyltransferase  activity  and  DNA  binding.  This  assay  not  only  allows  to 
rapidly  screen  for active methyltransferases, but also  to determine  substrate  specific DNA binding 
activity by testing up to four DNA substrates in direct competition. With this assay, we showed that 
Dnmt1 does not discriminate between different methylation states at the step of DNA binding, but 
rather  at  an  early  step of  the methyl  transfer  reaction,  the  covalent  complex  formation between 
enzyme and target cytosine residue.  
Furthermore, we systematically analyzed the DNA binding properties of the Dnmt1 CXXC domain and 
the Dnmt1  interacting cofactor Uhrf1  in order to characterize their respective functional role  in the 
regulation  of  Dnmt1.  We  could  show  that  the  CXXC  domain,  although  specifically  binding  to 
unmethylated DNA,  is dispensable  for DNA binding, enzymatic activity and  substrate  specificity of 
Dnmt1.  For  Uhrf1,  we  detected  and  confirmed  preferential  binding  to  DNA  containing 
hemimethylated CpG sites, which is however very low compared to the intrinsic preference of Dnmt1 
for methylation of these sites. These data together with the evidence for specific histone tail binding 
of Uhrf1  lead to the conclusion that the role of Uhrf1  in maintenance methylation  is more complex 
than previously suggested, exceeding the mere recruitment of Dnmt1 to hemimethylated CpG sites. 
At last, we addressed the question of Dnmt1 dimerization and its functional impact on Dnmt1 activity 
by single molecule  investigation of Dnmt1:DNA complexes using  fluorescence  intensity distribution 
analysis (FIDA) and fluorescence cross‐correlation spectroscopy (FCCS). Surprisingly, we obtained first 
evidence that Dnmt1 might be able to covalently bind two DNA substrates simultaneously, indicating 














and  function.  The  basis  of  cellular  differentiation  is  the  establishment  of  differential  and  stable 
tissue‐specific gene expression patterns during development. The decision on which set of genes  is 
expressed at any specific time point, and in which cell, can in principle be taken at different steps of 
gene  expression.  However,  transcriptional  regulation  is  the  most  important  control  mechanism. 
Transcriptional  control  is  accomplished  by  complex  protein  networks,  which  finally  affect  gene 
transcription  by  RNA  polymerase.  Components  of  these  regulatory  networks  are  i)  general  and 
sequence‐specific transcription factors, and ii) cis‐acting regulatory elements (promoters, enhancers, 
silencers and insulators). The resulting networks can dynamically respond to environmental changes 






regulation  is  accompanied  by  DNA methylation,  histone modification  and  chromatin  remodeling 
(Reik,  2007).  These  chromatin modifications  are  by  definition  epigenetic,  since  they  affect  gene 
expression and chromatin structure without alteration of the underlying genomic sequences.  
Epigenetic mechanisms are thought to regulate gene expression by controlling the condensation and 
accessibility  of  genomic DNA.  Importantly, DNA within  the  nucleus  is  packed  into  higher  ordered 






DNA binding proteins  as well  as DNA  sequence  and  flexibility; AT‐rich  sequences  for example  are 
easier  to  compress. Condensation of DNA  into a 30 nm  fiber  is achieved by generation of  regular 
arrays,  in which nucleosomes are packed on  top of each other,  involving binding of histone H1  to 
both  core  particle  and  linker DNA.  Levels  of  chromatin  organization  beyond  the  30  nm  fiber  are 





can  distinguish  different  levels  of  condensation  of  interphase  DNA.  The  less  condensed  and 
transcriptionally  active  form  is  called  euchromatin  and  the  highly  condensed  form  is  called 
heterochromatin.  Constitutive  heterochromatin  makes  up  around  10  %  of  the  genome  and  is 
concentrated in centromeric and telomeric regions. 




states  of  histone  tails  correlate  with  chromatin  activity.  Transcriptionally  active  regions  are  for 
example associated with histone H3 methylation at  lysine 4  (H3K4) and H3K9 acetylation, whereas 
transcriptionally  inactive  regions  are  associated  with  H3K9  trimethylation.  Interestingly,  histone 




Epigenetic mechanisms  that  regulate mammalian  gene  expression  at  the  transcriptional  level  are 
very complex and often work  in concert. Besides the already mentioned DNA methylation, histone 
modification  and  chromatin  remodeling  factors,  they  also  involve  regulatory  proteins  of  the 
Polycomb/Trithorax group and non‐coding RNA.  Some of  these epigenetic marks are  replicated  in 
each  cell  division  cycle  and  propagated  through  successive  cell  generations  and,  in  the  case  of 
genomic  imprinting, even passed on to the offspring. The work of this thesis focuses on aspects of 
DNA methylation, which  occurs  as  5‐methylcytosine  in mammals.  This  important modification  is 
required  for genome  integrity and  the  stable  repression of genes and  transposable elements.  It  is 
involved  in X chromosome  inactivation  (the mechanism of X‐chromosome dosage compensation  in 
female mammals), genomic imprinting and silencing of endogenous retroviral sequences. 
1.1.2 DISCOVERY OF 5‐METHYLCYTOSINE  IN DNA 
Already  in  1904, Wheeler  and  Johnson  anticipated  the  natural  occurrence  of  5‐methylcytosine  in 





in  1948,  Hotchkiss  established  a  paper  chromatographic  method  for  quantitative  separation  of 








and  spectral  analyses  and unambiguously  identified  5‐methylcytosine  in  calf  thymus DNA  (Wyatt, 
1950, 1951b). The  same author additionally analyzed preparations  from other animal and a plant 
species and showed that the 5‐methylcytosine content varies with the source, but  is very constant 
for  a  particular  DNA  source  (Wyatt,  1951a).  This  observation  suggested  the  percentage  of  5‐
methylcytosine  in  DNA  to  be  biologically  and  functionally  relevant.  Today,  we  know  that  DNA 
methylation is present in all kingdoms of life and that the level of DNA methylation is indeed species‐
specific.  In eukaryotes, methylation  levels are ranging from undetectable or far below 1 %  in some 
insects to very high levels in plants with up to 50 % of all cytosine bases being modified (Montero et 





equivalent  lengths of unmethylated DNA regions.  In contrast, vertebrate methylation  is distributed 
over the entire genome and constitutes a pattern of global DNA methylation. It has been suggested 
that  the  pattern  of  5‐methylcytosine  distribution  in  the  genome  reflects  its  functions  in  different 
organisms  (Colot  and  Rossignol,  1999).  Moreover,  not  only  the  C5  position  of  cytosine  can  be 
methylated in DNA, but also the N4 position of cytosine and the N6 position of adenine, giving rise to 
N4‐methylcytosine and N6‐methyladenine, respectively (Dunn and Smith, 1958; Ehrlich et al., 1985). 
Both  cytosine  and  adenine methylation  occur  in  bacteria  and  plants.  In  eukaryotes,  however,  5‐
methylcytosine  is  the  dominant  DNA  modification  with  some  exceptions  of  mainly  unicellular 
organisms showing also low levels of adenine methylation (Gorovsky et al., 1973; Hattman, 2005). 
The role of DNA methylation  in bacteria was already discussed  in the 1960s, where methylation of 
DNA was proposed  as mechanism  to  protect  (bacterial)  host DNA.  The modification of DNA with 
methyl groups was  suggested  to alter  its biochemical properties and  to  induce  structural changes, 
which would protect against restriction endonucleases that are directed against foreign (bacterial or 
viral) unmethylated DNA (Arber and Linn, 1969; Srinivasan and Borek, 1964). About a decade  later, 
two  independent publications  indicated a  role of DNA methylation  in  transcriptional  regulation  in 
mammals  (Holliday and Pugh, 1975; Riggs, 1975). Hollliday and Pugh suggested  that the enzymatic 
modification  of  specific  bases  in  repeated DNA  sequences might  be  the  basis  for  developmental 
clocks and regulate gene activity during development and cellular differentiation. Furthermore, Riggs 
proposed that DNA methylation affects the DNA binding ability of regulatory proteins and that DNA 





how such a tiny modification, the attachment of a methyl group, can contribute to development and 
cellular differentiation, which factors set these methylation marks, and how methylation patterns are 
maintainend during cell division. 
1.1.3  EUKA RYO TI C DNA  MET HY LT RA NS FER A S ES  
In mammalian cells, DNA methylation occurs at cytosine residues mainly of CpG dinucleotides, where 
a methyl group is covalently attached to the C5 position of the nucleobase. This modification is set 
and maintained by the DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b (Goll and Bestor, 2005; 
Rottach et al., 2009b). Another methyltransferase, Dnmt2, has been shown to methylate tRNA (Goll 
et al., 2006); the DNA methyltransferase activity of Dnmt2, however, is very low in vitro and its 
functional relevance in mammals is still controversially discussed (Hermann et al., 2003). All 
mammalian Dnmts contain a highly conserved catalytic domain, which is also very similar to 
prokaryotic methyltransferases (Figure 1). Thus, prokaryotic and mammalian DNA 
methyltransferases have also been proposed to use a similar catalytic mechanisms ((Bestor and 





Figure 1. Domain structure of the mammalian Dnmt family members. All but Dnmt2 possess a regulatory N-
terminal region in addition to the highly conserved catalytic domain. Conserved domains in the N-terminal 
parts of Dnmt1 and Dnmt3a/b/L are highlighted and described in the text (chapter 1.2.1 and 1.1.3, 
respectively). PBD: PCNA binding domain; TS: targeting sequence; CXXC: CXXC zinc finger domain; BAH: Bromo 
adjacent homology domain; PWWP: domain containing Pro-Trp-Trp-Pro motif; PHD: plant homeodomain. 








Dnmt1 was  the  first mammalian DNA methyltransferase  to be  identified and cloned  (Bestor et al., 
1988).  It  is constitutively expressed  in proliferating as well as post‐mitotic cells making  it  the most 
ubiquitous DNA methyltransferase. Dnmt1  is considered to be  the maintenance methyltransferase, 
responsible for copying the defined methylation pattern during semi‐conservative DNA replication by 
specific methylation  of  hemimethylated  CpG  sites  occurring  at  the  replication  fork.  Consistently, 
Dnmt1  is  transcribed mostly during S phase and has a strong preference  for hemimethylated DNA 
substrates  (Robertson et al., 2000b). Moreover,  in mammalian cells, Dnmt1 has been shown  to be 






genome,  leading  to chromosomal  instability and the development of aggressive tumors  (Gaudet et 
al., 2003). More specifically, Dnmt1 was shown to be essential for X chromosome inactivation and to 
be  required  for  the maintenance  of  genomic  imprints  (Howell  et  al.,  2001).  Furthermore, mouse 
embryos  lacking  Dnmt1  show  increased  transcription  of  intracisternal  A‐particle  (IAP) 










domain,  by  a  linker  of  seven  glycine‐lysine  repeats  (Figure  1).  Although  containing  all  conserved 
motifs  identified  to be  involved  in  the methyl  transfer  reaction of prokaryotic methyltransferases 
(Bestor and Verdine, 1994; Kumar et al., 1994), the catalytic domain of Dnmt1 is not active by itself, 








exact  mechanistic  basis  of  Dnmt1’s  maintenance  function  for  stable  inheritance  of  epigenetic 
information  remains  to  be  elucidated.  In  addition  to  the  intrinsic  preference  of  Dnmt1  for  DNA 
substrates containing hemimethylated CpG sites, also  interaction with regulatory cofactors such as 




Dnmt3a  and  Dnmt3b  are  known  to  establish  methylation  patterns  during  early  embryonic 
development  acting  as  de  novo  methyltransferases  (Kaneda  et  al.,  2004;  Okano  et  al.,  1999). 






Dnmt3b knock‐out mice die at  late embryonic stage and  lack methylation  in centric minor satellite 
repeats. Dnmt3a knock‐out mice show developmental abnormalities and die a few weeks after birth, 
due  to deficient methylation of  single‐copy  genes,  retrotransposons  and  genomic  imprints during 
germ cell development (Okano et al., 1999). Human patients with mutations in DNMT3B suffer from 
the  ICF  syndrome  (immunodefiency,  centromere  instability  and  facial  abnormalities).  They  show 





Like Dnmt1,  also Dnmt3a  and  3b  possess  an N‐terminal  regulatory  domain  in  addition  to  the  C‐
terminal catalytic domain (Figure 1). However, in contrast to Dnmt1, the N‐terminal part of Dnmt3a 













transcription  and  chromatin  factors,  that  contribute  to  the  establishment  of  specific  DNA 
methylation patterns. 
1.1.3.3  COOPERATIVE FUNCTION OF  DNMTS 




2002; Margot et al., 2003). On  the one hand,  some de novo methylation activity was  reported  in 
embryonic stem cells lacking Dnmt3a and Dnmt3b (Lorincz et al., 2002). On the other hand, Dnmt3s 
seem  to  be  required  for  proper maintenance  of  DNA methylation  patterns  in  both  somatic  and 
embryonic stem cells. Conditional dnmt3b‐/‐ mouse embryonic fibroblasts show hypomethylation of 
minor  satellite  and  type  C  retroviral  elements  (Dodge  et  al.,  2005). Mouse  embryonic  stem  cells 
lacking  Dnmt3a  and  Dnmt3b  show  altered  methylation  of  imprinted  genes  and  repeats  and 
moreover,  they  gradually  lose  DNA  methylation  with  increasing  cell  divisions  down  to  an 
undetectable level (Chen et al., 2003; Okano et al., 1999). These data provide convincing evidence for 




1.1.4.1  SPATIAL DISTRIBUTION OF  5‐METHYLCYTOSINE   
As  it was  introduced before, DNA methylation  in mammals exclusively occurs at  the C5 position of 
cytosine residues and mainly within CpG dinucleotides (Sinsheimer, 1955). CpG sites are distributed 
throughout the genome  including all types of sequences: promoter regions, gene bodies,  intergenic 
sequences  and  repetitive  elements.  However,  they  are  unevenly  distributed  and  preferentially 
localize to gene rich loci (Lander et al., 2001). CpG dinucleotides are methylated to approximately 60‐
80%  in  mouse  and  human  (Ehrlich  et  al.,  1982;  Gruenbaum  et  al.,  1981)  and,  although  the 
mammalian genome displays genome‐wide methylation, CpG methylation  is  like CpG dinucleotides 
unevenly distributed. Whereas gene bodies, repetitive sequences and some intergenic sequences are 
highly  methylated,  there  are  some  largely  unmethylated  regions  including  mainly  regulatory 
promoter sequences and enhancers, but also the first exons of genes (Lister et al., 2009; Rollins et al., 
2006; Schmidl et al., 2009).  Interestingly,  the CpG  site density of genomic DNA  sequences  is anti‐





called CpG  islands) are often unmethylated, whereas  sequences of  low CpG  content are generally 
highly methylated. 
Notably, CpG dinucleotides are significantly underrepresented  in the mammalian genome with only 
21% of  their  statistically expected occurrence  (Bird, 1980;  Lander et al., 2001). The main  (but not 
only)  reason  for  this underrepresentation  is  spontaneous deamination  [reviewed  in  (Pfeifer, 2006) 
and  (Walsh  and  Xu,  2006)].  Deamination  of  unmethylated  cytosine  to  uracil  generates  a  UG 
mismatch, which can be readily recognized and corrected by the DNA repair system  involving uracil 
DNA glycosylase. In contrast, if methylated cytosine (that mostly occurs within CpG dinucleotides) is 
deaminated  to thymine,  the emerging TG base pair  is not as efficiently repaired  (see also chapters 
1.1.5.2  and  1.1.6).  In  consequence,  methylated  cytosines  tend  to  mutate  to  thymines  over  the 
evolutionary time course  if methylated  in the germ  line,  leading to the underrepresentation of CpG 
sites  in the mammalian genome. CpG depletion  is very pronounced within the repetitive sequences 
of  transposable  elements:  LINE  transposons  and  LTRs  of  endogenous  retroviruses  (18‐19%  of 
expected)  as  well  as  SINE  transposons  (41%  of  expected,  with  mainly  quite  young  Alu  SINE 
transposons) (Lander et al., 2001). In contrast, CpG islands show the lowest depletion levels resulting 




(Bird,  1995). Recently,  a  genome‐wide  study  explored  the  relationship  between  promoter 
methylation  and  gene  expression  using  data  from  the  ENCODE  project  (Birney  and  consortium, 
2007). They found that highly expressed genes indeed show a pattern of low promoter methylation 
and  higher  gene  body  methylation,  whereas  the  weakly  expressed  genes  were  moderately 









cells,  CpG  islands  are  often  unmethylated  and  overlap with  promoter  regions.  Interestingly,  they 






2008).  Exceptions  to  the  rule  of  unmethylated  CpG  islands  promoters  include  the  inactive  X 
chromosome, some silent imprinted genes, and some tissue‐specific genes.  




the  fact  that  not  all  existing  transcription  start  sites  are  identified  or  that  the  prediction  of  CpG 
islands is not sufficiently accurate or both. Indeed, CpG island annotation has led to the discovery of 
additional, previously not annotated  transcription  start  sites. Additionally, CpG  island prediction  is 
somehow  arbitrary,  since  the  results  of  prediction  algorithms  highly  depend  on  the  chosen 




Recently,  a  definition  of  promoter  classes was  proposed  based  on  CpG  content  and methylation 
levels, distinguishing between non‐CpG  island promoters and CpG  island promoters  (Weber et al., 
2005).  Their  chromosome‐wide  analysis  revealed one  striking difference between  these promoter 
classes: whereas non‐CpG island promoters were highly methylated in most cases, strong CpG island 
promoters were methylated to only 3 % (Figure 2). It is interesting to note that for this latter class of 
CpG  island  promoters,  methylation  levels  differ  between  autosomal  and  X‐inactivated  genes 
suggesting a  role  for CpG  island promoters  in X  inactivation  (Weber et al., 2005). Moreover,  it has 
been  shown  that  a  fraction  of  CpG  islands  is  differentially methylated  between  different  somatic 
tissues and cell types  (Illingworth et al., 2008;  Illingworth and Bird, 2009). This suggests that a  few 
CpG  island  promoters  become methylated  during  normal  development.  Indeed,  some  CpG  island 
promoters of developmental or germ‐line specific genes have been shown to be methylated during 
embryogenesis, thereby  leading to persistent silencing of these genes  in somatic tissues  (Weber et 






genes  (Bird,  2002),  whereas  the  transcriptional  state  of  genes  associated  with  non‐CpG  island 
promoters does not reflect the methylation state of the promoter (Figure 2). This suggests that low 





repression by DNA methylation in promoter regions requires high levels and density of 5-
methylcytosine (Weber et al., 2007). Notably, DNA methylation is sufficient but not necessary to 
inactivate CpG island promoters, as silencing of CpG island promoters is not always associated with 
promoter methylation. This means that promoter methylation is not the only route towards gene 
inactivation and that there are other mechanisms for transcriptional silencing. Whether and how CpG 
islands distal to transcription start sites contribute to transcriptional regulation of gene expression is 




Figure 2. Regulation of gene expression by promoter methylation. Promoters can be subdivided into two 
principle classes: CpG-rich CpG island promoters and CpG-poor non-CpG island promoters. Characteristically, 
CpG density and CpG methylation levels negatively correlate within these promoter sequences. Interestingly, 
this anti-correlation is also observed for the total genomic DNA sequence. Whereas CpG island promoter 
methylation leads to gene silencing, non-CpG island promoter methylation does not preclude gene expression.  
 
As mentioned above, the characteristic clustering of CpG sites within CpG islands is thought to be a 
consequence of two factors: global loss of CpG sites due to mutagenic deamination of 5-
methylcytosine and resistance to de novo methylation during early development. Still, very little is 
known about how CpG islands are maintained unmethylated during the wave of global de novo 
methylation in early development. However, protection against methylation seems to involve active 
chromatin marks like H3K4 dimethylation (Weber et al., 2007) and H3K9/14 acetylation (Roh et al., 
2005). Furthermore, there is emerging evidence for a role of the zinc finger protein VEZF1 binding to 
G-rich methylation protection elements, which has been shown to maintain the APRT CpG island 
promoter unmethylated (Dickson et al., 2010). A recent study also showed that CXXC finger protein 1 
(CXXC1/Cfp1) binds to unmethylated CpG islands and thereby influences chromatin structure 
(Thomson et al., 2010). Interestingly, whereas the majority of inactive strong CpG island promoters 
remains unmethylated, a much higher proportion of inactive weak CpG promoters, with lower CpG 
density, becomes methylated. This implies that protection of CpG islands against de novo 








Repetitive  elements  including  transposable  elements  and  satellites make  up  almost  50 %  of  the 
mouse and human genome, and  the majority of 5‐methylcytosine  is  found within  these sequences 
(Ikegami et al., 2009). The methylation of these sequences has been suggested to be responsible for 
transposon suppression  in order  to accomplish genome stability  (Yoder et al., 1997) and  to reduce 
transcriptional noise (Bird, 1995). Indeed, endogenous retroviruses become transcriptionally silenced 
during  early  embryogenesis  and  aberrant  expression  of  retroviral  sequences  has  been  shown  to 
induce  cancerous  transformations  in  somatic  cells  (reviewed  in  (Maksakova  et  al.,  2008). 
Significantly, DNA hypomethylation  in mice  leads  to development of aggressive  tumors associated 
with activation of endogenous retroviral elements (Gaudet et al., 2003; Gaudet et al., 2004; Howard 
et al., 2008; Walsh et al., 1998). These studies provide strong evidence for a role of DNA methylation 
in  retroviral  silencing  in  somatic  cells  and  tissues.  Recently  however,  a methylation‐independent 
pathway  for silencing of  IAP retrotransposons has been proposed to occur  in embryonic stem cells 
(Deng et al., 2009). The protein KAP1 has been shown to control this process (Rowe et al., 2010) by 
recruiting  the  histone  methyltransferase  SETDB1,  heterochromatin  binding  protein  HP1  and  the 
NuRD histone deacetylase complex (Matsui et al., 2010). 
1.1.4.4  TEMPORAL DISTRIBUTION OF  5‐METHYLCYTOSINE 
Global changes of methylation levels and patterns occur at two stages of mammalian development: 
in  the  early  embryo  shortly  after  fertilization  and  in  primordial  germ  cells  during  gametogenesis. 
These  changes  include  a  phase  of  global  demethylation  to  almost  complete  5‐methylcytosine 









completely  understood  how methylation  of  some  sequences  is  selectively  maintained  against  a 
background of widespread demethylation. 
Furthermore, as introduced above, methylation of specific promoter sequences changes throughout 
development, and DNA methylation patterns differ markedly between different  cell  types. On  the 
one  hand,  differentiation‐specific  genes  have  to  be  kept  inactive  in  pluripotent  cells  until 





inactivated  in differentiated  cells  (Reik,  2007).  For  example,  key  transcription  factors  as  oct4  and 
nanog  form  a  regulatory  network  for  specific  gene  transcription  in  pluripotent  ES  cells.  Their 
promoter  regions  become  methylated  and  silenced  upon  differentiation  and  this  methylation‐
associated  inactivation  of  pluripotency‐associated  genes  is  very  stable  in  differentiated  cells. 
Likewise,  transposons  have  to  be  stably  silenced  to  insure  genome  stability  and  also  the 






DNA  methylation  is  essential  for  viability  and  genome  integrity  and  it  can  be  associated  with 
regulation of gene expression. Two principle molecular mechanisms have been  shown  to mediate 
transcriptional  control  by DNA methylation:  either  the methyl  group  directly  prevents  binding  of 
transcriptional regulators, or it leads to specific binding of methyl‐CpG binding proteins. 
1.1.5.1  REGULATION VIA  TRANSCRIPTIONAL REGULATOR BINDING 
It  is well established that the methylation of 5‐methylcytosine can directly  interfere with binding of 
transcriptional regulators (Becker et al., 1987). In general, DNA methylation  is associated with gene 
silencing.  However,  this  is  not  the  only  possible  consequence  of  DNA methylation.  In  fact,  it  is 
interesting  to note  that  in one well studied example, DNA methylation  leads  to activation of gene 
expression  at  the  imprinted  H19/Igf2  locus.  The  protein  CTCF  usually  functions  as  insulator  by 
blocking the action of an enhancer signal downstream the Igf2 gene promoter, and thereby represses 
gene expression. On  the paternally  imprinted gene  copy however, where  the CTCF binding  site  is 
methylated, CTCF binding and  function are  impaired  resulting  in active  Igf2  transcription  (Bell and 
Felsenfeld, 2000; Hark et al., 2000). 
1.1.5.2  REGULATION VIA  METHYL‐CPG BINDING PROTEINS 
Methylated  CpG  sites  are  recognized  by  a  family  of  methyl‐CpG  binding  proteins  (MBPs)  that 
translate  DNA  methylation  marks  into  specific  chromatin  states  by  recruitment  of  chromatin 
modifiers and remodeling complexes. Generally, these MBPs are thought to work as transcriptional 
repressors by binding  to DNA and  recruiting  corepressors. The  complexity of  this process and  the 
resulting protein  interaction network are enormous and  it  is not clear whether corepressors work 
simultaneously  as  complex  or  individually  on  different  targets  at  different  cell‐cycle  or 













finger  domain;  TRD:  transcriptional  repression  domain;  Ubl:  ubiquitin‐like  domain;  SRA:  SET  and  Ring‐







but  MBD4  recruit  nucleosome  remodeling  complexes  (NuRD),  both  associated  with  an  inactive 
chromatin state and transcriptional silencing (Hendrich and Tweedie, 2003; Kondo et al., 2005; Nan 
et  al.,  2007).  Furthermore,  MBD1  and  MeCP2  interact  with  and  recruit  histone  H3K9 
methyltransferases, which again set modification marks characteristic for silent chromatin (Fujita et 
al.,  2003;  Sarraf  and  Stancheva,  2004).  In  addition,  MBD1  and  MeCP2  interact  with  the 









minority  of MeCP2  target  promoters  is  highly methylated  (6%)  (Yasui  et  al.,  2007).  Interestingly, 
MBD4  contains  a  thymine  glycosylase  domain  and  functions  as  a  DNA  repair  enzyme  for  TG 
mismatches generated by deamination of 5‐methylcytosine (Walsh and Xu, 2006)  (see also chapter 
1.1.4.1). MBD4 was also  suggested  to  function  in active DNA demethylation  (discussed  in  chapter 
1.1.6). Considering the severe effects of DNA hypomethylation, it is surprising that mice lacking MBD 
family members show only very mild phenotypes. This finding suggests functional redundancy, but, 
the hypothesis of  redundancy contrasts not only with  the evidence  for different  functions of MBD 
proteins  due  to  different  knock‐out  phenotypes,  but  also  with  the  diversity  of  sequence  and 
structure  between MBD members  outside  their MBD  domain  (reviewed  in  (Sasai  and  Defossez, 
2009), Figure 3). In other words, the precise targets and functions of individual MBD family members 
remain elusive. 
Uhrf1  (also  called Np95 or  ICBP90) has been  shown  to bind DNA  containing hemimethylated CpG 
sites via  its SET‐ and Ring‐associated  (SRA) domain  (Figure 3).  In analogy  to MBD  family members, 
Uhrf1 was  reported  to  interact with both, histone H3K9 methyltransferase G9a and HDAC1, and  it 
was suggested to be involved in the silencing of tumor suppressor genes in breast cancer cells (Kim et 
al., 2009a; Unoki et al., 2004).  In addition, Uhrf1 was  shown  to bind  to histones via  three distinct 
domains.  First, Uhrf1 binds histone H3  and  functions  as  E3 ubiquitin  ligase  (Citterio  et  al., 2004). 
Second, crystallographic data  indicated  specific binding  to histone  trimethylated H3K9  tails via  the 
tandem Tudor domain  (PBD 3DB3). Third, Uhrf1 contains a plant homeodomain (PHD) domain that 
has been implicated in binding to histone H3. The PHD domain also seems to be required for large‐
scale  rearrangements  of  chromocenter  structures  by Uhrf1  (Papait  et  al.,  2008).  Thus, Uhrf1 was 
proposed  to  provide  a  direct  link  between  DNA methylation  and  histone modification.  Recently, 
Uhrf1 has been  shown  to  also directly  interact with Dnmt1  (Arita  et  al.,  2008; Avvakumov  et  al., 
2008; Bostick et al., 2007b; Rottach et al., 2009a; Sharif et al., 2007).  Its genetic ablation  leads  to 
remarkably  similar  phenotypes  to  those  of  Dnmt1  ablation  including  severely  reduced  DNA 
methylation levels (Sharif et al., 2007). These data strongly suggest that Uhrf1 is an essential cofactor 
for maintenance methylation (see also chapter 1.3.4). Moreover, Uhrf1 has recently been shown to 








via a Krüppel‐like C2H2 zinc  finger motif  ((Yoon et al., 2003), Figure 3).  In contrast to other methyl‐
CpG  binding  proteins  of  the  MBD  and  Uhrf  families,  stable  DNA  binding  of  Kaiso  requires  two 
consecutive methylated CpG sites. Kaiso has been implicated in methylation‐dependent repression of 






recruits  the N‐CoR  complex,  transcriptional  repression by  the  two Kaiso‐like proteins  ZBTB38  and 
ZBTB4  involves  the  CtBP  and  Sin3/HDAC  corepressor  complexes,  respectively.  Furthermore,  Kaiso 
and ZBTB4 have been shown to bind a specific unmethylated DNA sequence (Kaiso binding sequence, 
KBS), which,  in  the  case  of  Kaiso,  leads  to  transcriptional  repression  of  factors  involved  in Wnt 
signaling  (Kim  et  al.,  2004).  Ultimately,  all  remodeling  complexes,  which  are  recruited  by  Kaiso 
proteins,  contain  HDACs  and  other  remodeling  activities,  leading  to  transcriptional  silencing. 
Whether Kaiso and Kaiso‐like proteins are functionally redundant is not clear yet (reviewed in (Sasai 
and Defossez, 2009)). 
1.1.5.3  INTERCONNECTION OF DNA METHYLATION WITH OTHER EPIGENETIC  PATHWAYS 
As mentioned  above, DNA methylation  is  translated  by methyl‐CpG  binding  proteins  into  specific 
chromatin  states  by  recruiting  chromatin modification  and  remodeling  factors.  In  addition,  direct 




al., 2000a) and SNF2H  (Geiman et al., 2004),  the ATPase  subunit of  several  chromatin  remodeling 
complexes. Notably,  the  interaction of Dnmt1 with G9a at  replication  foci could allow coordinated 
replication of DNA and H3K9 methylation (Esteve et al., 2006). Another  interaction possibly helping 
to link the replication of DNA and histone modifications is the interaction of MBD1 with SetDB1 and 
Suv39h1.  As  mentioned  above  MBD1  also  interacts  with  HP1  (Fujita  et  al.,  2003;  Sarraf  and 
Stancheva,  2004).  HP1  in  turn  binds  to  Dnmt1,  H3K9 methyltransferases, methylated  H3K9  and 
MeCP2 and  induces transcriptional silencing  (Agarwal et al., 2007; Fuks et al., 2003; Lachner et al., 
2001;  Nielsen  et  al.,  2002).  Moreover,  Dnmt3s  have  been  shown  to  specifically  bind  particular 










non‐coding RNA and  transcription  factors  in directing Dnmt3 enzymes has been  suggested  (Aravin 
and Bourc'his, 2008; Hervouet et al., 2009). Furthermore, Dnmts have been shown to  interact with 
components  of  the  Polycomb  repressive  complex  2  (PRC2).  Polycomb  group  proteins  represent 
besides DNA methylation a second essential epigenetic system that heritably represses transcription. 






histone  modifiers  and  nucleosome  remodeling  factors  directly  and  indirectly  interact.  These  epigenetic 
pathways  work  in  concert  to  generate  chromatin  activity  states  which  finally  control  gene  expression.  In 
addition,  gene  regulatory  proteins  of  the  Polycomb/Trithorax  group  and  non‐coding  RNA  are  suggested  to 
interact  with  Dnmts  and  implicated  in  transcriptional  regulation  (not  shown).  Bidirectional  arrows  in  the 





mammalian genome  requires  several  factors  in addition  to active Dnmts. Genetic  targeting of  the 














The  functional  hierarchy  and  sequence  of  events  leading  to  gene  silencing  is  often  difficult  to 







methylation of  the CpG  island promoter or hyperacetylation of histone H4 occur  (Keohane et  al., 
1996; Lock et al., 1987; Wutz and Jaenisch, 2000). However, DNA methylation stably and irreversibly 
represses  the  inactive  X  chromosome  as  X  inactivation  can  be  reversed  by  silencing  of  Xist  RNA 
expression within the first 72 hours of differentiation, but not at a later time point, when CpG island 
promoters  are  methylated.  These  observations  lead  to  the  assumption  that  the  role  of  DNA 




development:  one  shortly  after  fertilization  and  one  in  primordial  germ  cells.  In  contrast  to  the 
maternal  genome,  which  is  thought  to  undergo  passive  demethylation,  the  paternal  genome  is 
thought  to  be  actively  demethylated  after  fertilization  (Mayer  et  al.,  2000; Oswald  et  al.,  2000). 
Likewise, DNA demethylation in primordial germ cells was suggested to be an active process (Hajkova 




maintain  genomic  imprints  ((Cardoso  and  Leonhardt,  1999;  Carlson  et  al.,  1992;  Hirasawa  et  al., 














Figure  5.  Proposed mechanisms  for  active  DNA  demethylation.  Demethylation  of  5‐methylcytosine  (1)  to 
cytosine  (6)  possibly  involves  the  intermediates  5‐hydroxymethylcytosine  (2),  5‐hydroxymethyluracil  (3), 
thymine  (4),  and/or  an  abasic  site  (5)  generated  by  oxidation,  deamination  and/or  deglycosylation, which 
activates base excision repair. Moreover, it was suggested that 5‐hydroxymethylcytosine can be dealkylated to 









Whereas  methyltransferases,  the  enzymes  that  set  and  maintain  methylation  marks,  are  well 
characterized and known since years, there is no clear evidence for a demethylase enzyme (Ooi and 
Bestor, 2008a). However, early evidence for a mechanism of active demethylation in the mammalian 
genome  came  from a  study  in 1982  (Gjerset and Martin, 1982),  in which  the authors describe an 
enzymatic demethylation  activity  in  the nucleoplasm of murine  erythroleukemia  cells.  Since  then, 
there have  been other  studies  showing demethylase  activities  in  cell  extracts  and  even providing 
evidence for several very different candidates to be involved in active demethylation. Of all proteins 
suggested  to  be  involved  in  active  demethylation,  exclusively MBD2  (Bhattacharya  et  al.,  1999; 
Ramchandani et al., 1999) has been claimed to remove methyl groups without the need for any other 
protein  or  pathway  to  be  involved.  However,  the  demethylation  activity  of MBD2  could  not  be 
reproduced by several groups (Ooi and Bestor, 2008a). 
Processes  involving  the  repair  machinery  have  been  suggested  to  start  either  directly  with  a 
deglycosylation  event  (base  excision)  or  alternatively, with  a  deamination  event  resulting  in  a  TG 
mismatch, which can be recognized by a thymine DNA glycosylase. Deglycosylation events generate 
an abasic site, which can be subsequently replaced with cytosine via BER involving an endonuclease, 
polymerase  and  ligase.  Interestingly,  the  thymine  DNA  glycosylases  TDG  (Zhu  et  al.,  2000b)  and 
MBD4  (Zhu  et  al.,  2000a)  have  been  suggested  to  possess  in  addition  to  their  thymine  DNA 




not  known  whether  these  activities  are  sufficient  for  a  role  of  these  glycosylases  in  global 
demethylation or rather in active demethylation of tissue‐specific genes during development. In case 
of  initial  deamination  of  5‐methylcytosine  to  thymine,  TDG  and  MBD4  could  be  involved  in 
demethylation  employing  their  thymine  DNA  glycosylase  activity  again  producing  an  abasic  site, 




catalyze  this  reaction.  Interestingly,  both  Dnmt3a  and  Dnmt3b  have  been  suggested  to  possess 
deaminase activity and have been reported to be responsible for dynamic transcriptional regulation 








donor  AdoMet  can  lead  to  deamination  of  both  cytosine  and  5‐methylcytosine  by  prokaryotic 




(BER).  In  addition,  activation–induced  cytidine  deaminase  (AID)  has  been  shown  to  deaminate  5‐
methylcytosine  in  DNA  creating  a  C  to  T  transition  (Morgan  et  al.,  2004).  Recently,  this  AID‐




DNA‐damage‐inducible protein 45α)  is a nuclear protein and was  shown  to  interact with  the NER 
repair endonuclease XPG leading to demethylation by DNA repair upon deamination. TAF12 was later 
shown  to  recruit Gadd45α  and  the  repair machinery  to  these  sites  of  active DNA  demethylation 
(Barreto  et  al.,  2007;  Ma  et  al.,  2009;  Rai  et  al.,  2008;  Schmitz  et  al.,  2009)  .  However,  the 
involvement  of  Gadd45α  is  still  controversially  discussed  (Jin  et  al.,  2008)  and  has  rather  been 
suggested to be involved in the demethylation of tissue‐specific gene promoters. 
An additional possibility for active demethylation would be the modification of 5‐methylcytosine to a 
base  that allows breakage of  the carbon‐carbon bond, by shifting chemical properties.  Indeed,  the 
mammalian  genome was  recently  shown  to  contain 5‐hydroxymethylcytosine  in  certain  cell  types 
(Kriaucionis and Heintz, 2009). This modification has been  reported  to  result  from oxidation of 5‐





with  siRNA knock‐down  (Okada et al., 2010)  identified  the elongator complex component Elp3  (or 
KAT9) as candidate for active demethylation. Moreover, knock‐down of other elongator components 








DNA  methylation  plays  a  profound  role  in  epigenetic  gene  regulation  and  Dnmt1  is  the  most 
ubiquitous  DNA methyltransferase  in mammals,  responsible  for maintenance methylation  during 
semi‐conservative DNA  replication  (see  chapter 1.1.3.1). The murine enzyme was  first  cloned and 
sequenced  by  Bestor  and  coworkers  in  1988  (Bestor  et  al.,  1988).  Four  years  later,  in  1992,  Yen 
cloned and  isolated the cDNA for human Dnmt1  (Yen et al., 1992). The precise extension of the N‐
terminus  of  the murine  enzyme,  however,  was  only  defined  in  1996  by  Tucker  and  coworkers, 
showing  that  the N‐terminal 171 amino acids, which were not  included  in  the  first  sequence, are 
necessary for stable Dnmt1 expression and function (Tucker et al., 1996). In total, the somatic form 
of  murine  Dnmt1  comprises  1619  amino  acids,  has  a  molecular  weight  of  about  180  kDa  and 
comprises  several distinct domains  (Figure 6). Human Dnmt1  is 3 amino acids  shorter. Mouse and 
human Dnmt1 protein sequences share 78 % identity.  
1.2.1 STRUCTURE 
Dnmt1  is a  large enzyme with a complex domain structure and  likely evolved by  fusion of at  least 
three genes (Margot et al., 2000). To date, there  is no three‐dimensional structure of the complete 
Dnmt1 enzyme known; only a crystal structure of the TS domain is available (PBD: 3EPZ, (Fellinger et 
al.,  2009)).  All  structural  information  presented  in  the  following  paragraphs  is  thus  based  on 
biochemical studies and/or the comparison with structures of prokaryotic enzymes. 
The Dnmt1 enzyme comprises a regulatory N‐terminal domain, which is connected to its C‐terminal 
catalytic  domain  by  a  linker  of  seven  glycine‐lysine  repeats.  As mentioned  above,  the  C‐terminal 
domain of Dnmt1  shows high  sequence  similarity  to prokaryotic DNA methyltransferases and was 
thereby  early  identified  as  the  domain  responsible  for  catalysis  of  the methyl  transfer  reaction 




and  that  the  combined  region  of  motifs  I,  II  and  III  strongly  resembles  the  Rossman  fold  of  a 
dinucleotide‐binding motif.  Importantly,  the  invariant  Pro‐Cys  dipeptide  in motif  IV  is  part  of  the 
catalytic site (Kumar et al., 1994). Between motifs VIII and IX resides the target recognizing domain 
(TRD), which is significantly longer in Dnmt1 than in prokaryotic DNA methyltransferases. This region 
has been  shown  to determine  the  sequence  specificity of  the prokaryotic enzymes  (Lauster et al., 









DNA methyltransferase  (here: M.Sss1). The catalytic motifs  I‐X and the  target recognizing domain, as well as 








terminal  domain  is  needed  for  activation  of  enzyme  activity,  numerous  attempts  have  been 
undertaken  to  find  the minimal active Dnmt1  construct  (Bacolla et al., 2001; Margot et al., 2000; 
Zimmermann  et  al.,  1997).  The  shortest  peptide  that  has  been  shown  to  still  possess  enzymatic 
activity  is  human Dnmt1∆1‐580.  In  contrast, Dnmt1∆672 was  shown  to  be  inactive  (Pradhan  and 
Esteve, 2003)  suggesting  that  the  first half of  the N‐terminal domain of Dnmt1  is dispensable  for 
enzymatic activity. 
The N‐terminal part of Dnmt1 contains the following well defined domains (Figure 6): PCNA binding 
domain  (PBD),  targeting  sequence  (TS), CXXC  zinc  finger domain  (CXXC), and  two Bromo  adjacent 
homology  domains  (BAH1  and  BAH2).  The  PBD  mediates  the  interaction  of  Dnmt1  with  PCNA 
(proliferating cell nuclear antigen), which has been shown to serve as dynamic  loading platform for 
factors  involved  in  replication  (Sporbert  et  al.,  2005).  Indeed,  this  interaction  is  required  for 
accumulation of Dnmt1 at replication foci and directly couples the replication of DNA sequence and 
DNA methylation. Furthermore, the TS domain directs association of Dnmt1 with heterochromatin. 









Based  on  the  striking  sequence  similarity  of  the  catalytic  domain  of  mammalian  Dnmt1  with 
prokaryotic  type  II  DNA  cytosine  methyltransferases,  prokaryotic  and  mammalian  Dnmts  were 
proposed  to  function  catalytically  in  a  similar multi‐step mechanism  ((Bestor  and  Verdine,  1994; 
Klimasauskas et al., 1994; Wu and Santi, 1987), Figure 7). Upon DNA binding, the target cytosine  is 
flipped  out  of  the  DNA  double  helix  and  a  covalent  complex with  the  C6  position  of  the  target 
cytosine  is  formed. After  transfer  of  a methyl  group  from  the methyl  group  donor  S‐Adenosyl‐L‐
Methionine  (AdoMet)  to  the C5 position of  the nucleobase,  the  covalent  enzyme‐DNA  complex  is 
released by β‐elimination. This mechanism was first described for the prokaryotic methyltransferase 
M.HhaI, but kinetic  investigations of mouse and human Dnmt1 (Flynn et al., 1996; Flynn and Reich, 
1998;  Pradhan  et  al.,  1999)  also  revealed  that  the methyl  transfer  reaction  is  a  sequential  Bi  Bi 












in  covalent  complex  formation  (Cheng  et  al., 1993; Wu  and  Santi, 1987). Accordingly,  single base 
mutations of  this conserved cysteine residue  (C‐>S or C‐>W) result  in catalytically  inactive proteins 
(Wyszynski et al., 1993). Interestingly, whereas also DNA binding activity was reduced for the C‐>W 
mutation, the C‐>S mutation did not diminish specific DNA binding, but rather enhanced affinity of 
M.HhaI  for DNA  (Wyszynski et al., 1993). Consistently,  the C‐>S mutant of human Dnmt1 was also 
proposed to bind tighter to DNA as the wild‐type enzyme (Araujo et al., 2001). 
Based on the positive correlation between methylation rate and DNA substrate  length,  it was early 
hypothesized  that Dnmt1 might  be  a  processive  enzyme  sliding  along  the DNA molecule  by  one‐





hemimethylated  DNA  substrates  processively  ignoring  fully  or  unmethylated  sites  in  between. 
Thereby, Dnmt1 was  suggested  to  keep  its orientation with  respect  to  the DNA  (Hermann  et  al., 
2004). Other  reports  specified  by  direct  analysis  of methylation  patterns  that Dnmt1 methylates 
hemimethylated DNA with 95‐99% fidelity processively, but unmethylated DNA with much less or no 
processivity (Goyal et al., 2006; Vilkaitis et al., 2005). Interestingly, the first 290 amino acids including 
the  PCNA  binding  domain  were  not  required  for  this  behavior  (Vilkaitis  et  al.,  2005).  Still,  the 
hypothesis of processivity is subject of discussion (Bacolla et al., 1999). 
1.2.3 SUBSTRATE SPECIFICITY 
The  substrate  for Dnmt1  is DNA  containing CpG  sites.  In  vitro, Dnmt1 has been  shown  to have  a 
strong preference for DNA substrates with hemimethylated over substrates with unmethylated CpG 
sites. It has been suggested that optimal binding sites for Dnmt1 carry the CpG site within a G/C‐rich 




its  role  in maintenance methylation,  the  question  remains  at which  step  of  the methyl  transfer 
reaction substrate discrimination occurs. On the one hand,  it has been suggested that Dnmt1 binds 
equally  well  to  un‐  and  hemimethylated  DNA,  indicating  that  a  later  step  of  the  reaction  is 
responsible  for preferential methylation of hemimethylated DNA  (Flynn et al., 1996). On  the other 
hand,  it was claimed  that Dnmt1 preferentially binds  to hemimethylated DNA  (Araujo et al., 2001; 
Bacolla et al., 2001). Dnmt1  is unique among other DNA methyltransferases not only  in terms of  its 
preference  for hemimethylated DNA, but also  for  its  large  regulatory N‐terminal domain. Thus,  to 
address  the question whether  the N‐terminal domain  is  involved  in substrate recognition, a hybrid 
mouse‐prokaryotic  DNA  methyltransferase,  consisting  of  the  mouse  Dnmt1  N‐terminus  and  the 
M.HhaI sequence, was generated and tested for substrate specificity. Remarkably, the hybrid enzyme 
retained the nucleotide sequence specificity of M.HhaI (GCGC sites), but gained a 2.5 fold preference 
for  hemi‐  over  unmethylated  substrate  compared  to  an  around  2  fold  preference  for  un‐  over 
hemimethylated DNA of  the wild‐type M.HhaI enzyme  (Pradhan and Roberts, 2000). These  results 
suggest a role for the N‐terminal part of Dnmt1  in the preference for hemimethylated substrate.  If 
this  is  the  case,  the  responsible  sequences  seem  to  be  located within  the  second  half  of  the N‐









motif 1, was  suggested  to decrease  the preference  for hemimethylated DNA by  stimulation of de 














Dnmt1  is  controlled  by  alternative  splicing  of  sex‐specific  5’  exons  in mammalian  germ  cells.  In 
oocytes,  this  leads  to  a  shorter  Dnmt1  transcript  and  expression  of  a  shorter  Dnmt1  isoform, 








crucial as determined by deletion analysis. This region  includes  the CXXC domain of Dnmt1  (amino 
acids 651‐698) (Cardoso and Leonhardt, 1999). Dnmt1o only transiently enters the nucleus  in 8‐cell 
embryos suggesting that this variant of Dnmt1 provides maintenance methylation at  imprinted  loci 
during  the  fourth  embryonic  S  phase  (Howell  et  al.,  2001).  Interestingly,  an  alternative  Dnmt1 
transcript was  identified  in skeletal muscle, specifically expressed  in differentiated myotubes when 
the ubiquitously expressed Dnmt1 isoform is down‐regulated. This longer transcript is identical to the 
one  previously  reported  to  be  unique  for  sperm  cells  and  to  be  untranslatable  (Mertineit  et  al., 
1998). However,  a  later work  suggested  that  the  transcript  is  after  all  translated  and  results  in  a 
protein identical to Dnmt1o (Aguirre‐Arteta et al., 2000). 
In  addition  to  the  5’  alternative  splice  variants,  there  is  a  one‐codon  alternative  splice  variant  in 
mouse somatic cells  leading to a protein differing by 2 amino acids shortly before the PBD domain 
(amino  acid  145  F  ‐>  SV)  (Lin  et  al.,  2000).  Similar  abundance was  suggested  for  both  isoforms. 













Dnmt1  is  subject  to  several posttranslational modifications, namely phosphorylation, methylation, 
SUMOylation  and  ubiquitylation,  which  were  reported  to  regulate  Dnmt1  activity  or  stability. 
Phosphorylation of the SV variant of mouse Dnmt1 at serine 146 (Lin et al., 2000) has been recently 
suggested  to  reduce DNA binding activity of Dnmt1  (Sugiyama et al., 2010). Moreover,  serine 514 
phosphorylation within  the TS domain has been reported  to regulate enzyme activity  (Glickman et 
al.,  1997;  Goyal  et  al.,  2007),  but  this  hypothesis  could  not  be  confirmed  in  our  laboratory 
(unpublished data, Karin Fellinger and Andrea Rottach). Methylation at lysine 1096 and other lysine 
residues has been shown to destabilize Dnmt1. Dnmt1 levels are thus controlled by the action of the 
enzymes  that  set  and  remove  these methyl  groups,  that  is  the methyltransferase  Set7/9  and  the 
demethylase  LSD1,  respectively  (Wang et al., 2009). SUMOylation of Dnmt1 has been  reported  to 
enhance Dnmt1 activity; however, the exact position of this modification could not be mapped (Lee 
and Muller, 2009). At  last,  two  studies proposed  that Dnmt1  levels are  regulated by proteasomal 
degradation  pathways  triggered  by  ubiquitylation  of Dnmt1  (Agoston  et  al.,  2005; Ghoshal  et  al., 




(Bacolla  et  al.,  2001;  Bacolla  et  al.,  1999).  Binding  of methylated  DNA  to  this  allosteric  site was 




1999).  The  allosteric  effect of methylated DNA was proposed  to be  important  for methylation of 
unmethylated  CpG  sites  in  proximity  to  methylated  sites  by  a  mechanism  called  methylation 
spreading. Furthermore, it was suggested that the enzyme is allosterically inhibited by unmethylated 
DNA  affecting  both  enzyme  activity  and  processivity  (Svedruzic  and  Reich,  2005).  This might  be 
important  for  regulation  of  Dnmt1  activity  in  vivo  and  contribute  to  the  fidelity  of  Dnmt1’s 
maintenance function.  
Steady‐state  kinetic  analyses  indicated  that  the  methyl  transfer  reaction  of  Dnmt1  might  be 
repressed by the first 501 N‐terminal amino acids, as Dnmt1∆1‐501 was suggested to possess higher 















Moreover,  numerous  DNA  binding  domains  of murine  and  human  Dnmt1  have  been  described, 
which could possibly  regulate enzyme activity. Proposed DNA binding domains  include besides  the 
catalytic domain  itself (Fatemi et al., 2001), the very N‐terminal region of mouse Dnmt1 (Fatemi et 
al.,  2001;  Suetake  et  al.,  2006),  sequences  shortly  before  and/or within  the  first  part  of  the  TS 





proteases.  This  domain was  shown  to  bind  to DNA  via  amino  acids  119‐197  including  the  PCNA 
binding domain, and to preferentially bind to the minor groove of AT rich sequences (Suetake et al., 
2006). Second, the N‐terminal domain of human Dnmt1 comprises a DNA binding motif DB1 adjacent 





accordance  to  the human protein, a peptide  sequence  corresponding  to  this  region  in  the murine 
enzyme was also shown to bind to DNA (Chuang et al., 1996; Pradhan and Esteve, 2003). In addition, 






were  shown  to possess DNA binding activity: amino acids 510‐789  (Pradhan and Esteve, 2003) or 
amino acids 645‐737 (Pradhan et al., 2008) of the human enzyme, and amino acids 613‐748 (Fatemi 
et al., 2001) of the murine enzyme. 
Two of these DNA binding domains have been  independently suggested to be  involved  in allosteric 
activation  of  Dnmt1.  The  KKHR  motif  of  the  human  enzyme  was  proposed  to  be  involved  in 
methylated DNA‐mediated  allosteric  activation based on  analysis of point mutants which  showed 
reduced  activation  upon  addition  of methylated DNA  (Pradhan  and  Esteve,  2003). Moreover,  the 
CXXC  domain  of mouse  Dnmt1  has  been  suggested  to  interact  with  the  catalytic  domain  upon 
binding  of methylated  DNA  and  thereby  to  allosterically  activate  enzyme  activity  (Fatemi  et  al., 
2001). However, methylation spreading on unmethylated CpG sequences by allosteric activation was 




The DNA binding specificity of the CXXC domain and  its role  in enzyme regulation  is controversially 
discussed. However, the observation that deletion of the first 580 amino acids of the Dnmt1 does not 





In  addition  to  the  intrinsic  preference  of Dnmt1  for  hemimethylated  substrate  and  the  allosteric 
regulation of Dnmt1 activity by DNA or intramolecular interaction, other factors control the reliable 















From  late  S  until  early  G1  phase,  Dnmt1  is  associated  with  (preferentially  constitutive) 
heterochromatin via  its TS domain  in a replication‐independent mechanism  (Easwaran et al., 2004; 
Leonhardt et al., 1992). This prolonged association of Dnmt1 with chromatin after DNA replication 




Uhrf1  ablation  leads  to  global DNA  hypomethylation,  a  phenotype  similar  to  that  obtained  upon 
Dnmt1  ablation  (Bostick  et  al.,  2007a;  Sharif  et  al.,  2007).  To  this  end, Uhrf1 has been  shown  to 
preferentially bind  to DNA with hemimethylated CpG  sites via  its SRA domain, but also  to directly 
interact with Dnmt1 and to colocalize with Dnmt1 at replication foci ((Arita et al., 2008; Avvakumov 
et al., 2008; Bostick et al., 2007b; Sharif et al., 2007), see also chapter 1.1.5.2). Based on these data, it 
was  suggested  that  Uhrf1  recruits  Dnmt1  to  hemimethylated  CpG  sites  at  the  replication  fork. 
However,  the  exact  mechanism  and  the  hierarchy  of  events  necessary  for  Uhrf1‐dependent 
maintenance methylation  are  far  from  being  understood.  The  high  intrinsic  preference  of Dnmt1 
even  in  the absence of Uhrf1 and  the emerging evidence  that Uhrf1 also strongly binds  to histone 




self‐interaction would  allow  another  level of enzymatic  regulation. To  further  test  this hypothesis 









Although  the  biological  importance  and  the  sequence  of  the  most  ubiquitous  mammalian  DNA 
methyltransferase Dnmt1 are known for two decades, its mechanistic regulation still remains elusive. 
Therefore,  the  main  objective  of  this  PhD  thesis  was  to  study  the  molecular  basis  of  Dnmt1 
regulation with respect to stable maintenance of DNA methylation patterns. 
At  first,  I aimed at elucidating  the  functional  role of  the CXXC domain of Dnmt1. This domain has 
been  reported  to  allosterically  activate Dnmt1  by  intramolecular  interaction with  the  catalytic  C‐
terminal domain. Moreover,  the observation  that CXXC domains of numerous other proteins bind 
preferentially  to unmethylated DNA substrates suggests  that  the CXXC domain of Dnmt1 might be 
involved  in  substrate  discrimination  by  blocking  enzymatic  activity  of  Dnmt1  upon  binding  to 
unmethylated  DNA.  To  address  this  hypothesis,  I  developed  a  non‐radioactive  assay  for  DNA 
methyltransferase activity and DNA binding (chapter 2.1). Besides the advantage of avoiding the use 
of  isotope  labeled molecules,  this assay was designed  to distinguish different  steps of  the methyl 
transfer reaction. Furthermore, by using distinct fluorescent DNA labels, I aimed at comparing up to 
four different DNA substrates in direct competition. Using this assay, I tested the binding properties 
of  the  CXXC  domain  of  Dnmt1  and  its  functional  relevance  for  enzymatic  activity  and  substrate 
specificity (chapter 2.3). 
It  is well  established  that  Dnmt1  requires  other  factors  for  reliable maintenance  of methylation 




activity  and  specificity of Uhrf1  and  a  variety of Uhrf1 domains with  the newly  established  assay 
(chapter 2.4). 
Moreover, it was recently suggested that Dnmt1 forms a stable dimer (Fellinger et al., 2009), which 
potentially  represents  a  further process  that  regulates Dnmt1  activity.  Thus,  I  also  addressed  the 
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ABSTRACT
We present a simple, non-radioactive assay for DNA
methyltransferase activity and DNA binding. As
most proteins are studied as GFP fusions in living
cells, we used a GFP binding nanobody coupled to
agarose beads (GFP nanotrap) for rapid one-step
purification. Immobilized GFP fusion proteins were
subsequently incubated with different fluorescently
labeled DNA substrates. The absolute amounts and
molar ratios of GFP fusion proteins and bound DNA
substrates were determined by fluorescence spec-
troscopy. In addition to specific DNA binding of GFP
fusion proteins, the enzymatic activity of DNA
methyltransferases can also be determined by
using suicide DNA substrates. These substrates
contain the mechanism-based inhibitor 5-aza-dC
and lead to irreversible covalent complex formation.
We obtained covalent complexes with mammalian
DNA methyltransferase 1 (Dnmt1), which were resis-
tant to competition with non-labeled canonical DNA
substrates, allowing differentiation between methyl-
transferase activity and DNA binding. By compari-
son, the Dnmt1C1229W catalytic site mutant showed
DNA-binding activity, but no irreversible covalent
complex formation. With this assay, we could also
confirm the preference of Dnmt1 for hemimethyl-
ated CpG sequences. The rapid optical read-out in
a multi-well format and the possibility to test several
different substrates in direct competition allow rapid
characterization of sequence-specific binding and
enzymatic activity.
INTRODUCTION
The modiﬁcation of DNA by DNA methyltransferases is
widespread and has a variety of biological functions (1). In
bacteria, DNA methylation is involved in host defense
mechanisms and strand discrimination during mismatch
repair. In eukaryotic cells, DNA methylation is part of a
highly complex epigenetic network regulating genome
structure and activity (2,3). In contrast to the bacterial
enzymes, eukaryotic DNA methyltransferases contain
large regulatory domains that are involved in numerous
intermolecular interactions and control enzyme activity
through a largely unknown mechanism (4). The biochem-
ical and cell biological characterization of DNA methyl-
transferases is pivotal for the understanding of epigenetic
network regulation.
The basic biochemistry of the 5-methyl cytosine (5mC)
methylation reaction is by now well understood. In a post-
replicative reaction, DNA methyltransferases catalyze the
transfer of a methyl group from S-adenosyl-L-methionine
(AdoMet) to the C5 position of the nucleobase. During
this multi-step reaction, the target cytosine is ﬂipped out
of the double helix (base ﬂipping) and the recipient C5
position is activated by a transient, covalent complex for-
mation with the enzyme at the C6 position (5,6). After
methyl group transfer, the enzyme is released by b-elim-
ination together with the proton at the C5 position. This
last and crucial step of the enzymatic reaction can be
exploited for a speciﬁc and mechanism-based inhibition
with DNA substrates containing nucleotide analogs like
5-aza-dC or zebularine that are missing the essential
proton at the C5 position (7–9). Although the catalytic
mechanism of the 5mC DNA methyltransferases is
known, the crucial question how eukaryotic enzymes rec-
ognize and discriminate target sites for methylation
remains elusive.
Over the past decades, a variety of biochemical assays
has been developed to determine the activity of DNA
methyltransferases. The most commonly used methyl-
transferase activity assays measure the transfer of radio-
actively labeled methyl groups from the cofactor AdoMet
to DNA substrates (10–14). Alternatively, DNA methyla-
tion by active methyltransferases can be monitored as pro-
tection against nucleolytic cleavage by restriction enzymes.
The amount of methylated DNA can be measured as
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release or retention of terminal aﬃnity probes of DNA
substrates (15,16). Another indirect approach uses bisul-
ﬁte treatment followed by incorporation and detection of
hapten-labeled dCTPs at non-converted sites (17). Also
direct detection of methylated cytosine residues by
MALDI-TOF mass spectrometry (18) or monitoring of
conversion of AdoMet to S-adenosyl-homocysteine
(AdoHcy) by liquid chromatography and mass spectros-
copy has been used (19). All these methods depend on
either radioisotopes, expensive and demanding equipment,
and/or multiple-step protocols.
Here, we present a simple, non-radioactive and versatile
method to measure DNA methyltransferase activity. The
assay measures methyltransferase activity as irreversible
covalent complex formation with ﬂuorescently labeled
DNA substrates containing the mechanism-based inhibi-
tor 5-aza-dC. The variation of DNA sequence and ﬂuo-
rescent label allows detection of DNA sequence speciﬁcity
and discrimination of methyltransferase activity from
DNA binding. We tested this assay using mammalian
DNA methyltransferase 1 and mutants thereof.
MATERIALS AND METHODS
Expression vectors
The eukaryotic expression vectors for enhanced GFP
(pEGFP-C1, Clontech, USA) and fusions with mouse
Dnmt1 and its catalytically inactive mutant
Dnmt1C1229W were previously described (7). For GFP
expression in bacteria, the pRSET-EGFP vector was gen-
erated. The GFP-coding sequence was ampliﬁed from
pEGFP-C1 by PCR to add ﬂanking XbaI/EcoRI restric-
tion sites and a C-terminal His6-tag. The PCR fragment
was digested with XbaI and EcoRI and subsequently
ligated into the bacterial expression vector pRSET
(Clontech, USA).
Cell culture and transfection
Human embryonic kidney (HEK) 293T cells were cultured
in DMEM supplemented with 10% fetal calf serum and
50 mg/ml gentamycine (PAA, Germany). HEK 293T cells
were transiently transfected with expression plasmids for
GFP, GFP-Dnmt1 and GFP-Dnmt1C1229W using poly-
ethylenimine as transfection reagent (Sigma, Germany)
(20). After 48 h, about 80–90% of the cells were expressing
GFP as determined by ﬂuorescence microscopy. Cells
were harvested, washed twice with PBS and stored at
808C.
GFP purification
A 2 l culture of BL21 (DE3) Escherichia coli transformed
with pRSET-EGFP was grown to OD 0.6 and induced
with 1mM IPTG for 20 h at RT. Bacteria were harvested
and resuspended in 20ml of binding buﬀer (500mM
NaCl, 20mM imidazole, 1mM PMSF in PBS). Lysis of
E. coli was performed by soniﬁcation in the presence of
1 mg/ml lysozyme and 25 mg/ml DNase I. After centrifuga-
tion, 10ml of soluble E. coli protein extract was loaded
onto a His-Trap HP column containing 1ml of Ni-NTA
resin (GE Healthcare, Germany) using an A¨KTA puriﬁer
(GE Healthcare, Germany). After extensive washing of
the bound material, the protein was eluted with elution
buﬀer (500mM NaCl, 250mM imidazole in PBS) and
1ml fractions were collected. Aliquots of elution fractions
were subjected to SDS–PAGE and coomassie brilliant
blue staining. Pure fractions of GFP were pooled and
dialyzed three times against 1 l of PBS. The GFP concen-
tration was determined by an analytical SDS–PAGE and
coomassie brilliant blue staining with carbonic anhydrase
as concentration standard.
Preparation of DNA substrates
DNA oligonucleotides were purchased from Metabion
(Germany) or from IBA (Germany) and the sequences
are listed in Table 1. Double-stranded DNA substrates
were synthesized by primer extension using the large
(Klenow) fragment of E. coli DNA polymerase I
(Figure 1, Supplementary Figure 1A).
To prepare the DNA substrates, one upper (CG-up or
MG-up) and one lower strand (Fill-In, Fill-In-550 or Fill-
In-647N) oligonucleotide were denatured in NEB2 buﬀer
(50mM NaCl, 10mM Tris–HCl, 10mM MgCl2, 1mM
dithiothreitol) for 2min at 958C and annealed by slowly
cooling down to 378C. Upon addition of 0.05 u/ml Klenow
fragment (NEB, Germany), dTTP, dGTP, dATP
(PeqLab, Germany) at 1mM ﬁnal concentration, and
either CTP at 1mM, 5-aza-dCTP or 5-methyl-dCTP at
50 mM (Jena Bioscience, Germany), the Fill-In oligonu-
cleotide was extended to produce either unmethylated,
hemimethylated or fully methylated canonical DNA
substrates or un- or hemimethylated suicide DNA sub-
strates containing 5-aza-dC at the CpG site. 5-aza-dC
containing suicide DNA substrates are referred to as ‘trap-
ping substrates’ and DNA substrates not containing
5-aza-dC as ‘binding substrates’. The design of the oligo-
nucleotides allows the preparation of 15 diﬀerent unla-
beled, ATTO550 or ATTO647N labeled substrates with
only ﬁve diﬀerent oligonucleotides (Supplementary
Figure 1B). Hemimethylated ATTO550 labeled and







e22 Nucleic Acids Research, 2009, Vol. 37, No. 3 PAGE 2 OF 8
 at Universitatsbibliothek M






unmethylated ATTO647N labeled binding and trapping
substrates were therefore prepared as described earlier,
using MG-up and Fill-In-550 or CG-up and Fill-In-
647N oligos. Unlabeled hemimethylated competitor
DNA substrate was prepared using MG-up and Fill-In
oligos.
Calibration measurements for GFP, ATTO550 and
ATTO647N
Calibration curves for the ﬂuorescent DNA substrates and
proteins were determined by measuring the ﬂuorescence
signal of known concentrations of the DNA-coupled
ﬂuorophores and puriﬁed GFP and calculated by linear
regression. For this, we used the PolarStarOptima
ﬂuorimeter (BMG, Germany) and the following
excitation/emission band path ﬁlter sets: 485 8 nm/
520 17 nm for GFP, 545 5 nm/575 5 nm for
ATTO550 and 645 5 nm/675 5 nm for ATTO647N.
The beads do not cause ﬂuorescence background, and
within the measurement error, no change of ﬂuorescence
intensity of the ATTO dyes was observed upon addition of
beads. Interestingly, the GFP ﬂuorescence signal is
enhanced by binding to the GFP-binding protein (GBP),
which is the active part of the GFP nanotrap. With the
indicated ﬁlter set for GFP detection, the ﬂuorescence
signal is about 1.7 times enhanced (Supplementary
Figure 3). This eﬀect was taken into account for later con-
version of the ﬂuorescent signal into ﬂuorophore concen-
tration and calculation of binding and trapping rates as
the ratio of ATTO and GFP signal.
Pull-down of GFP or GFP fusion proteins
Extracts from 1 107 cells were prepared by resuspen-
sion and incubation of the cell pellet in 200 ml lysis buﬀer
(20mM Tris–HCl pH 7.5, 150mM NaCl, 0.5mM EDTA,
2mM PMSF, 0.5% NP40, 1 mammalian protease
inhibitor mix) for 30min on ice. After centrifugation,
supernatants were diluted to 500 or 1000 ml with immuno-
precipitation buﬀer (20mM Tris–HCl pH 7.5, 150mM
NaCl, 0.5mM EDTA). Extracts were incubated with
1 mg of a GBP coupled to agarose beads (GFP nanotrap;
Chromotek, Germany) (21) for 1–2 h at 48C with constant
mixing. GFP or GFP fusion proteins were pulled down by
centrifugation at 540g. The beads were washed twice with
1ml of wash buﬀer (20mM Tris–HCl pH 7.5, 300mM
NaCl, 0.5mM EDTA). The amount of protein on the
beads was determined with the PolarStarOptima ﬂuori-
meter after resuspension in 100ml wash buﬀer or by west-
ern blot. In the latter case, beads were resuspended in 2
Laemmli buﬀer (22) and 25% was loaded onto a 6%
SDS–PAGE. After blotting to a nitrocellulose membrane,
GFP-Dnmt1 was detected with a speciﬁc antibody against
Dnmt1 (kindly provided by Nowak, D. and Cardoso,
M.C.) and an HRP-labeled secondary antibody.
Binding and trapping assay
The pull-down of GFP or GFP fusion protein was per-
formed as described earlier. After the second washing step,
beads were equilibrated with assay buﬀer (100mM KCl,
10mM Tris–HCl pH 7.6, 1mM EDTA, 1mM DTT). For
determination of binding and trapping rates, the beads
were resuspended in 500 or 1,000 ml of assay buﬀer sup-
plemented with 160 ng/ml BSA and 100mM S-adenosyl-L-
methionine (AdoMet), and 0.1 mM binding or trapping
DNA substrate, unless indicated otherwise. For qualita-
tive determination of DNA methyltransferase activity,
binding (with canonical-binding substrates) and trapping
(with suicide trapping substrates) were performed at 378C
for 90min, unless indicated otherwise. After washing twice
with assay buﬀer to remove unbound substrate, beads
were resuspended in 100 ml assay buﬀer and transferred
into a 96-well microplate. The amounts of protein and
DNA were determined by ﬂuorescence measurements




















Figure 1. Outline of the binding and activity assay. The covalent com-
plex formation is the ﬁrst and crucial step of the methylation reaction.
The incorporation of the mechanism-based inhibitor 5-aza-dC (depicted
as a star) in DNA substrates leads to an irreversible complex formation
with catalytically active DNA methyltransferase (trapping). Capture
and detection of this reaction intermediate thus serves as a measure
of enzyme activity. (A) Un-, hemi- or fully methylated canonical or
5-aza-dC containing double-stranded DNA substrates (binding and
trapping substrates, respectively) are 42 base pairs long including one
central CpG site and can be unlabeled, labeled with ATTO550 or
labeled with ATTO647N. The asterisk marks 5-aza-dC. (B) The GFP
fusion protein of interest, e.g. a DNA methyltransferase (MTase), is
puriﬁed from cell lysates using a GFP nanotrap and incubated with
binding or trapping DNA substrates. After pull-down of protein–DNA
complexes, unbound DNA substrate is removed by two washing steps.
Protein and DNA substrate amounts are calculated from ﬂuorescence
measurements of GFP, ATTO550 and ATTO647N, respectively.
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Trapping and binding assays were performed as described
earlier, except that for binding competition, referred to as
binding or trapping with competitor, a further incubation
step with 1 mM hemimethylated unlabeled binding DNA
was performed for 45min at 378C to compete for binding
of labeled non-covalently bound substrate in the binding
and trapping sample. Before ﬂuorescence measurement,
two ﬁnal washing steps with assay buﬀer were performed.
RESULTS AND DISCUSSION
Assay design
We previously generated a set of ﬂuorescent Dnmt1
fusions and mutants thereof and characterized their cell-
cycle dependent dynamics in living cells (23,24). To com-
plement these data and to gain further insights into the
structure, function and regulation of DNA methyltrans-
ferases, it is crucial to determine their sequence speciﬁc
DNA binding and methyltransferase activity. For fast bio-
chemical characterization of these GFP fusion proteins,
we developed a simple, non-radioactive assay.
The assay is based on immunoprecipitation of fusion
proteins with a GBP coupled to agarose beads [GFP
nanotrap (21)]. Bound GFP fusion proteins were incu-
bated with ﬂuorescently labeled double-stranded DNA
substrates. After removal of unbound substrate, the con-
centrations of ﬂuorescent protein and bound DNA sub-
strate were measured with a ﬁlter-based ﬂuorescence
spectrometer in a multi-well format (Figure 1).
The design of DNA oligonucleotides combined with a
primer extension method allows preparation of a variety
of substrates (Figure 1A, Supplementary Figure 1).
Canonical DNA substrates (binding substrates) were
used for binding studies and suicide DNA substrates con-
taining 5-aza-dC at the CpG site (trapping substrates) for
monitoring irreversible covalent enzyme–DNA complex
formation as the ﬁrst and crucial step of the DNA methy-
lation reaction. The capture of these reaction intermedi-
ates serves as a measure of enzyme activity, although the
ﬁnal step of the methylation reaction, the methyl group
transfer, is not detected. As DNA substrates can be
labeled with diﬀerent ﬂuorophores, several diﬀerent
sequences, containing, e.g. un-, hemi- or fully methylated
CpG sites, can be tested in direct competition. The ﬂuo-
rescence of protein and substrate allows direct determina-
tion of concentrations, molar ratios and speciﬁc activity.
Linear GFP-Dnmt1 pull-down with the GFP nanotrap
The GFP nanotrap allows fast and eﬃcient one-step puri-
ﬁcation of GFP or GFP fusion proteins. For demonstra-
tion of linearity, we incubated a constant amount of the
GFP nanotrap with diﬀerent lysate volumes of GFP-
Dnmt1 overexpressing HEK 293T cells and determined
the concentration of GFP fusion protein bound by the
beads. The amount of bound GFP-Dnmt1 did indeed
increase linearly with the amount of lysate added, as quan-
tiﬁed by ﬂuorescence detection and western blot.
Importantly, quantiﬁcation with a ﬂuorescence plate
reader was very sensitive and showed a larger linear
range than the corresponding western blot (Figure 2).
This demonstrates the strength of the ﬂuorescence-based
readout of this assay. The exact quantiﬁcation of the pro-
tein input allows the comparison of diﬀerent samples and
takes into account possible diﬀerences in pull-down
eﬃciency.
Characterization and optimization of assay conditions
To optimize assay conditions, we ﬁrst determined the time
course of DNA binding and irreversible covalent complex
formation (trapping) of GFP-Dnmt1 with hemimethy-
lated DNA substrates. The time course of GFP-Dnmt1
binding to hemimethylated substrate followed the classi-
cal-binding kinetics with an observed rate constant of
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Figure 2. Linear GFP-Dnmt1 pull-down. Diﬀerent amounts of cell
lysate (0, 10, 20, 25, 50, 100, 150 and 200ml) from GFP-Dnmt1 over-
expressing HEK 293T cells were incubated with constant aliquots of
the GFP nanotrap. (A) The concentration of precipitated GFP-Dnmt1
was calculated from the measured intensity of the GFP ﬂuorescence
signal. (B) Aliquots of the same samples were analyzed by western
blot with an anti-Dnmt1 antibody. Shown are two diﬀerent exposure
times (2min and 15 s). The band intensities were quantiﬁed with the
Image J software using the higher exposure time for data points 0, 10,
25 and the lower exposure time for data points 50, 100, 150 and 200.
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The trapping rate (ratio of bound suicide DNA substrate
per protein) increased linearly within the ﬁrst 50min of
reaction and reached a plateau at about 90min
(Figure 3A). For substrate speciﬁcity and qualitative
methyltransferase activity assays, we chose 90-min incu-
bation time to obtain maximal signals. For determination
of initial reaction velocities, shorter incubation times were
used to stay within the linear range of this assay.
To test the dependence of binding and trapping rate
on the initial DNA substrate concentration, we incubated
a constant amount of GFP-Dnmt1 with hemimethylated
trapping substrate at diﬀerent concentrations (Figure 3B).
The ﬁtting of binding data is shown in Supplementary
Figure 2B. For substrate concentrations below the concen-
tration of methyltransferase molecules, the trapping rate
increased linearly with the substrate concentration until a
plateau was reached at excess concentration of DNA sub-
strate. Likewise, in the presence of an excess of DNA
substrate, the concentration of bound ﬂuorescent DNA
increased with the amount of precipitated methyltransfer-
ase (Supplementary Figure 4), indicating that the trapping
rate is constant in this range.
To test for unspeciﬁc DNA binding, we incubated a
constant amount of the GFP nanotrap with increasing
volumes of cell lysate from GFP overexpressing
HEK 293T cells followed by incubation with trapping
substrate. The concentration of precipitated GFP
increased linearly with the amount of lysate added. In
contrast, the minor unspeciﬁc binding of substrate was
shown to be independent of the amount of precipitated
protein (Supplementary Figure 5). The unspeciﬁc binding
to the agarose beads was below the detection limit for
DNA coupled ATTO647N (Supplementary Figure 5B
and D) and negligible for DNA coupled ATTO550
(Supplementary Figure 5A and C), when compared with
the values obtained for binding to GFP-Dnmt1 and its
mutant GFP-Dnmt1C1229W. Thus, the minor unspeciﬁc
binding is attributable to the agarose beads rather
than to the protein indicating that diﬀerent amounts of
precipitated GFP fusions can be compared reliably.
The trapping rates were slightly dependent on the
lysate preparation likely reﬂecting the percentage of
active enzyme, but highly reproducible results were
obtained with independent samples from the same exper-
imental setup.
Discrimination of enzymatic activity-dependent trapping
fromDNA binding
To evaluate the possibility to distinguish between DNA
binding and covalent complex formation, the crucial ﬁrst
step of the methyl transfer reaction, we incubated GFP-
Dnmt1 and the catalytic site mutant GFP-Dnmt1C1229W
with DNA binding and trapping substrates and measured
the ﬂuorescence after precipitation (Figure 4A).
Interestingly, wild-type and mutant protein showed simi-
lar speciﬁc DNA-binding activity. However, GFP-Dnmt1
showed a higher trapping than binding rate, whereas
GFP-Dnmt1C1229W did not. The diﬀerence between bind-
ing and trapping rate is due to the accumulation of cova-
lent protein-DNA complexes over time, and thus conﬁrms
previously published results on Dnmt1 and its catalytic
site mutant (7).
The trapping rate obtained for the active methyltrans-
ferase GFP-Dnmt1 after 90min at excess initial substrate
concentration reﬂects almost exclusively covalently bound
DNA substrate. This was demonstrated by an additional
competition step with unlabeled binding substrate to com-
pete with non-covalently bound labeled substrate
(Figure 4B). The maximal trapping rate after this binding
competition step did not change, whereas the maximal
binding rate decreased proportionally. These results
show that the combination of DNA binding and trapping
substrates with non-ﬂuorescent competitors allows the dis-
tinction between DNA binding and enzyme activity
dependent covalent complex formation of DNA
methyltransferases.
Cofactor dependence of covalent complex formation
Covalent complex formation of cytosine methyltrans-
ferases with DNA has been shown to be independent
from the cofactor AdoMet. In the absence of AdoMet,



















































Figure 3. Optimization of trapping assay conditions. (A) Time course
of binding and trapping reaction. GFP-Dnmt1 (25 nM) was incubated
with 100 nM hemimethylated ATTO550 labeled binding (open square)
or trapping substrate (ﬁlled square). The reactions were stopped by
washing after 15, 30, 45, 60, 120 and 240min, respectively. (B)
Dependence of binding and trapping rate on the initial DNA substrate
concentration. GFP-Dnmt1 (20 nM) was incubated with increasing
amounts of hemimethylated ATTO550 labeled binding (open square)
or trapping substrate (ﬁlled square). Binding and trapping rates are
shown for initial substrate concentrations of 0.5, 1, 2.5, 5, 10, 25, 50
and 100 nM.
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instead of methylation at position 5. AdoMet as well as its
analog and competitor S-Adenosyl-L-homocysteine
(AdoHcy) signiﬁcantly bind to the enzyme only after the
DNA substrate is bound (25–27). We tested GFP-Dnmt1
binding and trapping with hemimethylated DNA sub-
strate and compared maximal rates at diﬀerent conditions
(Figure 5). An additional competition step with unlabeled
competitor DNA to compete for non-covalently bound
labeled DNA was included to monitor irreversible cova-
lent complex formation. In accordance with the prior bio-
chemical studies (25–27), we found that GFP-Dnmt1
forms a covalent complex with DNA in the presence
and absence of AdoMet and AdoHcy, albeit at diﬀerent
eﬃciencies. Similarly, this assay could be used for inhibi-
tor studies and to screen for small molecules that prevent
covalent enzyme-DNA complex formation.
Competition assay to directly determine substrate preference
A unique feature of this method is the possibility to com-
pare diﬀerent DNA substrates in direct competition. The
trapping rates of GFP-Dnmt1 with either un- or hemi-
methylated DNA trapping substrate or with both sub-
strates in direct competition clearly showed a preference
for hemimethylated DNA (Figure 6A). This result demon-
strates that substrate preference can be detected in a single
measurement by direct competition. Interestingly, the
preference for hemimethylated DNA was only pro-
nounced in the rate of covalent complex formation (trap-
ping assay) and not in the DNA-binding assay. The direct
competition of un- and hemimethylated DNA-binding
substrates revealed even a slight preference of GFP-
Dnmt1 for unmethylated substrate (Figure 6B). The
substrate preference of GFP-DNMT1 was tested in four
independent experiments and revealed on average about
15-fold higher activity on hemimethylated than on
unmethylated DNA substrate (Figure 6C). These results
are consistent with data obtained with previous biochem-
ical activity assays measuring the transfer of radioactively
labeled methyl groups by puriﬁed Dnmt1 or GFP-Dnmt1
and catalytic site mutants (28–31).
In summary, we present a novel, non-radioactive assay
for fast characterization of DNA methyltransferase activ-
ity and DNA binding. We show that the DNA binding,
substrate speciﬁcity and activity of DNA methyltrans-
ferases fused with GFP can reliably be measured with
this method. The simplicity and versatility of this assay
allows fast and inexpensive screening of enzymes, com-
plexes and mutants. By careful selection of ﬂuorophores
with distinct excitation and emission spectra, multiple ﬂu-
orescent substrates can be analyzed simultaneously in
direct competition. We applied the assay to the mamma-
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Figure 4. Binding and trapping assay with competitors. (A) Binding and trapping assays were performed with GFP-Dnmt1 and GFP-Dnmt1C1229W
and hemimethylated ATTO550 labeled DNA. Shown are the means of maximal binding and trapping rates with standard error bars from three
independent experiments for the GFP control and GFP-Dnmt1 and two independent experiments for GFP-Dnmt1C1229W. (B) Assays with substrates
for binding [B], trapping [T], binding with competitor [BC] and trapping with competitor [TC] were performed with GFP-Dnmt1 as described earlier.
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GFP GFP-Dnmt1
Figure 5. Covalent complex formation in dependence on AdoMet and
AdoHcy. Maximal binding and trapping rate were determined for
GFP-Dnmt1 and hemimethylated ATTO550 labeled DNA substrate
with or without unlabeled competitor DNA. The assay buﬀer was
supplemented with 10 mM AdoMet or AdoHcy as indicated. GFP
was used as negative control.
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substrates containing hemimethylated CpG sites. In addi-
tion, we could show that the active site mutation
(C1229W) abolishes covalent complex formation, but
not DNA binding. The usage of GFP fusion proteins
allows a direct link of biochemical data to cell biological
data on subcellular localization and mobility of the very
same molecule obtained by ﬂuorescence microscopy and
photobleaching experiments. However, endogenous DNA
methyltransferases could analogously be assayed by incu-
bation with ﬂuorescent binding and/or trapping substrates
and subsequent precipitation with speciﬁc antibodies.
Alternatively, samples incubated with ﬂuorescent trapping
substrates could also be separated by SDS–PAGE and
catalytically active methyltransferases could be detected
in gel and identiﬁed by western blot or mass spectrometry.
This assay can easily be adapted for general DNA- and
RNA-binding studies providing a time-saving alternative
to electrophoretic gel shift assays (32).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors thank Ulrich Rothbauer for preparation
of the GFP nanotrap and members of the Leonhardt
group for critical discussions and proofreading of the
manuscript.
FUNDING
This work was supported by grants from the Deutsche
Forschungsgemeinschaft (DFG), the Nanosystem
Initiative Munich (NIM) and the Center for
NanoScience (CeNS) to H.L. C.F. acknowledges support
from the International Max Planck Research School for
Molecular and Cellular Life Sciences (IMPRS-LS) and by
the International Doctorate Program
‘NanoBioTechnology’ of the Elite Network of Bavaria.
Funding for open access charge: the Deutsche
Forschungsgemeinschaft (DFG).
Conﬂict of interest statement. H.L. is a co-founder of
Chromotek.
REFERENCES
1. Goll,M.G. and Bestor,T.H. (2005) Eukaryotic cytosine methyl-
transferases. Annu. Rev. Biochem., 74, 481–514.
2. Hermann,A., Gowher,H. and Jeltsch,A. (2004) Biochemistry and
biology of mammalian DNA methyltransferases. Cell Mol. Life Sci.,
61, 2571–2587.
3. Robertson,K.D. (2005) DNA methylation and human disease. Nat.
Rev. Genet., 6, 597–610.
4. Spada,F., Rothbauer,U., Zolghadr,K., Schermelleh,L. and
Leonhardt,H. (2006) Regulation of DNA methyltransferase 1. Adv.
Enzyme Regul., 46, 224–234.
5. Klimasauskas,S., Kumar,S., Roberts,R.J. and Cheng,X. (1994)
HhaI methyltransferase ﬂips its target base out of the DNA helix.
Cell, 76, 357–369.
6. Cheng,X., Kumar,S., Posfai,J., Pﬂugrath,J.W. and Roberts,R.J.
(1993) Crystal structure of the HhaI DNA methyltransferase com-









































































Hemimethylated substrate (ATTO550) Unmethylated substrate (ATTO647N)
Figure 6. Substrate preference of GFP-Dnmt1. (A) Maximal trapping rates were determined by incubation of constant concentrations of GFP-
Dnmt1 with unmethylated ATTO647N labeled DNA trapping substrate [UT], hemimethylated ATTO550 labeled DNA trapping substrate [HT] or
unmethylated ATTO647N and hemimethylated ATTO550 labeled DNA trapping substrate in competition [UHT]. (B) Maximal binding and trapping
rates for GFP-Dnmt1 are given for incubation with either unmethylated ATTO647N or hemimethylated ATTO550 labeled binding substrate (B), or
unmethylated ATTO647N and hemimethylated ATTO550 labeled trapping substrate [T] in competition. (C) The trapping rates for GFP-Dnmt1 on
unmethylated ATTO647N and hemimethylated ATTO550 labeled trapping substrate in competition were determined in four independent experi-
ments. The value for unmethylated substrate was set to one and the relative rate for hemimethylated substrate was calculated accordingly. Means of
the relative trapping rates are shown with standard error bars. GFP was used as negative control.
PAGE 7 OF 8 Nucleic Acids Research, 2009, Vol. 37, No. 3 e22
 at Universitatsbibliothek M






7. Schermelleh,L., Spada,F., Easwaran,H.P., Zolghadr,K.,
Margot,J.B., Cardoso,M.C. and Leonhardt,H. (2005) Trapped in
action: direct visualization of DNA methyltransferase activity in
living cells. Nat. Methods, 2, 751–756.
8. Kuch,D., Schermelleh,L., Manetto,S., Leonhardt,H. and Carell,T.
(2008) Synthesis of DNA dumbbell based inhibitors for the human
DNA methyltransferase Dnmt1. Angew Chem. Int. Ed. Engl., 47,
1515–1518.
9. Yoo,C.B. and Jones,P.A. (2006) Epigenetic therapy of cancer: past,
present and future. Nat. Rev. Drug Discov., 5, 37–50.
10. Roth,M. and Jeltsch,A. (2000) Biotin-avidin microplate assay for
the quantitative analysis of enzymatic methylation of DNA by
DNA methyltransferases. Biol. Chem., 381, 269–272.
11. Yokochi,T. and Robertson,K.D. (2004) DMB (DNMT-magnetic
beads) assay: measuring DNA methyltransferase activity in vitro.
Methods Mol. Biol., 287, 285–296.
12. Kim,B.Y., Kwon,O.S., Joo,S.A., Park,J.A., Heo,K.Y., Kim,M.S.
and Ahn,J.S. (2004) A column method for determination of DNA
cytosine-C5-methyltransferase activity. Anal. Biochem., 326, 21–24.
13. Hubscher,U., Pedrali-Noy,G., Knust-Kron,B., Doerﬂer,W. and
Spadari,S. (1985) DNA methyltransferases: activity minigel analysis
and determination with DNA covalently bound to a solid matrix.
Anal. Biochem., 150, 442–448.
14. Margot,J.B., Aguirre-Arteta,A.M., Di Giacco,B.V., Pradhan,S.,
Roberts,R.J., Cardoso,M.C. and Leonhardt,H. (2000) Structure and
function of the mouse DNA methyltransferase gene: Dnmt1 shows
a tripartite structure. J. Mol. Biol., 297, 293–300.
15. Woo,Y.H., Rajagopalan,P.T. and Benkovic,S.J. (2005) A non-
radioactive DNA methyltransferase assay adaptable to high-
throughput screening. Anal. Biochem., 340, 336–340.
16. Tamura,T., Kataoka,A., Shu,L.Y., Ashida,A., Tanaka,H. and
Inagaki,K. (2002) An in vitro screening method for DNA cytosine-
C5-methylase inhibitor. Nat. Prod. Lett., 16, 25–27.
17. Yamamoto,T., Nagasaka,T., Notohara,K., Sasamoto,H.,
Murakami,J., Tanaka,N. and Matsubara,N. (2004) Methylation
assay by nucleotide incorporation: a quantitative assay for regional
CpG methylation density. Biotechniques, 36, 846–850, 852, 854.
18. Humeny,A., Beck,C., Becker,C.M. and Jeltsch,A. (2003) Detection
and analysis of enzymatic DNA methylation of oligonucleotide
substrates by matrix-assisted laser desorption ionization time-
of-ﬂight mass spectrometry. Anal. Biochem., 313, 160–166.
19. Salyan,M.E., Pedicord,D.L., Bergeron,L., Mintier,G.A.,
Hunihan,L., Kuit,K., Balanda,L.A., Robertson,B.J., Feder,J.N.,
Westphal,R. et al. (2006) A general liquid chromatography/mass
spectroscopy-based assay for detection and quantitation of
methyltransferase activity. Anal. Biochem., 349, 112–117.
20. Boussif,O., Lezoualc’h,F., Zanta,M.A., Mergny,M.D.,
Scherman,D., Demeneix,B. and Behr,J.P. (1995) A versatile vector
for gene and oligonucleotide transfer into cells in culture and
in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA, 92,
7297–7301.
21. Rothbauer,U., Zolghadr,K., Muyldermans,S., Schepers,A.,
Cardoso,M.C. and Leonhardt,H. (2007) A versatile nanotrap for
biochemical and functional studies with ﬂuorescent fusion proteins.
Mol. Cell Proteomics., 7, 282–289.
22. Laemmli,U.K., Beguin,F. and Gujer-Kellenberger,G. (1970) A
factor preventing the major head protein of bacteriophage T4 from
random aggregation. J. Mol. Biol., 47, 69–85.
23. Easwaran,H.P., Schermelleh,L., Leonhardt,H. and Cardoso,M.C.
(2004) Replication-independent chromatin loading of Dnmt1 during
G2 and M phases. EMBO Rep., 5, 1181–1186.
24. Schermelleh,L., Haemmer,A., Spada,F., Rosing,N., Meilinger,D.,
Rothbauer,U., Cardoso,M.C. and Leonhardt,H. (2007) Dynamics
of Dnmt1 interaction with the replication machinery and its role in
postreplicative maintenance of DNA methylation. Nucleic Acids
Res., 35, 4301–4312.
25. Svedruzic,Z.M. and Reich,N.O. (2004) The mechanism of target
base attack in DNA cytosine carbon 5 methylation. Biochemistry,
43, 11460–11473.
26. Svedruzic,Z.M. and Reich,N.O. (2005) DNA cytosine C5 methyl-
transferase Dnmt1: catalysis-dependent release of allosteric inhibi-
tion. Biochemistry, 44, 9472–9485.
27. Wu,J.C. and Santi,D.V. (1987) Kinetic and catalytic mechanism of
HhaI methyltransferase. J. Biol. Chem., 262, 4778–4786.
28. Jeltsch,A. (2006) On the enzymatic properties of Dnmt1: speciﬁcity,
processivity, mechanism of linear diﬀusion and allosteric regulation
of the enzyme. Epigenetics, 1, 63–66.
29. Pradhan,M., Esteve,P.O., Chin,H.G., Samaranayke,M., Kim,G.D.
and Pradhan,S. (2008) CXXC domain of human DNMT1 is
essential for enzymatic activity. Biochemistry, 47, 10000–10009.
30. Pradhan,S., Bacolla,A., Wells,R.D. and Roberts,R.J. (1999)
Recombinant human DNA (cytosine-5) methyltransferase. I.
Expression, puriﬁcation, and comparison of de novo and mainte-
nance methylation. J. Biol. Chem., 274, 33002–33010.
31. Hermann,A., Goyal,R. and Jeltsch,A. (2004) The Dnmt1 DNA-
(cytosine-C5)-methyltransferase methylates DNA processively with
high preference for hemimethylated target sites. J. Biol. Chem., 279,
48350–48359.
32. Man,T.K. and Stormo,G.D. (2001) Non-independence of Mnt
repressor-operator interaction determined by a new quantitative
multiple ﬂuorescence relative aﬃnity (QuMFRA) assay. Nucleic
Acids Res., 29, 2471–2478.
e22 Nucleic Acids Research, 2009, Vol. 37, No. 3 PAGE 8 OF 8
 at Universitatsbibliothek M






  Frauer and Leonhardt - Supplementary Information 
1 
 
A versatile non-radioactive assay for DNA methyltransferase activity and 
DNA binding 
 
Carina Frauer and Heinrich Leonhardt* 
 
Ludwig Maximilians University Munich, Department of Biology, Center for Integrated 
Protein Science Munich (CIPSM), 82152 Planegg-Martinsried, Germany. 
 
*Corresponding author: e-mail: h.leonhardt@lmu.de; Fax +49 89 2180-74236; Tel. +49 89 
2180-74232. 
 









Supplementary Figure 1. DNA substrate preparation. (A) Experimental strategy for preparation of different 
DNA substrates from a small set of oligonucleotides. (B) Outline of the structure of the 15 possible different 
DNA substrates. 
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Supplementary Figure 2. Fitting of DNA binding data for GFP-Dnmt1 and hemimethylated ATTO550 labeled 
binding substrate in dependence on time and initial DNA substrate concentration. (A) The data of DNA bound 
over time were fitted using the equation  
)1(max
kxeYy −−⋅= , 
resulting in Ymax= 2.59 +/- 0.06 nM and an observed rate constant of k=0.034 +/-0.002 min-1 (R²=0.983, 
SigmaPlot). 




⋅= max , 
resulting in Ymax= 2.58 +/- 0.84 nM and a dissociation constant Kd= 94.63 +/- 52.77 nM (R²=0.956, SigmaPlot). 
The data for this analysis were taken from Figure 3. 
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Supplementary Figure 3. Determination of GFP fluorescence upon GBP binding. GFP 
(1 µM) was incubated with an increasing concentration of GBP (0, 0.05, 0.1, 0.3, 0.5, 0.8, 1, 1.2 and 1.5 µM) 
and the fluorescence signal was detected with a 485±8 nm excitation filter and a 520±17 nm emission filter. The 
fluorescence signal of GFP alone was set to 1. The mean relative fluorescence signal with standard deviation 
bars of three measurements was plotted against the amount of GBP added. The results show that GBP binding 


































Supplementary Figure 4. Linearity of the trapping assay. Trapping was performed with an increasing 
concentration of GFP-Dnmt1 at a concentration of 100 nM hemimethylated ATTO550 labeled trapping 
substrate. The concentration of DNA that was pulled down with the beads was plotted against the concentration 










Supplementary Figure 5. Determination of unspecific DNA binding. Increasing amounts of GFP lysate were 
added to equal aliquots of beads and incubated with ATTO550 (A, C) or ATTO647N labeled DNA substrate (B, 
D). In (A) and (B) the concentration of precipitated GFP was plotted against the volume of lysate added to the 
beads. (C) and (D) show the concentration of GFP and DNA precipitated relative to the volume of lysate added. 





























T E C H N I C A L  R E P O R T S
Protein conformation is critically linked to function and 
often controlled by interactions with regulatory factors. Here 
we report the selection of camelid-derived single-domain 
antibodies (nanobodies) that modulate the conformation and 
spectral properties of the green fluorescent protein (GFP). One 
nanobody could reversibly reduce GFP fluorescence by a factor 
of 5, whereas its displacement by a second nanobody caused an 
increase by a factor of 10. Structural analysis of GFP–nanobody  
complexes revealed that the two nanobodies induce subtle 
opposing changes in the chromophore environment, leading to 
altered absorption properties. Unlike conventional antibodies, 
the small, stable nanobodies are functional in living cells. 
Nanobody-induced changes were detected by ratio imaging 
and used to monitor protein expression and subcellular 
localization as well as translocation events such as the 
tamoxifen-induced nuclear localization of estrogen receptor. 
This work demonstrates that protein conformations can be 
manipulated and studied with nanobodies in living cells.
Green fluorescent protein (GFP) is a barrel-shaped protein with a 
central p-hydroxybenzylidene-imidazolidone chromophore. The for-
mation of the chromophore results from an oxidative backbone cycliza-
tion involving residues Ser65, Tyr66 and Gly67 (refs. 1–3). The original 
wild-type GFP (wtGFP) is characterized by a dual-peak excitation 
spectrum with a major absorption maximum at 395 nm and a minor 
one at 477 nm. Excitation at either wavelength results in the emission 
of green fluorescence at ~507 nm. This dual absorption of GFP stems 
from the existence of two interconvertible alternative states of the 
chromophore. The neutral phenol state of the chromophore absorbs 
at 395 nm, whereas the deprotonated phenolate anion absorbs at 
477 nm4. During the past decade, the fluorescence properties of GFP 
have been successfully modified by mutagenesis5–7. For example, the 
most widely used mutant, enhanced GFP (eGFP), features increased 
brightness, improved photostability and a single excitation peak at 
488–490 nm5. Additional types of bioimaging applications became 
possible with the photoactivatable (paGFP) variant8. Recently, new 
permuted GFP derivates were described as molecular sensors to moni-
tor the presence of calcium, which induces structural rearrangements 
that block solvent access to the chromophore9,10.
Here we investigated whether spectral properties of fluorescent 
 proteins can be modulated with antibody derivatives. For this purpose, 
we tested so-called ‘nanobodies’, which are small, antigen-binding, 
single-domain polypeptides derived from the variable heavy chain 
(VHH) of the heavy chain–only antibodies of camelids11. Nanobodies 
are potent alternatives to conventional antibodies, with enhanced 
 stability and reduced size but similar antigen-binding characteristics12. 
Applications described thus far include targeting and tracing of anti-
gens in live cells and targeted modulation of enzymes as well as their 
usage as immobilized nanotraps to precipitate protein complexes 
in vivo and in vitro13–17.
RESULTS
Generation of GFP-binding nanobodies
To isolate and characterize GFP-binding nanobodies, we generated a 
phagemid library by cloning the VHH repertoire from the heavy-chain 
antibodies of GFP-immunized camelids. Next, we displayed the VHH 
repertoire on phage particles and selected individual GFP-specific 
binders after panning followed by a solid-phase ELISA screening. 
Seven unique GFP-specific binders were determined by DNA sequence 
analysis of the clones. We termed the resulting proteins GFP-binding 
proteins (GBPs) 1–7. The GBPs were cloned with a C-terminal hexa-
histidine (His6) tag, expressed in Escherichia coli and purified by 
immobilized metal affinity chromatography (IMAC). All GBPs coelute 
with wtGFP in an apparent 1:1 complex in gel filtration chromato-
graphy, verifying their stable binding to wtGFP (data not shown).
Nanobodies affecting GFP fluorescence intensity
To screen for nanobodies that alter GFP fluorescence properties, 
we added increasing amounts of GBP1–7 to wtGFP and measured 
the fluorescence intensity. We identified two nanobodies, GBP1 and 
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GBP4, that had a pronounced effect on the fluorescence emission 
of wtGFP (Fig. 1a and Supplementary Fig. 1a). Whereas binding of 
GBP1 leads to a fourfold fluorescence enhancement, binding of GBP4 
reduces the fluorescence by a factor of 5. Overall, there is a remarkable 
20-fold difference in fluorescence intensity between the two GFP–
nanobody complexes under the conditions used. According to their 
observed impact on GFP fluorescence, we termed GBP1 and GBP4 
‘Enhancer’ and ‘Minimizer’, respectively. The augmented fluorescence 
of the GFP–Enhancer complex is comparable to the improved spectral 
properties of eGFP. This raised the question of whether Enhancer 
might be able to further increase the optimized fluorescence of eGFP. 
Indeed, binding of Enhancer to recombinantly purified eGFP resulted 
in an additional fluorescence increase of about 1.5-fold. In contrast, 
binding of Minimizer reduced the fluorescence intensity of eGFP 
by a factor of 8 (Supplementary Fig. 1b,c). A comparable fluores-
cence modulation was also observed after addition of Enhancer or 
Minimizer to soluble cell extract derived from human embryonic 
kidney (HEK) 293T cells expressing eGFP (Supplementary Fig. 1c). 
To investigate whether selected nanobodies recognize different 
epitopes, we performed sandwich-binding assays. Additive binding 
to already-constituted GFP–Enhancer complexes could be detected 
for GBP2, GBP5, GBP6 and GBP7 but not for Minimizer, suggesting 
that Enhancer and Minimizer compete for overlapping epitopes of 
GFP (Supplementary Fig. 2a).
Based on the opposite effects of Enhancer and Minimizer binding, 
we investigated the wtGFP fluorescence modulation in the presence 
of both nanobodies (Fig. 1b,c). Notably, after a primary addition of 
Enhancer, wtGFP fluorescence increases and is only slightly reduced 
by the consecutive addition of Minimizer (Fig. 1c). In contrast, when 
Minimizer is added first, the reduction of fluorescence can be com-
pletely reversed, and fluorescence further enhanced, by subsequent 
addition of Enhancer (Fig. 1c). Although the ability of Enhancer 
to displace Minimizer at equimolar concentrations suggests that 
Enhancer has a higher affinity for wtGFP, no substantial difference 
in binding constants (Kd) was detected (Supplementary Fig. 2b and 
Supplementary Table 1).
Structure of GFP–Enhancer and GFP–Minimizer complexes
To elucidate the molecular mechanism underlying the observed 
fluorescence modulation, we determined crystal structures of the 
GFP–Enhancer and GFP–Minimizer complexes to 2.15 and 1.6 Å 
resolution, respectively (Table 1). Both nanobodies recognize two dif-
ferent, slightly overlapping epitopes on the GFP surface (Fig. 2a,b). 
Thus, the observed competition for binding seems to result from 
a steric clash between the nanobodies. Enhancer binds wtGFP in a 
frontwise manner at an exposed loop region between GFP β-strands 
6 and 7 as well as parts of β-strand 8, making specific contacts with all 
three complementarity-determining regions (CDR) of the nanobody 
(Fig. 2a). Previous structural studies of nanobodies have shown that 
CDR3 normally folds over the framework 2 region, which in the case 
of classical antibodies binds to the variable domain of the light chain 
(VL)18. In contrast, the extremely short CDR3 of Enhancer is stretched 
out, thereby making the framework 2 region accessible to solvent in the 
antigen-free form. Unexpectedly, the entire framework 2 area participates 
in GFP recognition, in contrast to the structure of classical antibodies 
where the framework 2 area would contact the VL domain. The major-
ity of the specific contacts are formed between CDR3 and GFP, whereas 
CDR1 and 2 remain exposed to the solvent. Notably, the interaction 
between GFP and Enhancer is predominantly electrostatic, spanning an 
interface of 672 Å2 (Supplementary Table 2). An additional nonpolar 
contact is mediated by Phe98Enhancer, which binds a hydrophobic surface 
patch on GFP formed by Ala206GFP, Leu221GFP and Phe223GFP.
In contrast, the Minimizer nanobody has its CDR3 folded over the 
framework 2 region and binds wtGFP in a sideways orientation, using 
its elongated CDR3 to target β-strands 6 and 7 of GFP (Fig. 2c). The 
interaction with GFP is quite remarkable, since the nanobody targets 
the rigid and flat surface rather than the more flexible and easily 
 accessible loops at the top and the bottom of the β-can. In comparison 
to Enhancer, Minimizer occupies a smaller surface area (652 Å2) on 
GFP and the overall number of contacts is smaller (Supplementary 
Table 3). This observation is in line with its ready displacement by 
Enhancer in the competition assay (Fig. 1c). However, it is difficult 
Figure 1 Identification of nanobodies modulating the fluorescence of 
GFP. (a) Fluorescence in vitro binding assay. Titration of seven unique GFP 
binding proteins (GBP1–7) from 0–50 nM on 50 nM purified wtGFP. The 
fluorescence signal intensity of wtGFP was quantified using a laser scanner. 
(b) Minimizer can be displaced by Enhancer but not vice versa. Upper 
row, GFP was either mock incubated or incubated with equimolar amounts 
of Enhancer, or Enhancer was added followed immediately (5–15 s) by 
equimolar amounts of Minimizer. Lower row, same experimental setup as 
above but with Minimizer being added first. GFP emission was detected as 
described for a. (c) Quantification of GFP fluorescence as shown in b. The 
order of addition of Enhancer or Minimizer is indicated by numbers 1 and 2.  
Means and s.d. (error bars) of three independent experiments are shown.
GBP1
(enhancer)
















































Table 1 Data collection and refinement statistics
SeMet–GFP–Enhancer GFP–Minimizer
Data collection
Space group P4222 P212121
Cell dimensions
 a, b, c (Å) 160.5, 160.5, 78.8 50.8, 81.6, 94.5
Peak
Wavelength (Å) 0.9793 0.98137
Resolution (Å) 2.15 1.5
Rsym 4.6 (45.4)a 5.7 (39.1)
I / σI 14.95 (2.25) 16.91 (2.84)
Completeness (%) 99.3 (98.9) 97.5 (86.3)
Redundancy 3.13b 3.85
Refinement
Resolution (Å) 46.00-2.15 47.00-1.61
No. reflections 56,271 49,989
Rwork/Rfree 21.3/25.5 16.1/19.4
No. atoms
 Protein 5,385 2,818
 Water 407 685
B-factors
 Protein (Å2) 46.5 13.7
 Water (Å2) 48.4 30.1
R.m.s. deviations
 Bond lengths (Å) 0.008 0.005
 Bond angles (°) 1.14 1.04
aThe structures of SeMet–GFP–Enhancer and of native GFP–Minimizer were determined with 
one crystal each. Values in parentheses are for highest-resolution shell. bFor SeMet–GFP– 
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to quantitatively judge binding strengths from the structurally 
observed number of contacts or buried surface areas.
Induced rearrangements in the GFP chromophore environment
In general, association of the nanobodies has no substantial global influ-
ence on the overall fold of GFP. Unbound GFP (PDB 1EMB (ref. 4)) 
has r.m.s. deviations of 0.391 Å (Cα atoms) and 0.359 Å (Cα atoms) 
from GFP in complex with Enhancer and Minimizer, respectively. From 
previous structural studies of GFP, however, it is well established that 
slight perturbations in the chromophore environment can have vast 
effects on its fluorescence properties4. Indeed, a comparison of the GFP 
nanobody structures with previously published GFP structures reveals 
that the GFP–Enhancer complex harbors the deprotonated, negatively 
charged state of the GFP chromophore, which has been described for 
the mutant GFPS65T (ref. 4) (Fig. 2d). Binding of Enhancer induces 
slight structural shifts in the loop region from Glu142GFP to His148GFP 
and fixes Arg168GFP in close proximity to His148GFP. The conforma-
tion of the Arg168GFP side chain is stabilized by direct contacts with 
Enhancer residues Tyr37Enhancer and Glu101Enhancer (nanobody residues 
numbered as previously described19). These structural rearrangements 
bring the proton acceptor His148GFP into very close proximity to the 
hydroxyl group of the GFP chromophore (distance 2.7 Å, compared to 
2.8 Å for GFPS65T and 3.4 Å for wtGFP). Thus, it is likely that binding of 
Enhancer facilitates improved proton extraction from the chromophore 
hydroxyl by His148GFP, thereby stabilizing the phenolate anion 
of the chromophore and enhancing the fluorescence intensity. In 
contrast, the chromophore environment of the GFP–Minimizer 
complex is considerably different and shows similarities to the situ-
ation present in wtGFP4. Notably, Arg168GFP is rather flexible in 
comparison to the Enhancer complex: we could trace two alterna-
tive conformations of its guanidine group in the electron density. 
In one of the conformations, Arg168GFP is tilted away from His148GFP 
and instead makes specific contacts with the backbone carbonyl of 
Leu100kMinimizer (following the Kabat numbering19; the 15 residues 
corresponding to this position in Minimizer were labeled a-o). This 
 nanobody-induced conformational change reduces the electrostatic 
forces exerted on His148GFP, which is pulled back from the hydroxyl 
group of the chromophore and positioned with 3.5-Å distance (wtGFP: 
3.4 Å) (Fig. 2b), too far to efficiently stabilize the phenolate anion. 
Instead, binding of Minimizer likely stabilizes an arrangement of 
the chromophore’s surrounding environment that favors the neutral 
phenol state of the chromophore. In support of this model, binding of 
Enhancer to eGFP—where the phenolate anion state is stabilized by an 
engineered mutation—leads to an increase by a factor of 1.5 compared 
to a factor of 5 for wtGFP for wtGFP, whereas the fluorescence intensity 
is suppressed by Minimizer binding by a factor of 8 for eGFP compared 
to a factor of 4 for wtGFP. In summary, these two nanobodies appear to 
recognize and thermodynamically stabilize two conformational states 
of GFP, which affect the protonation state and thereby the spectral 
properties of the chromophore.
Enhancer and Minimizer modulate spectral properties of GFP
To directly test our structure-derived hypothesis that the interactions 
of the two nanobodies stabilize either the neutral or the ionized state of 
the chromophore, we analyzed the fluorescence absorption spectra of 
GFP in complex with either Enhancer or Minimizer (Fig. 3a,b). 
In support of our model, Enhancer increased absorption at 
475 nm while reducing it at 395 nm for both wtGFP and eGFP. 
Minimizer modulated the absorption in exactly the opposite man-
ner, reducing absorption at 475 nm and increasing it at 395 nm. 
We did not observe substantial changes in fluorescence lifetime 























































Figure 2 Structures of the GFP–nanobody complexes. (a–d) Enhancer (a; light blue ribbon model) and Minimizer (c) (orange ribbon model) recognize two 
different nonlinear epitopes on the surface of the GFP β-can (green ribbon model). The insets in a and c show details of the binding sites with selected 
residues and the GFP chromophore (Cro66GFP) highlighted as sticks. The chromophore environments for the GFP–Enhancer (b) and GFP–Minimizer 
complexes (d), respectively, are superimposed with 2Fo − Fc density maps (contoured at 1.0σ). Two alternative conformations of R168GFP are marked 
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Therefore, the fluorescence modulation upon nanobody binding 
is likely due to a change in the absorption efficiency at different 
wavelengths, which correlates with the magnitude of fluores-
cence emission and can be attributed to the protonation state of 
the chromophore.
Modulation of spectral properties of GFP in living cells
We next tested whether the nanobody-induced fluorescence modu-
lation observed in vitro also occurs in living cells. To this end, we 
 transfected human embryonic kidney (HEK) 293T cells with expres-
sion vectors encoding wtGFP or eGFP in combination with con-
structs encoding Enhancer, Minimizer or a control nanobody fused to 
 monomeric red fluorescent protein (mRFP). Two days after transfec-
tion, we performed combined excitation and emission scans of GFP 
fluorescence intensities in living cells (Fig. 4a,b and Supplementary 
Figs. 3 and 4). Indeed, both nanobodies induced similar spectral 
changes in wtGFP and eGFP fluorescence, which demonstrates that 
Enhancer as well as Minimizer can effectively modulate GFP fluores-
cence in living cells. To obtain a concentration-independent measure 
of Enhancer or Minimizer binding and test whether subcellular differ-
ences can be detected, we determined the induced shift of GFP absorp-
tion maxima from 405 nm to 488 nm by ratio imaging. We tethered 
the Enhancer to the nuclear lamina by transfecting HeLa cells with an 
expression construct coding for an Enhancer–lamin B1 fusion. This 
fusion protein is incorporated into the nuclear lamina, generating an 
intranuclear binding site for GFP. After coexpressing wtGFP in excess, 
we acquired images with excitations at 405 nm and at 488 nm to detect 
relative differences in GFP fluorescence intensities at the nuclear 
lamina due to binding to locally immobilized Enhancer–lamin B1 
fusion protein. Although GFP was bound and enriched at the nuclear 
lamina, this structure was barely detectable after excitation at 405 nm. 
However, excitation at 488 nm led to an increased signal at the nuclear 
 lamina (Fig. 4c). The presence of Enhancer at this distinct subcellular 
structure could be visualized by calculating the ratio between pixel 
Figure 3 Nanobody-induced modulation of GFP spectral properties. 
Absorption spectra of the unbound (gray, solid line), Minimizer-bound 
(gray, dashed line) or Enhancer-bound (black, dashed line) wtGFP (a) 
or eGFP (b). The absorption at 395 nm corresponds to the protonated 
chromophore and absorption at 475 nm to the anionic chromophore  
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Figure 4 Nanobodies modulate GFP fluorescence in living cells.  
(a,b) Binding of Minimizer and Enhancer shifts excitation and  
emission spectra of both wtGFP (a) and eGFP (b) in living cells.  
(c) Ratio imaging. Shown are cells expressing wtGFP, which is 
dispersedly distributed. The topmost cell coexpresses Enhancer  
fused to lamin B1 (GBP1–lamin B1). Whereas only a weak signal  
at the nuclear lamina is detectable with excitation at 405 nm, the 
relative and absolute signal increased with excitation at 488 nm. 
Bound and unbound GFP can be distinguished independently by  
matrix algebra calculating the ratio between the signal intensities obtained with excitation at 488 nm and 405 nm for every pixel.  
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intensities obtained at 405 nm and at 488 nm and displaying the ratio 
images in false color, thereby distinguishing bound and unbound GFP 
(Fig. 4c). This example illustrates how fluorescence-modulating 
nanobodies can provide novel optical readouts.
Tracking of subcellular translocation processes
Finally, we tested whether the fluorescence-enhancement effect 
induced by binding of GFP to Enhancer localized in a defined subcel-
lular compartment could be used to track subcellular translocation 
events in a high-throughput approach. As an example, we used the 
inducible translocation of the human estrogen receptor. Hormone 
binding leads to a conformational change in the receptor that results in 
its dissociation from chaperone proteins and ultimately in its binding 
as a homodimer to cognate sites in steroid-responsive genes20. This 
subcellular trafficking event can be induced by the synthetic steroid 
hormone tamoxifen and followed with a GFP-labeled receptor and 
high-resolution fluorescence microscopy21. Because this procedure is 
based on single-cell imaging, it is poorly suited for high-throughput 
analyses. We generated a mammalian (HeLa-Kyoto) cell line that stably 
expresses nuclear-localized Enhancer fused to mRFP (nls-Enhancer). 
As described previously, GFP nanobodies can specifically recognize 
and bind to their respective epitopes in various subcellular compart-
ments in living cells16. The cellular expression of the nanobodies has 
no obvious cytotoxic effect, as no differences in cell-based prolifera-
tion analysis of the nls-Enhancer–encoding cell line compared to the 
parental cell line could be detected (data not shown). We used the 
newly constructed cell line to transiently coexpress the steroid-binding 
domain of the human estrogen receptor (ER286–595) fused to wtGFP 
(GFP-ER286–595). According to our assay, translocation of this con-
struct from the cytoplasm to the nucleus should be detectable by an 
increase of the GFP fluorescence intensity upon binding of GFP to the 
nls-Enhancer in the nucleus (Fig. 5a). Using fluorescence microscopy, 
we confirmed that both GFP-ER286–595 and nls-Enhancer are almost 
exclusively localized in their designated compartments. Upon addition 
of tamoxifen to the medium, GFP-ER286–595 translocated from the 
cytoplasm into the nucleus (Fig. 5b). After entering the nucleus, GFP 
becomes accessible for binding to nls-Enhancer, which results in a 
three-fold increase in GFP fluorescence intensity (Fig. 5c). Notably, 
the translocation event can be followed in a statistically significant 
number of cells by scanning the fluorescence intensities of living cells 
in multiwell formats. The fluorescence enhancement is directly cor-
related with translocation efficiency. By quantifying the fluorescence 
intensities, we detected a clear dose dependence of translocation on 
addition of increasing amounts of tamoxifen (Fig. 5d). Because our 
assay is based on living cells, we were able to follow the dynamics 
of the translocation event over time. These data demonstrate that 
fluorescence-modulating nanobodies are potent tools for studying 
subcellular relocalization, a key process of signal transduction, in real 
time and in a quantitative manner.
DISCUSSION
Alternative protein conformations can be accurately analyzed with a 
variety of biophysical methods in vitro but are notoriously difficult to 
study in vivo. We therefore tested whether recombinantly expressed 
nanobodies could discriminate between alternative protein confor-
mations in living cells. As a target we chose GFP, as it provides a 
direct optical readout. Out of several GFP-specific nanobodies, we 
identified two, Minimizer and Enhancer, that shift the absorption 
of GFP in opposite directions. The corresponding crystal structures 
clearly show the structural changes induced by these two nanobodies 
and explain the functional consequences on GFP fluorescence.
This ability to manipulate protein conformation in living cells 
enables a number of new applications. As a first example, we use 
the modulation of GFP fluorescence for new bioimaging applica-
tions. The expression and subcellular distribution of Minimizer and 
Enhancer can be detected by ratio imaging, allowing the distinction of 
bound and unbound GFP. This indirect optical readout can be used as 
reporter for gene expression, virus infection and translocation assays. 
The nanobody-mediated enhancement of GFP fluorescence should 
also improve the tracing of low- to high-abundance GFP fusion 
 proteins in live cells as well as ultrahigh resolution microscopy. We 
have recently demonstrated that cellular structures can be imaged at 
subdiffraction resolution by three-dimensional structured illumina-
tion microscopy (3D-SIM)22. To obtain ultrahigh resolution, however, 
Figure 5 Nucleocytoplasmic translocation 
detected by nanobody-mediated fluorescence 
enhancement. (a) Schematic outline  
of the translocation assay: GFP-ER286–595  
and nls-Enhancer are present in separate 
compartments, the cytoplasm and the  
nucleus. Addition of tamoxifen induces 
translocation of GFP-ER286–595 to the  
nucleus, where it binds to nls-Enhancer,  
leading to an increase of the fluorescence 
intensity. (b) Representative cells were  
analyzed by fluorescence microscopy (scale bar:  
10 µM). Untreated cells (−Tamoxifen, upper 
row) show an almost exclusive distribution of 
GFP-ER286–595 to the cytoplasm, whereas the 
nls-Enhancer is localized in the nucleus. After 
addition of tamoxifen (+Tamoxifen, lower row) 
GFP-ER286–595 colocalizes with nls-Enhancer  
in the nucleus. (c,d) Nucleocytoplasmic 
translocation was measured in a plate  
format in living cells by detection of GFP  
fluorescence intensity. (c) After translocation  
of GFP-ER286–595 into the nucleus upon 
addition of tamoxifen, binding of nls-Enhancer 
leads to a three-fold increase in fluorescence intensity. (d) Detection of the dose-dependent translocation efficiency after addition of increasing 
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this new microscopy technology requires hundreds of images and thus 
mostly relies on bright synthetic chromophores. The signals obtained 
with physiological levels of GFP-labeled proteins are barely sufficient, 
and in particular, in vivo application of structured illumination23 
would greatly benefit from any fluorescence enhancement by a 
coexpressed Enhancer nanobody.
Translocation events have a central role in signal transduction and are 
therefore a prime target for drug screenings. Presently, translocations are 
monitored either with reporter gene assays, which take at least a day, or 
by microscopy, which requires costly and technically demanding high-
throughput image acquisition and analysis tools. Our nanobody-based 
assay can be performed with a simple plate reader and measures trans-
location as fluorescence enhancement after drug addition. We demon-
strate the feasibility of this assay principle using the tamoxifen-induced 
nuclear translocation of the estrogen receptor. Aside from steroid 
hormone receptors, notch-type signaling in differentiation and cancer 
could also be directly monitored in cell-based drug screens.
This work outlines new experimental possibilities as it exemplifies 
applications of nanobodies ranging from affinity purification and 
crystallization of proteins to the manipulation of conformational 
states and protein function in vitro and in living cells. In particular, 
the detection and manipulation of alternative protein conformations 
in living cells enable novel types of studies in molecular and cellular 
biology. The functional relevance of alternative protein conforma-
tions is clearly illustrated by the prion protein. Here we outline and 
demonstrate an experimental strategy to address the role of alterna-
tive protein conformations in cellular systems. Our results show that 
nanobodies can be generated to recognize, induce and stabilize alter-
native protein conformations and thus enable studies of functional 
properties of specific protein conformations in vitro and in vivo.
METHODS
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Coordinates and structure 
 factors for the GFP-Enhancer and GFP-Minimizer complex were 
deposited with accession codes 3K1K and 3G9A, respectively.
Note: Supplementary information is available on the Nature Structural & Molecular 
Biology website.
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ONLINE METHODS
Protein production and purification. We carried out expression of nanobodies 
and GFP as described previously15,24. We produced selenomethionine (SeMet)-
containing GFP in E. coli B834 (Rosetta (DE3)) grown in minimal medium 
containing 50 mg l−1 l-selenomethionine. For complex purification of wtGFP-
Enhancer and wtGFP-Minimizer, we purified nanobodies by prebinding them 
via their C-terminal His6 tag to a HiTrap-column (GE Healthcare Life Sciences). 
Subsequently, we isolated wtGFP from crude cell extracts by binding to the pre-
charged column. After elution by increasing concentration of imidazole, we sepa-
rated complexes from unbound protein by gel filtration chromatography using 
a Superdex 200 column (GE Healthcare).
Fluorescence spectroscopy. We performed fluorescence assays either by scan-
ning a 96-well microplate (Nunc) on a Typhoon Trio (GE Healthcare; exGFP, 
488 nm, em, 520 ± 20 nm) or by using a monochromator-based microplate reader 
(Infinite M1000, Tecan; exwtGFP, 395 nm, exeGFP, 488 nm, em, 507 ± 10 nm). 
We recorded fluorescence excitation spectra with a FluoroMax-P fluorimeter 
(HORIBA Jobin Yvon). Typically, a 0.5-µM protein in PBS was measured in a 
1-ml quartz cuvette (ex./em. bandpass, 5 nm). Samples were excited at 395 nm 
and 475 nm, and excitation spectra were recorded in the range from 480–600 nm. 
We recorded fluorescence absorption spectra on a UV/Vis Spectrophotometer 
(Beckman Coulter). Absorptions of 0.5-µM GFP alone or 0.5-M GFP–Enhancer 
and –Minimizer complexes were detected with continuous excitation steps 
(1 nm) from 250 nm–700 nm.
Crystallization and data collection. We crystallized purified GFP–nanobody 
complexes by hanging-drop vapor diffusion by mixing 1 µl of protein solution at 
10 mg ml−1 concentration with 1 µl of the reservoir solution (SeMet-GFP–Enhancer: 
60% (v/v) 2-methyl-2,4-pentanediol (MPD), 100 mM sodium acetate pH 4.6, 
10 mM CaCl2; GFP–Minimizer: 100 mM 2-(N-morpholino)ethanesulfonic 
acid, pH 6.5, 30% (v/v) PEG8000, 15% (v/v) glycerol). Initial crystallographic 
data obtained from native GFP–Enhancer (data not shown) suffered from crystal 
twinning, and coordinate refinement after molecular replacement did not result 
in acceptable R values. Crystals of SeMet-GFP–Enhancer, originally grown to 
obtain experimental phases by anomalous dispersion, grew in a different space 
group without twinning. After flash freezing the crystals, we recorded single-
wavelength diffraction data at the K absorption edge of selenium (λ = 0.9793 Å) 
at the X06SA beamline (Swiss Light Source) to 2.15 Å. GFP–Minimizer crystals 
were flash frozen in liquid nitrogen. Data collection was performed at the beam-
line ID29 (λ = 0.98137 Å) at the European Synchrotron Radiation Facility to a 
resolution of 1.6 Å.
Structure determination. We processed diffraction data of both complexes 
with XDS25. In the case of the GFP–Enhancer structure, we located three sele-
nium sites per complex using autoSHARP (Global Phasing). Single-wavelength 
anomalous dispersion phasing and solvent flipping yielded an interpretable 
experimental electron density map. We built models for GFP and Enhancer 
with COOT26 and refined them with PHENIX27, using overall anisotropic 
B-factors and bulk solvent corrections, individual B-factor refinement, simu-
lated annealing, and crystallographic and positional refinement. We deter-
mined the GFP–Minimizer structure by molecular replacement with PHASER 
using an individual GFP and a nanobody polypeptide chain from the previ-
ously determined GFP–Enhancer structure as independent search models. 
We manually altered and refined the replacement model with COOT using 
similar procedures as described for the GFP–Enhancer structure. All structure 
figures were prepared using the program PyMol (http://www.pymol.org/). Data 
collection and model statistics are summarized in Table 1.
Spectral analysis in living cells. We detected the overall fluorescence intensities 
of GFP and expression levels of mRFP fusions in HEK293T cells by fluorescence 
spectroscopy on a microplate reader (exGFP, 490 ± 5 nm, emGFP, 511 ± 5 nm, 
exmRFP, 586 ± 5 nm, emmRFP, 608 ± 5 nm). For spectral analysis we scanned the 
cells in intervals of 5 nm for excitation from 300–500 nm and for emission from 
500–580 nm. To quantify and normalize the data to the relative expression levels 
of GFP, we lysed remaining cells and performed immunoblot analysis using a 
GFP antibody (Roche). Preparation of cells and calculations of GFP fluorescence 
values were performed as described in Supplementary Methods.
Ratio imaging. We recorded cells expressing wtGFP and the Enhancer fusion 
GBP1–lamin B1 with excitation laser lines at 405 nm or 488 nm (emGFP, 527 ± 
27 nm) using a spinning disk microscope (UltraVIEW VoX, Perkin Elmer). For 
noise reduction, a Gaussian filter (σ = 2) was applied to both images. To visualize 
altered spectral properties of GFP induced by Enhancer, binding signal intensities 
recorded with excitation at 488 nm were divided by the corresponding 405-nm 
intensities for each pixel. This 488/405 ratio was displayed in a false color gradient 
from blue (unbound) to yellow (bound). Image analysis operations were executed 
in Priithon, a Python-based image analysis and algorithm development platform. 
Preparation of cells was performed as described in Supplementary Methods.
Translocation assay. For the nucleocytoplasmic translocation assay, we trans-
fected HeLaK cells stably expressing the Enhancer fused to mRFP comprising 
an N-terminal nuclear localization signal (nls-Enhancer) with an expression 
plasmid for a tamoxifen-responsive estrogen receptor domain fused to wtGFP 
(GFP-ER286–595). Eighteen hours after transfection, about 50% of the cells 
were expressing GFP-ER286–595 preferentially in the cytoplasm, whereas the 
nls-Enhancer–mRFP fusion protein was slightly enriched in the nucleoli as deter-
mined by fluorescence microscopy. We incubated ~1 × 107 cells with DMEM con-
taining 0–25 µM tamoxifen for 30 min. We used an equal number of cells from the 
same transfection as an untreated control. We harvested the cells, washed them 
twice and resuspended them in 1 ml PBS. Roughly 3 × 106 cells were transferred 
to a 96-well plate (Greiner). We determined fluorescence intensities of GFP and 
mRFP by fluorescence spectroscopy (Tecan Infinite M1000 plate reader, exGFP, 
490 ± 5 nm, emGFP, 511 ± 5 nm, exmRFP, 586 ± 5 nm, emmRFP, 608 ± 5 nm). We 
subtracted background fluorescence intensities from untransfected cells and nor-
malized GFP fluorescence intensities against mRFP fluorescence intensity.
Materials. Purified Enhancer and Minimizer protein is commercially available 
from ChromoTek (Germany). Enhancer and Minimizer encoding vectors 
for intracellular studies can be requested from the Ludwig-Maximilians 
University, Munich.
24. Frauer, C. & Leonhardt, H. A versatile non-radioactive assay for DNA methyltransferase 
activity and DNA binding. Nucleic Acids Res. (2009).
25. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially 
unknown symmetry and cell constants. J. Appl. Cryst. 26, 795–800 (1993).
26. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta 
Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
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Supplementary Methods 
VHH libraries. Llama immunization, VHH-library construction and selection of the 
GFP-binding proteins (GBP) were done as previously described1. 
 
Affinity determination. For affinity measurements, purified Enhancer or Minimizer 
were immobilized on an Carboxyl-Chip (Attana AB. Sweden) by amine-coupling 
according to the manufacturer’s instructions. Binding kinetics of the wtGFP to the 
immobilized nanobody were determined with an Attana 100C Quartz Crystal 
Microbalance (Attana AB, Sweden) by injection of 5 different concentrations of 
wtGFP (0.13 µg, 0.25 µg, 0.55 µg, 1.1 µg and 2.2 µg). 
 
Nature Structural & Molecular Biology: doi:10.1038/nsmb.1727
 Expression plasmids. The expression plasmid encoding wtGFP was constructed by 
replacing the eGFP coding sequence in pEGFP-C1 (Clontech, CA, USA) with the 
wtGFP coding sequence by PCR amplification with the following primers (F: 5‘-CCC 
CGC TAG CGC TAC CGG TCG CCA CCA TGA GTA AAG GAG AAG AAC T-3‘; R: 
5’-GGG GCT TAA GCT TCG AAC TCG AGC TCT A GA CTC AGG CCT AAA CAT 
ATC AAG TAG GTA C-3’).The expression plasmid encoding a translational fusion of 
Enhancer and mRFP was derived by PCR amplification of the Enhancer coding 
region with F: 5´-GGG GGC TCG AGC CGG CCA TGG CCG ATG TGC AG-3´ and 
R: 5´-GGG GGA ATT CCT TGA GGA GAC GGT GAC-3´. The XhoI/EcoRI digested 
PCR-fragment was ligated into a modified pEYFP-N1 vector (Clontech, CA, USA), 
where the YFP sequence had been replaced by the mRFP1 coding region. The 
Minimizer-mRFP as well as the control nanobody plasmid was constructed likewise. 
The control nanobody is directed against the capsid protein of the HI-Virus-1 and 
does not cross-react with GFP or other cellular targets (unpublished results). The 
expression plasmid encoding the nuclear localized Enhancer-mRFP (nls-Enhancer) 
was constructed by adding a N-terminal nuclear localization sequence (nls) to the 
Enhancer by PCR amplification (F: 5’-GGG GAG ATC TCC GGC CAT GGC TCC 
AAA GAA GAA GAG AAA GGT CCA GGT GCA GCT GGT GGA GTC T-3’) and 
recloning it into the modified pEYFP-N1 vector as described above. The expression 
plasmid encoding a translational fusion of wtGFP and ER286-595 (GFP-ER286-595) was 
derived by PCR amplification of the ER286-595 coding region with primers (F: 5’-GGG 
GAG ATC TAT GAG AGC TGC CAA CCT TTG G-3’ and R: 5’- GGG GAA GCT TTC 
AGA CTG TGG CAG GGA AA CC-3'). The digested fragment was ligated into the 
modified pEGFP-C1 vector, where eGFP had been replaced by wtGFP, as described 
above. For Enhancer-Lamin B1, the Lamin B1 was amplified from GFP-LaminB1 
(kindly provided by Jan Ellenberg) by PCR with primers (F: 5’-CCC CGA TAT CGG 
CGA CTG CGA CCC CC-3’ and R: 5’-GGG GGC GGC CGC CTA GTG ATG GTG 
ATG GTG GTG TTA CAT AAT TGC ACA GCT TC-3’). The PCR product was 
purified, digested, and ligated into pEYFP-N1 vector, containing Enhancer. All 
resulting constructs were sequenced and tested for expression in HEK 293T cells 
followed by Western blot analysis. 
 
Sample preparation for spectral analysis in living cells. Human embryonic kidney 
HEK 293T cells were cultured in DMEM supplemented with 10% fetal calf serum and 
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 50 µg/ml gentamycine (PAA, Germany). HEK 293T cells were transiently 
cotransfected with expression plasmids for wtGFP/eGFP and mRFP fusions of 
Enhancer, Minimizer or control nanobody using polyethylenimine as transfection 
reagent (Sigma, Germany). After 48 h about 90% of the cells were expressing GFP 
and mRFP as determined by fluorescence microscopy. Cells were harvested and 
transferred to a 96 well plate (Greiner, Germany). 
 
Sample preparation for high-throughput image acquisition and ratio imaging. 
Human HeLa-Kyoto cells were cultured in DMEM supplemented with 10% fetal calf 
serum and 50 µg/ml gentamycine (PAA, Germany). About 150 000 cells were seeded 
on gridded 18x18 mm coverslips in a 6-well-format. To allow for comparable overall 
GFP expression levels, equal amounts (2 µg) of expression plasmids for 
wtGFP/eGFP and mRFP fusions of Enhancer, Minimizer or control nanobody were 
transiently cotransfected, using polyethylenimine as transfection reagent (Sigma, 
Germany). After 24 h, cells were PFA-fixed and mounted in Vectashield anti-fading 
reagent (Vector Laboratories, USA) on object slides. 
 
Translocation Assay Normalization. For normalization we lysed the pellet of 
~3x106 cells in a SDS containing sample buffer by boiling it for 10 min at 95°C and 
subjected it to immunoblot analysis using an anti-GFP-antibody (Roche, Germany) 
and anti ß-actin antibody (Sigma). 
 
Structure visualization and analyzation. Calculation of buried surface areas were 
performed with the protein interfaces, surfaces and assemblies service PISA at 
European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/prot_int/pistart. 
html)2. Superpositions of structures and calculation of RMSD values were conducted 
using the CaspR RMSDcalc web-server3. Images of crystal structures were prepared 
with PyMol (http://www.pymol.org). 
 
Time-resolved fluorescence-measurements. Fluorescence-lifetime measurements 
of GFP both in presence and in absence of nanobodies were conducted on a 
dedicated TCSPC-lifetime spectrometer (Fluorocube 01-NL, Horiba Jobin Yvon, 
Germany). Protein samples were prepared as described in the methods section of 
the manuscript. Concentrations were adjusted to ~1 µM by dilution in phosphate 
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 buffered saline (PBS, pH 7.4). Samples were excited at 460 nm using a pulsed LED 
(1 MHz repetition rate) as excitation source, while the fluorescence emission was 
detected at 505 nm with a spectral resolution of 12 nm. The time to amplitude 
conversion range was set to 58.4 ns divided in 2.048 channels leading to a time 
resolution of 28.5 ps per channel. The acquisition was stopped at 10.000 counts per 
peak. The lifetime decays were then deconvoluted using a pre-acquired instrument 
response function (1.2 ns full width path maximum) and fitted exponentially using the 
software DAS6 (Horiba Jobin Yvon). 
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 Supplementary Figure 1| Quantification of the fluorescence intensities of GFP 
after nanobody binding. (a) Quantification of the laser scanning experiment shown 
in Fig. 1a. Indicated values represent three independent experiments. (b) Titration of 
Enhancer and Minimizer from 0 - 50 nM on 50 nM purified eGFP. After complex 
formation the emission intensity of eGFP was quantified using a laser scanner 
(Typhoon 9410, GE Healthcare, excitation 488 nm).(c) Determination of the 
nanobody induced fluorescence modulation in soluble cell extracts of HEK 293T cells 
expressing eGFP. Emission intensity of eGFP was detected as described above. 
Means and s.d. (error bars) of 3 independent experiments are shown. 





Supplementary Figure 2 | Nanobody binding assay 
(a) Competitive Epitope Binding Assay. Enhancer (GBP1) was immobilized on a 
Carboxyl-Chip via amine-coupling. After GFP binding GBP1 – 7 were subsequently 
injected at constant concentrations (5 µg/ml) during GFP dissociation. Additional 
binding to the preformed Enhancer-GFP-Complex was measured using a Quartz 
Crystal Microbalance system. Simultaneous GFP binding was observed in 
combination with GBP2, GBP5, GBP6 or GBP7 while no binding was detectable in 
combination with GBP3 or Minimizer (GBP4) indicating overlapping epitopes.  
(b) Affinity measurements for Enhancer and Minimizer. Each ligand was immobilized 
on a Carboxyl-Chip by amine-coupling. Binding kinetics were determined by injection 
of increasing concentrations of wtGFP (0.13 µg, 0.25 µg, 0.55 µg, 1.1 µg, 2.2 µg). For 
evaluation of binding kinetics see Supplementary Table 1. 
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Supplementary Figure 3 I Spectral analysis of the fluorescence modulation in 
living cells – excitation. Excitation spectra of wtGFP (a) and eGFP (b) in cells 
coexpressing Enhancer, Minimizer and a control nanobody. GFP emission at 511+/-5 
nm was recorded for excitation between 300+/- 5 and 500+/- 5 nm. 
b 







Supplementary Figure 4 I Spectral analysis of the fluorescence modulation in 
living cells – emission. Emission spectra of wtGFP (a) and eGFP (b) in cells 
coexpressing Enhancer, Minimizer and a control nanobody. GFP emission between 
500+/-5 and 700+/-5 nm was recorded upon excitation at 395+/- 5 nm, 475+/- 5 nm 
or 490+/- 5 nm. 
a b 
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Supplementary Table 1: Comparison of Enhancer and Minimizer binding 
affinities 
 
Dissociation constant (KD), the on-rate (ka) and the off-rate (Kd) of Enhancer and 
Minimizer were calculated according to a one-site binding model by ClampXP 
evaluation software (Attana AB, Sweden). 
 KD [nM]  ka [1/Ms]  kd [1/s]  
Enhancer  0.59 ±0.11  2.45  x 105 (±0.2 %)  1.45 x 10-4   (±3.1 %)  
Minimizer 0.45 ±0.04  1.33  x 105 (±0.2 %)  6.01 x 10 -5 (±5.6 %)  
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 Supplementary Table 2: Direct contacts between GFP and Enhancer  
 
Salt bridges and hydrogen bonds 
GFP Residue  GFP Atom  Enhancer Residue  Enhancer Atom  Distance [Å]  
     
Glu142  OE2  Ser33  OG  2.42 
Glu142  OE1  Ser33  OG  2.96 
Glu142  OE2  Arg35 NH2  2.54  
Tyr145  O  Asn95  ND2  2.93 
Asn 146 OD1 Asn95 ND2 3.07 
Ser147  N  Glu101 OE2  2.79 
Lys166  NZ  Glu44  OE1  2.61 
Arg168  NH1  Glu101  OE2  3.19 
Arg168  NH2  Glu101  OE1  2.82 
Arg168  NH2  Tyr37  OH  3.25  
Asp173  O  Ser58  OG  2.88 
Gly174  O  Arg35  NH1  3.08 
Ser175  O  Arg35  NH1  2.42  
Hydrophobic interactions 
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 Supplementary Table 3: Salt bridges and hydrogen bonds between GFP and 
Minimizer  
 
GFP Residue  GFP Atom  Minimizer Residue  Minimizer Atom  Distance [Å]  
     
Asn 149 ND2 Val 100f O 3.12 
Tyr 151 OH Val 100f O 2.63 
Tyr 151 OH Asp100l O 3.19 
Asn 164 ND2 Tyr 100m OH 3.09 
Lys 166 N2 Asp 95  OD1 2.70 
Arg 168 NH2 Leu 100k O 2.97 
Asp 180 OD1 Thr 98 N 2.98 
Asp 180 OD2 Thr 98 OG1 2.66 
Asn 198 ND2 Val 100c O 3.05 
Tyr 200 OH Glu 44 OE1 2.64 
 
 
Supplementary Table 4: GFP fluorescence-lifetime measurements 
 wtGFP (ns) eGFP (ns) 
   
uncomplexed 3.064 ± 0.005 2.704 ± 0.005 
+ Enhancer 2.915 ± 0.003 2.801 ± 0.004 
+ Minimizer 2.903 ± 0.004 2.806 ± 0.005 
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About a dozen mammalian proteins contain CXXC zinc finger domains. Although many of them are 
involved in chromatin and DNA modification, the contribution of the CXXC domain to their functions 
is poorly understood. In particular, there are conflicting reports on the role of the CXXC domain in 
the DNA methyltransferase Dnmt1 and no functional data are available for a similar domain in the 
methylcytosine hydroxylase Tet1. Using a homology modeling approach we have designed isolated 
CXXC domain and deletion constructs for mouse Dnmt1 and Tet1 to maximize the probability of 
native peptide folding. We show that the CXXC domain of Tet1 has no DNA binding activity, while 
that of Dnmt1 selectively binds DNA substrates containing unmethylated CpG sites. However, both in 
vitro and in vivo approaches show that the CXXC domain of Dnmt1 is dispensable for DNA binding 
specificity, binding kinetics, allosteric activation and methyltransferase activity. Thus, we suggest a 
subtle, possibly developmental stage- or tissue-specific regulatory function for the CXXC domain of 
Dnmt1. 




In mammals DNA methylation is restricted to cytosine residues and mainly involves CpG 
dinucleotides. CpG methylation is widespread across mammalian genomes, including gene bodies 
regardless of their transcriptional activity (1-2). However, highly CpG-rich regions (CpG islands) are 
refractory to methylation and mostly coincide with promoters of constitutively active genes. The 
methylation state of other regulatory sequences with moderate to low CpG density, including 
promoters and enhancers, shows developmental and/or tissue-specific variations and often 
correlates with a transcriptionally silent state (1,3-6). Furthermore, dense methylation of repetitive 
sequences is thought to maintain these elements in a silent state and thus contribute to genome 
stability (7-9). In mammals, cytosine methylation is catalyzed by a family of DNA methyltransferases 
(Dnmts) (10). Dnmt3a and Dnmt3b establish methylation patterns during embryonic development of 
somatic as well as germ cell lineages and, consistently, show developmental stage and tissue specific 
expression patterns. In contrast, Dnmt1 is ubiquitous and generally the most abundant DNA 
methyltransferase in mammalian tissues, where it restores symmetrical methylation at 
hemimethylated CpG sites generated by semi-conservative DNA replication. Thus, Dnmt1 maintains 
methylation patterns with high fidelity and is essential for embryonic development and genome 
integrity (7,11-13). 
Dnmt1 is a large enzyme with a complex domain structure that likely evolved by fusion of at least 
three genes (14). It comprises a regulatory N-terminal region and a C-terminal catalytic domain 
connected by a linker made of seven glycine-lysine repeats (Figure 1A) (15). The N-terminal part 
contains a PCNA binding domain (PBD), a heterochromatin targeting sequence (TS), a CXXC-type zinc 
finger domain and two Bromo-Adjacent Homology domains (BAH1 and BAH2). The C-terminal 
domains of mammalian Dnmts contain all ten motifs identified as essential for catalysis in bacterial 
DNA (cytosine-5) methyltransferases (10) and thus, prokaryotic and mammalian cytosine 
methyltransferases are thought to adopt a very similar catalytic mechanism. However, the C-terminal 
domain of Dnmt1 is the only DNA methyltransferase domain in Dnmts that is not catalytically active 
when expressed separately and interaction with the N-terminal part is required for allosteric 
activation of the enzyme (16). Remarkably, the first 580 amino acids (aa) of human DNMT1 are 
dispensable for both enzymatic activity and substrate recognition, whereas deletion of the first 672 
aa results in an inactive enzyme (17). Interestingly, this truncation eliminates part of the CXXC 
domain, suggesting an involvement of this domain in allosteric activation. However, addition of the 
isolated CXXC domain to the catalytic domain in trans was not sufficient for catalytic activation (18). 
CXXC-type zinc finger domains are found in several other proteins with functions related to DNA or 
chromatin modification, including the histone H3 lysine 4 methyltransferases mixed-lineage leukemia 
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(MLL) proteins 1 and 4, the CpG-binding protein (CGBP, also known as CFP1 or CXXC1), the methyl-
CpG binding domain protein 1 (MBD1), the H3 lysine 36 demethylases KDM2A and B (also known as 
JHD1A/FBXL11 and JHD1B/FBXL10) and the MLL1 fusion partner TET1 (19-26). The CXXC domains of 
some of these proteins were shown to mediate specific binding to double stranded DNA templates 
containing unmethylated CpG sites (19-20,27). A region of Dnmt1 which mainly includes the CXXC 
domain (aa 628-753) was also shown to bind Zn ions and DNA (18,28-29). However, available data on 
the selectivity of this DNA binding activity are conflicting. Whereas a fragment including aa 613-748 
of mouse Dnmt1 was shown to bind DNA with a slight preference for hemimethylated CpG sites (18), 
aa 645-737 of human DNMT1, were shown to selectively bind unmethylated DNA (29). As these 
studies used different constructs and species, questions remain as to the DNA binding selectivity of 
the Dnmt1 CXXC domain with regard to the CpG methylation state and whether the CXXC domain is 
crucial for allosteric activation, substrate discrimination or both.  
Notably, not all CXXC domains show this specificity, as exemplified by the fact that only one of the 
three CXXC domains in MBD1 binds DNA (27). Interestingly, TET1 was recently shown to be a 
2 oxoglutarate- and Fe(II)-dependent oxigenase responsible for converting genomic 5-methylcytosine 
to 5-hydroxymethylcytosine (30). However, it is not known whether the TET1 CXXC domain is 
involved in recognition of methylated DNA substrates. 
Here we report a systematic functional study and characterization of the CXXC domains in mouse 
Dnmt1 and Tet1 proteins, respectively. Isolated Dnmt1 CXXC domain and deletion constructs were 
generated based on structural homology models with the aim of preserving native peptide folding. 
We show that the CXXC domains of Dnmt1 and Tet1 differ drastically in DNA binding properties and 
that the CXXC domain is dispensable for DNA binding and catalytic activity of Dnmt1 in vitro and in 
vivo. 
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MATERIAL AND METHODS  
Bioinformatic methods 
Alignments were performed using the ClustalW2 software (31). The CXXC domain homology tree 
(Figure 1C) was generated from the alignment in Figure 1B with Jalview 2.4 by unweighted pair group 
method with arithmetic mean (UPGMA). The neighbor-joining method gave the same result. Average 
distances between the sequences were calculated using the BLOSSUM62 matrix. To build homology 
models for the CXXC domains of Dnmt1 (aa 645-696) and Tet1 (aa 561-614), we submitted the 
respective sequences to the HHpred server (32). The best template was the CXXC domain of MLL1 
(PDB-ID: 2J2S). The 49 Zn finger residues of Dnmt1 can be aligned to this domain with 45% sequence 
identity and only a single amino acid gap after residue 661 (Figure 1B). 3D models were calculated 
with the homology modeling software MODELLER (33) (version 9.5) using this alignment. Distance 
restraints were given to MODELLER to enforce a distance of 2.3 ± 0.1 Å between the eight sulphurs in 
the zinc-coordinating cysteines and the zinc ions. TM-align (34) was used to superpose the model 
structure with the template domain. Images were generated using the PyMol software (35). The 
quality of the models and the underlying alignments were checked with DOPE (36) and Verify3D (37) 
and results for both models were found to be comparable to the template structure (2J2S). 
 
Expression constructs  
Fusion constructs were generated using enhanced green fluorescent protein, monomeric red 
fluorescent protein or monomeric cherry and are here referred to as GFP, RFP and Cherry fusions, 
respectively. Mammalian expression constructs for GFP, mouse GFP-Dnmt1, GFP-NTR and human 
RFP-PCNA were described previously (38-41). The deletion construct GFP-Dnmt1∆CXXC was obtained 
by replacing the sequence coding for aa 655-696 by codons for three alanine residues in the 
GFP-Dnmt1 construct as described (42). To generate GFP-CXXCDnmt1 and GFP-CXXCTet1 sequences 
coding for the respective CXXC domains (aa 643-700 for Dnmt1 and 561-614 for Tet1) were amplified 
by PCR using the GFP-Dnmt1 and cDNA from E14 embryonic stem cells (ESCs), respectively. PCR 
fragments were then cloned into the AsiSI-NotI site of the same vector backbone as used for 
GFP-Dnmt1. GFP-NTR∆CXXC was obtained by replacing the BglII-XhoI fragment of GFP-NTR with the 
same fragment of GFP-Dnmt1∆CXXC. Ch-CTD-His was generated by replacing the GFP coding sequence 
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Cell culture, transfection and cell sorting 
HEK293T cells and mouse C2C12 myoblasts were cultured in DMEM supplemented with 50 µg/ml 
gentamicin and 10% and 20% fetal calf serum, respectively. For overexpression of fusion proteins 
HEK293T cells were transfected with polyethylenimine (Sigma). For live cell imaging, C2C12 cells 
were grown to 40% confluence on Lab-Tek chambers (Nunc) or µ-slides (Ibidi) and transfected with 
TransFectin transfection reagent (BioRad) according to the manufacturer’s instructions. Mouse 
embryonic stem cells (ESCs) were cultured as described (43) and transfected with FuGENE HD 
(Roche) according to the manufacturer’s instructions. ESCs were sorted with a FACS Aria II 
instrument (Becton Dikinson). The dnmt1-/- J1 ESCs used in this study are homozygous for the c allele 
(11). 
 
In vitro DNA binding and trapping assays 
In vitro DNA binding and trapping assays were performed as described previously (44-45) with the 
following modifications. DNA substrates labeled with four different ATTO fluorophores 
(Supplementary tables 1 and 2) were used at a final concentration of 125 nM each in the pull-down 
assay with immobilized GFP fusions. After removal of unbound substrate, the amounts of protein and 
DNA were determined by fluorescence intensity measurements with a Tecan Infinite M1000 plate 
reader using calibration curves from purified GFP or DNA coupled ATTO fluorophores, respectively. 
The following excitation/emission ± detection bandwidth settings were used: 490/511 ± 10 nm for 
GFP, 550/580 ± 15 nm for ATTO550, 600/630 ± 15 nm for ATTO590, 650/670 ± 10 nm for ATTO647N 
and 700/720 ± 10 nm for ATTO700. Cross detection of GFP and different ATTO dyes was negligible 
with these settings. Binding and trapping ratios were calculated dividing the concentration of bound 
DNA substrate by the concentration of GFP fusion on the beads. 
 
Co-immunoprecipitation 
Co-immunoprecipitation was performed as described previously (41,46). Shortly, HEK293T cells were 
transiently co-transfected with expression plasmids for GFP fusions and the Ch-CTD-His construct, 
harvested and lysed. GFP fusions were pulled down using the GFP-Trap (47) (Chromotek) and 
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Live cell microscopy and Fluorescence Recovery after Photobleaching (FRAP) analysis 
Live cell imaging and FRAP experiments were performed as described previously (43). For each 
construct 6-15 nuclei were averaged and the mean values as well as the standard errors were 
calculated. For presentation, we used linear contrast enhancement on entire images. 
 
Live cell trapping assay  
The DNA methyltransferase trapping assay was described previously (40). Briefly, transfected cells 
were incubated with 30 µM 5-aza-dC (Sigma) for the indicated time periods before photobleaching 
experiments. FRAP analysis was performed with a confocal laser scanning microscope (TCS SP5, 
Leica) equipped with a 63x/1.4 NA Plan-Apochromat oil immersion objective. Microscope settings 
were as described except that a smaller region of interest (3 µm x 3 µm) was selected for 
photobleaching. Mean fluorescence intensities of the bleached region were corrected for 
background and for total loss of nuclear fluorescence over the time course, and normalized by the 
mean of the last 10 prebleach values. 
 
DNA Methylation Analysis 
Genomic DNA was isolated with the QIAmp DNA Mini Kit (Qiagen) and 1.5 µg were bisulfite 
converted using the EZ DNA Methylation-Gold Kit (Zymo research) according to the manufacturer’s 
instructions. Primer sets and PCR conditions for IAP-LTR´s, skeletal α-actin and H19 promoters were 
as described (43). Primer sequences for major satellites were AAAATGAGAAACATCCACTTG (forward 
primer) and CCATGATTTTCAGTTTTCTT (reverse primer). For amplification we used Qiagen Hot Start 
Polymerase in 1x Qiagen Hot Start Polymerase buffer supplemented with 0.2 mM dNTPs, 0.2 µM 
forward primer, 0.2 µM reverse primer, 1.3 mM betaine (Sigma) and 60 mM tetramethylammonium-
chloride (TMAC, Sigma). Promoter regions and IAP-LTR´s were amplified in two subsequent rounds of 
amplification (nested PCR) and major satellites were amplified in a single amplification. 
Pyrosequencing reactions were carried out by Varionostic GmbH (Ulm, Germany). 
  




Sequence homology and structural modeling identify distinct CXXC domain subtypes 
Dnmt1 contains a zinc finger domain of the CXXC type (CXXC, Figure 1A), which is present in 
numerous mammalian proteins including MLL (Figure 1B) and highly conserved among Dnmt1 
sequences from various animal species (Supplementary Figure 1). The primary structure of CXXC 
domains spans two clusters of 6 and 2 cysteine residues separated by a stretch of variable sequence 
and length. Sequence alignment and homology tree construction identified three distinct groups of 
CXXC domains (Figure 1B and C). The sequence between the two cysteine clusters in the CXXC 
domains of Dnmt1, CGBP/CFP1, Fbxl19, Mll and Kdm2 proteins and CXXC domain 3 of Mbd1 is highly 
conserved and contains a KFGG motif. The two other homology groups, the CXXC domains in Tet1, 
CXXC4/Idax and CXXC5 on the one side and the CXXC domains 1 and 2 of Mbd1 on the other side, 
lack the KFGG motif and diverge from the first group and from each other in the sequence between 
the cysteine clusters. We generated structural homology models for the CXXC domains of mouse 
Dnmt1 and Tet1 using the NMR structure of the MLL1 CXXC domain as a template (Figure 1D and E) 
(48). The CXXC domains of these proteins adopt an extended crescent-like structure that 
incorporates two Zn ions each coordinated by four cysteine residues. The peptide of the MLL1 CXXC 
domain predicted to insert into the major groove (cyan in Fig. 1E) is located on one face of the 
structure and is contiguous to the KFGG motif (48). The predicted structure of the Tet1 CXXC domain 
lacks the short 310 helix (η1 in Figure 1E) formed by residues PKF and partially overlapping the KFGG 
motif, but is similar to the MLL1 CXXC domain in the region of the DNA-contacting peptide. However, 
the two predicted beta strands in Tet1 each carry three positive charges, whereas in CXXC domains 
of MLL1 and DNMT1 carry only one or no charge in their C-terminal strand. Depending on the 
orientation of the positively charged side chains, it cannot be excluded that the charge density 
prevents strand pairing in the Tet1 CXXC domain. 
 
The Dnmt1 CXXC domain binds unmethylated DNA 
To investigate the binding properties of the Dnmt1 CXXC domain, we generated a GFP fusion 
construct including aa 652-699 (GFP-CXXCDnmt1). According to our homology model the ends of this 
fragment form an antiparallel β-sheet that structurally delimits the domain as in MLL1. First we 
compared the localization and mobility of GFP-CXXCDnmt1 and GFP in mouse C2C12 myoblasts. While 
GFP was diffusely distributed in both nucleus and cytoplasm, GFP-CXXCDnmt1 was exclusively nuclear 
with a punctuated pattern throughout the nucleoplasm and was enriched in nucleoli (Figure 2A). 
Enrichment in the nucleus and nucleoli is frequently observed with constructs containing stretches 
with high density of basic residues. After photobleaching half of the nuclear volume we observed a 
slower fluorescence recovery rate for GFP-CXXCDnmt1 than for GFP (Figure 2B). To rule out a 
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contribution of nucleolar interactions to the slower kinetics of GFP-CXXCDnmt1, we separately 
bleached nucleoplasmic and nucleolar regions and found that GFP-CXXCDnmt1 has even faster kinetics 
within the nucleolus (Supplementary Figure 2). These results are consistent with a binding activity of 
GFP-CXXCDnmt1 in the nucleus and very transient, unspecific binding in the nucleolus. To investigate 
whether the CXXC domain of Dnmt1 binds DNA and its possible selectivity with respect to CpG 
methylation we used a recently developed fluorescent DNA binding assay (44-45). GFP-CXXCDnmt1 was 
transiently expressed in HEK293T cells, immunopurified with the GFP-trap and incubated with 
fluorescent DNA substrates containing either no CpG site or one central un-, hemi- or fully 
methylated CpG site in direct competition. As shown in Figure 2C, GFP-CXXCDnmt1 displayed an 
approximately 10-fold preference for the substrate containing one unmethylated CpG site. This result 
is consistent with the reported binding preference of other CXXC domains belonging to the same 
homology group as the Dnmt1 CXXC (19-20,27).  
 
The CXXC domain of Tet1 shows no specific DNA binding activity in vitro 
It was recently shown that Tet1 oxidates genomic 5-methylcytosine (mC) to 
5-hydroxymethylcytosine. Although Tet1 must be able to discriminate mC containing substrates, the 
domain responsible for this specificity is not known. Our model for the structure of the Tet1 CXXC 
domain diverged from the structure of the MLL1 CXXC domain in correspondence of the KFGG motif 
but not of the DNA-contacting peptide, suggesting that the Tet1 CXXC domain may still bind DNA. To 
test this we generated a GFP tagged Tet1 CXXC construct (GFP-CXXCTet1) following the same criteria 
as for GFP-CXXCDnmt1 and subjected it to the same competitive fluorescent DNA binding assay. 
Binding of GFP-CXXCTet1 to any of the four substrates was indistinguishable from the basal levels of 
the GFP control (Figure 2C). We conclude that the isolated CXXC domain of Tet1 has no specific DNA 
binding activity. Like the CXXC domain of Tet1, the CXXC-1 and 2 domains of Mbd1 lack the KFGG 
motif and do not bind DNA, while mutation of this motif prevents DNA binding by the MLL1 CXXC 
domain (27,49). Thus, our result with the Tet1 CXXC domain is consistent with a requirement for the 
KFGG motif to bind DNA. 
 
Deletion of the CXXC domain does not affect the activity of Dnmt1 in vitro 
To explore the role of the CXXC domain in Dnmt1 function we generated a GFP-Dnmt1 fusion 
construct where the CXXC domain, as defined by our homology model, was deleted (GFP-Dnmt1∆CXXC; 
Figure 3A) -
sheet (the latter included; Figure 1D) would have the highest chances to preserve native folding of 
the rest of the protein. We also introduced the same deletion within the context of a GFP fusion with 
only the N-terminal region of Dnmt1 (GFP-NTR∆CXXC; Figure 3A). We then compared DNA binding 
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properties, catalytic activity and interaction between N-terminal region and C-terminal catalytic 
domain of ∆CXXC and corresponding wild type constructs. 
A competitive DNA binding assay with the same set of substrates as used for the experiments with 
GFP-CXXCDnmt1 reported above (Figure 2C) showed that both GFP-Dnmt1 and GFP-Dnmt1∆CXXC bind 
DNA independently of the presence and methylation state of the CpG site (Figure 3B). As the isolated 
CXXC domain preferentially bound the substrate containing an unmethylated CpG site, the result 
with GFP-Dnmt1 and GFP-Dnmt1∆CXXC indicates that the CXXC domain contributes negligibly to the 
DNA binding specificity of the full-length enzyme. 
Several groups reported that interaction between N-terminal region and C-terminal catalytic domain 
of Dnmt1 leads to allosteric activation of Dnmt1 (14,16-18,50). To test whether the CXXC domain is 
involved in this intramolecular interaction, we co-expressed either GFP-NTR or GFP-NTR∆CXXC with a 
Cherry- and His-tagged C-terminal domain construct (Ch-CTD-His) in HEK293T cells and performed 
co-immunoprecipitation experiments. Ch-CTD-His co-precipitated both GFP-NTR and GFP-NTR∆CXXC, 
indicating that the CXXC domain is dispensable for the interaction between N-terminal region and C-
terminal domain of Dnmt1 (Figure 3C).  
To investigate whether the CXXC domain is needed for enzymatic activity or substrate recognition, 
we separately tested covalent complex formation and methyl group transfer, two successive steps of 
the enzymatic reaction, using GFP-Dnmt1 and GFP-Dnmt1∆CXXC. We first employed an assay to 
monitor covalent complex formation that exploits the formation of an irreversible bond between the 
enzyme and the mechanism-based inhibitor 5-aza-2-deoxycytosine (5-aza-dC), as opposed to the 
reversible complex formed with naturally occurring 2-deoxycytosine (dC) (44). Thus, 5-aza-dC 
containing substrates irreversibly trap cytosine methyltransferases. GFP-Dnmt1 fusions were 
separately incubated with fluorescent DNA substrates containing dC (binding) or 5-aza-dC (trapping) 
at a single CpG site. DNA-protein complexes were then isolated by GFP pulldown and molar 
DNA/protein ratios were calculated from fluorescence measurements (Figure 3D). Irreversible 
covalent complex formation was then estimated by comparison of the trapping and binding 
activities. GFP-Dnmt1 and GFP-Dnmt1∆CXXC showed comparable covalent complex formation rates 
(relative trapping ratios), which were about 15- and 12-fold higher for hemi- than un-methylated 
substrates assayed in direct competition, respectively (Figure 3E). This result indicates that the 
preference of Dnmt1 for hemimethylated substrates is determined at the covalent complex 
formation step rather than upon DNA binding and that the CXXC domain does not play a major role 
in determining either the efficiency or the methylation state-specificity of covalent complex 
formation. We also tested whether deletion of the CXXC domain affects the ability of Dnmt1 to 
transfer [3H]-methyl groups from the donor S-adenosylmethionine (SAM) to a poly(dI·dC)-poly(dI·dC) 
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substrate, a standard DNA methyltransferase activity assay. This showed that GFP-Dnmt1 and 
GFP-Dnmt1∆CXXC are equally active methyltransferases (Supplementary Figure 3). 
In conclusion, we showed that, in vitro, the deletion of the CXXC domain does not affect the 
interaction between N-terminal region and C-terminal domain, DNA binding, preference for 
hemimethylated substrates upon covalent complex formation or methyltransferase activity of 
Dnmt1. These data strongly argue against an involvement of the CXXC domain in allosteric activation 
of Dnmt1. 
 
Deletion of the CXXC domain does not affect Dnmt1 activity in vivo 
We then undertook a functional characterization of our CXXC domain deletion construct in vivo. First, 
we compared localization and binding kinetics of GFP-Dnmt1 or GFP-Dnmt1∆CXXC in mouse C2C12 
myoblasts co-transfected with RFP-PCNA, which served as S-phase marker (38). GFP-Dnmt1∆CXXC 
showed the same cell-cycle dependent nuclear localization pattern as previously shown for GFP-
Dnmt1 and endogenous Dnmt1 (Figure 4A)(39). Interaction with PCNA via the PBD directs Dnmt1 to 
replication foci throughout S-phase. In late S-phase and G2, however, Dnmt1 is enriched at 
chromocenters, clusters of pericentric heterochromatin (PH) that are observed as discrete domains 
densely stained by DNA dyes in mouse interphase cells. Association of Dnmt1 with PH at these stages 
is mediated by the TS. Thus, the CXXC domain clearly does not contribute to localization of Dnmt1 at 
this level of resolution.  
We also measured the binding kinetics of GFP-Dnmt1 or GFP-Dnmt1∆CXXC in living C2C12 myoblasts by 
fluorescence recovery after photobleaching (FRAP). These experiments revealed that the binding 
kinetics of Dnmt1 is not affected by deletion of the CXXC domain in early-mid as well as late S-phase 
(Figure 4B).  
To test the ability of covalent complex formation in vivo, we used a previously established trapping 
assay (40). Mouse C2C12 myoblasts were cotransfected with either GFP-Dnmt1 or GFP-Dnmt1∆CXXC 
and RFP-PCNA and treated with 5-aza-dC. Consequently, Dnmt1 constructs were irreversibly trapped 
at the site of action and irreversible covalent complex formation was measured by FRAP analysis 
(Figure 4C). GFP-Dnmt1 and GFP-Dnmt1∆CXXC showed highly similar trapping kinetics, the trapped 
enzyme fraction reaching almost 100 % after 20 and 40 minutes in early-mid and late S-phase, 
respectively. This result clearly shows that the CXXC domain is dispensable for covalent complex 
formation also in vivo. 
To further investigate the role of the CXXC domain in vivo we compared the ability of GFP-Dnmt1 and 
GFP-Dnmt1∆CXXC to restore DNA methylation patterns in mouse dnmt1-/- embryonic stem cells (ESCs). 
Cells transiently expressing either GFP-Dnmt1 or GFP-Dnmt1∆CXXC were FACS sorted 48 h after 
transfection. Isolated genomic DNA was then bisulfite treated and fragments corresponding to major 
FRAUER ET AL. 
82 
 
satellite repeats, intracisternal type A particle (IAP) interspersed repeats, skeletal α-actin and H19a 
promoters were amplified and subjected to pyrosequencing. As shown previously, under these 
condition GFP-Dnmt1 partially restored methylation of major satellite and IAP repeats and the 
skeletal α-actin promoter, but not of the imprinted H19a promoter, which requires passage through 
the germ line (43,51). Methylation patterns of all these sequences in cells expressing GFP-Dnmt1∆CXXC 
were very similar to those in GFP-Dnmt1 expressing cells, suggesting that the CXXC domain is not 
required for maintenance of DNA methylation patterns by Dnmt1. 
Thus, the CXXC domain does not play a major role in subcellular localization and in vivo binding 
kinetics of Dnmt1 and, consistent with the in vitro data reported above, is dispensable for the 
catalytic activity of Dnmt1 in vivo. 




We generated homology models based on the reported structure of the MLL1 CXXC domain to 
design isolated CXXC domain constructs for Dnmt1 and Tet1 and a CXXC domain deletion construct 
for Dnmt1 that may preserve native peptide folding. According to these models CXXC domains are 
delimited by an antiparallel -sheet, a discrete structural element. Our data show that the CXXC 
domain of mouse Dnmt1 preferentially binds DNA substrates containing unmethylated CpG sites as 
previously shown for CXXC domains of other mammalian proteins. We note that sequences C-
terminal to the corresponding peptide in CGBP were reported to be required for DNA binding in vitro 
(20) and that only a significantly larger peptide spanning the CXXC-3 domain of Mbd1a was tested for 
DNA binding. However, sequences C-terminal to CXXC domains are poorly conserved (Figure 1B) and 
not required for DNA binding by the Dnmt1 CXXC domain. Nevertheless, all the CXXC domains 
reported to selectively bind unmethylated CpG sites cluster in a distinct homology group and contain 
the KFGG motif that was shown to be crucial for DNA binding by the CXXC domain of MLL1 (49). We 
identify two other CXXC domain homology groups that lack the KFGG motif. Consistent with a role of 
this motif in DNA binding, members of these groups such as CXXC-1/2 of Mbd1 (27) and the CXXC 
domain of Tet1 (this study) show no DNA binding activity. While no specific function is known for 
Mbd1 CXXC-1/2, the CXXC domain of Tet1 is closely related to those in CXXC4/Idax and CXXC5 that 
were shown to mediate protein-protein interactions (52-54). This suggests that the CXXC domain of 
Tet1, rather than discriminating methylated DNA substrates, is a protein interaction domain. 
Although we observed a clear DNA binding activity by the isolated CXXC domain of Dnmt1, we found 
that, within the context of the full length enzyme, this domain is dispensable for DNA binding, 
preference for hemimethylated substrates at the covalent complex formation step, 
methyltransferase activity and allosteric activation as well as for the ability to restore methylation of 
representative sequences in dnmt1 null cells. Consistent with our data, a recent report showed a 
preference of the CXXC domain of human DNMT1 for substrates containing unmethylated CpG sites. 
However, the same report showed that deletion of the CXXC domain from the human enzyme results 
in a significant decrease in methyltransferase activity on hemimethylated substrates and 25% lower 
methylation at rDNA repeats upon overexpression in HEK293 cells, suggesting a dominant negative 
effect of the deletion construct (29). These discrepancies may be due to deletion of a slightly shorter 
fragment (aa 648-690) that may not preserve native folding, the analysis of non-physiological 
expression levels in HEK293 cells or species-specific differences. In this regard we would like to stress 
that genetic complementation of dnmt1 null cells constitutes a more physiologically relevant test for 
the function of protein domains in vivo. 
FRAUER ET AL. 
84 
 
Notably, binding of unmethylated CpG sites by KFGG motif-containing CXXC domains does not 
exclude a role in protein-protein interaction as the CXXC domain of MLL1 was reported to interact 
with both DNA and Polycomb Repressive Complex 1 components HPC2/CBX4 and BMI-1 (19,55). 
Therefore, it is possible that the CXXC domain of Dnmt1 has regulatory functions in specific cell types 
or developmental stages that may involve DNA binding and/or interaction with other proteins. 
Testing this possibility will require the generation of dedicated animal models. 
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Figure 1. Sequence and predicted structural homology of CXXC domains. (A) Schematic 
representation of the domain structure in Dnmt1 and Tet1. The catalytic domain and the N-terminal 
region of Dnmt1 are connected by seven lysine-glycine repeats [(KG)7]. PBD: PCNA binding domain; 
TS: targeting sequence; CXXC: CXXC-type zinc finger domain; BAH: bromo-adjacent homology 
domain; NLS: nuclear localization signal; Cys-rich: cysteine rich region. (B) Alignment of mammalian 
CXXC domains. Numbers on the right side indicate the position of the last amino acid in the 
corresponding protein. The Mbd1a isoform contains three CXXC motifs (CXXC_1-3). Absolutely 
conserved residues, including the eight cysteines involved in zinc ion coordination are highlighted in 
red and the conserved KFGG motif is in red bold face. Positions with residues in red face share 70% 
similarity as calculated with the Risler algorithm (56). All sequences are from M. musculus. Accession 
numbers (for GenBank unless otherwise stated): Dnmt1, NP_034196; Mll1, NP_001074518; Mll4, 
O08550 (SwissProt); CGBP, NP_083144; Kdm2a, NP_001001984; Kdm2b, NP_001003953; Fbxl19, 
NP_766336; Mbd1, NP_038622; CXXC4/Idax, NP_001004367; CXXC5, NP_598448. (C) A homology 
tree was generated from the alignment in (B). The three subgroups of CXXC domains identified are in 
different colors. Average distances between the sequences are indicated. (D-E) Homology models of 
the mouse Dnmt1 (D; red) and Tet1 (E; blue) CXXC domains superimposed to the CXXC domain of 
MLL1 (green; (48)). MLL1 residues that are thought to contact DNA according to chemical shift 
measurements (48) are in cyan in (E), while cysteines involved in coordination of the two zinc ions 
are yellow. Arrows point to the KFGG motif in MLL1 and Dnmt1. 
 
  






Figure 2. Properties of isolated Dnmt1 and Tet1 CXXC domains. (A-B) Subcellular localization (A) and 
binding kinetics (B) of GFP-CXXCDnmt1 and GFP in mouse C2C12 myoblasts. Localization and binding 
kinetics were independent from the cell-cycle stage (data not shown). Arrowheads in (A) point to 
nucleoli. Scale bar: 5 µm. Binding kinetics were analyzed by FRAP. (C) DNA binding specificity of the 
Dnmt1 and Tet1 CXXC domains. GFP, GFP-CXXCDnmt1 and GFP-CXXCTet1 were pulled down from 
extracts of transiently transfected HEK293T cells and incubated with fluorescent DNA substrates 
containing no CpG site or one central un-, hemi- or fully methylated CpG site in direct competition 
(noCGB, UMB, HMB, FMB, respectively). Shown are the mean DNA/protein ratios and corresponding 









Figure 3. DNA binding  specificity,  intramolecular  interaction and  trapping of wild‐type Dnmt1 and 
CXXC deletion constructs  in vitro. (A) Schematic representation of Dnmt1 expression constructs. (B) 
DNA binding specificity of GFP‐Dnmt1 and GFP‐Dnmt1∆CXXC were assayed as described  in Figure 2C. 
(C) Co‐immunoprecipitation of  the C‐terminal domain of Dnmt1  (Ch‐CTD‐His) with  the N‐terminal 
region with and without deletion of the CXXC domain (GFP‐NTR and GFP‐NTR∆CXXC, respectively). GFP 
fusions  were  detected  using  an  anti‐GFP  antibody,  while  the  C‐terminal  domain  construct  was 
detected using an anti‐His antibody. GFP was used as negative control.  (D) Comparison of binding 
and trapping activities for GFP‐Dnmt1 and GFP‐Dnmt1∆CXXC to monitor irreversible covalent complex 
formation  with  hemimethylated  substrates.  (E)  Relative  covalent  complex  formation  rate  of 












Figure 4. Cell-cycle dependent cellular localization, protein mobility and trapping of wild-type Dnmt1 
and CXXC deletion constructs in mouse C2C12 myoblasts. (A) Cell-cycle dependent localization of 
GFP-Dnmt1 and GFP-Dnmt1∆CXXC constructs. Scale bar: 5 µm. (B) Analysis of binding kinetics of 
GFP-Dnmt1 and GFP-Dnmt1∆CXXC in early-mid and late S-phase cells by FRAP. The recovery curve for 
GFP is shown for comparison. (C) In vivo trapping by FRAP analysis in cells treated with 5-aza-dC. The 
trapped enzyme fraction is plotted over time for early-mid and late S-phase cells. In (A-C) RFP-PCNA 
was co-transfected to distinguish cell cycle stages in living cells. 
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Figure 5. The CXXC deletion construct of Dnmt1 restores methylation in dnmt1 null cells. Mouse 
dnmt1-/- ESCs transiently expressing GFP-Dnmt1 or GFP-Dnmt1∆CXXC were isolated by FACS-sorting 48 
h after transfection and CpG methylation levels within the indicated sequences were analyzed by 
bisulfite treatment, PCR amplification and direct pyrosequencing. Methylation levels of 
untransfected wild type and dnmt1-/- ESCs are shown for comparison. 
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SUPPLEMENTARY INFORMATION  
 
SUPPLEMENTARY TABLE 1 
 
Supplementary Table 1. Sequences of DNA oligonucleotides used for preparation of double stranded 
DNA substrates. M: 5-methylcytosine. 
Name Sequence 
CG-up 5’- CTCAACAACTAACTACCATCCGGACCAGAAGAGTCATCATGG -3’ 
MG-up  5’- CTCAACAACTAACTACCATCMGGACCAGAAGAGTCATCATGG -3’ 
noCG-up 5’- CTCAACAACTAACTACCATCTGGACCAGAAGAGTCATCATGG -3’ 
Fill-In-550 5’- ATTO550-CCATGATGACTCTTCTGGTC -3’ 
Fill-In-590 5’- ATTO590-CCATGATGACTCTTCTGGTC -3’ 
Fill-In-647N 5’- ATTO647N-CCATGATGACTCTTCTGGTC -3’ 
Fill-In-700 5’- ATTO700-CCATGATGACTCTTCTGGTC -3’ 
 
 
SUPPLEMENTARY TABLE 2 
 
Supplementary Table 2. DNA substrates used for the in vitro DNA binding and trapping assays. 
Name CpG site Label Oligo I Oligo II dCTP reaction  Purpose 







UMB 590 590 Fill-In-590 
UMB 647N 647N Fill-In-647N 
UMB 700 700 Fill-In-700 







HMB 647N 647N Fill-In-647N 
HMT 550 550 Fill-In-550 
5-aza-dCTP Trapping 
HMT 647N 647N Fill-In-647N 
FMB 647N fully methylated 647N MG-up Fill-In-647N 5methyl dCTP Binding 
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Supplementary Figure 1. Dnmt1 domain structure and alignment of Dnmt1 CXXC domains from 
different species. Numbers on the right side indicate the position of the last amino acid in each 
sequence. PBD: PCNA binding domain; TS: targeting sequence; CXXC: CXXC-type zinc finger domain; 
BAH: bromo-adjacent homology domain; (KG)7: seven lysine-glycine repeats. Absolutely conserved 
residues are highlighted in red. Positions with residues in red face share 70% similarity as calculated 
with the Risler algorithm (56). The alignment was generated with ClustalW2 and displayed with 
ESPript 2.2. GenBank accession numbers are: Mus musculus: NP_034196; Homo sapiens: 
NP_001124295; Bos taurus: NP_872592; Monodelphis domestica: NP_001028141; Gallus gallus: 
NP_996835; Xenopus laevis: NP_001084021; Danio rerio: NP_571264; Paracentrotus lividus: Q27746 
(Swiss Prot); Bombyx mori: NP_001036980; Apis mellifera: NP_001164522 (Dnmt1a). 
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Supplementary Figure 2. Differential mobility of GFP-CXXCDnmt1 in nucleoli and nucleoplasm of mouse 
C2C12 myoblasts measured by FRAP analysis. Identical regions of interest over the nucleoplasm or 
nucleoli (as exemplified in the inset) were bleached and recovery curves were recorded over 30 
seconds. GFP-CXXCDnmt1 kinetics are faster in nucleoli than in the nucleus, which indicates more 
transient (possibly unspecific) binding in the former than in the latter. Scale bar: 5µm. 
 
 




Supplementary Figure 3. Radioactive methyltransferase activity assay for GFP-Dnmt1 and 
GFP-Dnmt1∆CXXC. The transfer of [3H]-methyl groups to poly(dI·dC)-poly(dI·dC) substrate was 
measured for increasing volumes of GFP fusion proteins immunopurified from transiently transfected 
HEK293T cells. Counts per minute (cpm) were normalized to the relative protein concentration as 
determined by SDS-PAGE analysis. GFP was used as negative control. Numbers above the bars 
indicate the volume of protein solution added. 
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SUPPLEMENTARY METHODS  
 
In vitro methyltransferase activity assay 
The GFP-binding protein (GBP) was fused to a 6xHis tag, expressed in E. coli and purified as described 
(47). For coupling to Ni-NTA agarose beads (Qiagen), 8 mg of His-tagged GBP were added to 1 ml of 
equilibrated beads and incubated in PBS for 2 h at 4°C. Unbound protein was washed out twice with 
PBS. Extracts of HEK293T cells expressing GFP or a GFP fusions were prepared in 200 µl lysis buffer II 
(50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM imidazole, 0.5 % Tween-20, 2 mM MgCl2, 1 mg/ml 
DNaseI, 2 mM PMSF, 1X mammalian protease inhibitor mix). After centrifugation, supernatants were 
diluted to 500 µl with immunoprecipitation buffer II (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 0.05 % Tween-20) and precleared by incubation with 25 µl of equilibrated Ni-NTA agarose 
beads for 30 min at 4°C followed by centrifugation. Precleared extracts were then incubated with 40 
µg of His-tagged GBP coupled to Ni-NTA beads for 2 hours at 4°C with constant mixing. GFP or GFP 
fusions were pulled down by centrifugation at 540 g. After washing twice with wash buffer II (50 mM 
NaH2PO4 pH 8.0, 300 mM NaCl, 20 mM imidazole, 0.05 % Tween-20), complexes were eluted with 60 
µl of elution buffer (10 mM Tris pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 250 mM imidazole) for 
10 min at 25°C with constant mixing. 10 µl aliquots of all eluates were subjected to western blot 
analysis using a mouse monoclonal anti-GFP antibody (Roche) and quantified by densitometry. 
Indicated volumes of eluate were incubated with 1 µg of poly(dI·dC)- poly(dI·dC) substrate (Sigma), 
0.5 µg/µl of BSA and 1 µCi of S-adenosyl-[3H-methyl]-methionine in 50 µl of trapping buffer (10 mM 
Tris pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM DTT) for 60 min at 37°C. 15 µl of each sample were 
spotted onto blotting paper and the DNA was precipitated with ice cold 5 % TCA. After washing twice 
with 5% TCA and once with cold 70 % ethanol, paper filters were air dried and analyzed by 
scintillation in 4 ml scintillation cocktail (Rotiszint® eco plus, Roth) for 5 min. 
 
Supplementary references 
47. Rothbauer, U., Zolghadr, K., Muyldermans, S., Schepers, A., Cardoso, M.C. and Leonhardt, H. 
(2007) A versatile nanotrap for biochemical and functional studies with fluorescent fusion 
proteins. Mol Cell Proteomics. 
56. Mohseni-Zadeh, S., Brezellec, P. and Risler, J.L. (2004) Cluster-C, an algorithm for the large-
scale clustering of protein sequences based on the extraction of maximal cliques. Comput 
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ABSTRACT
DNA methylation and histone modifications play
a central role in the epigenetic regulation of gene
expression and cell differentiation. Recently, Np95
(also known as UHRF1 or ICBP90) has been found
to interact with Dnmt1 and to bind hemimethylated
DNA, indicating together with genetic studies a
central role in the maintenance of DNA methylation.
Using in vitro binding assays we observed a
weak preference of Np95 and its SRA (SET- and
Ring-associated) domain for hemimethylated CpG
sites. However, the binding kinetics of Np95 in
living cells was not affected by the complete loss
of genomic methylation. Investigating further links
with heterochromatin, we could show that Np95
preferentially binds histone H3 N-terminal tails
with trimethylated (H3K9me3) but not acetylated
lysine 9 via a tandem Tudor domain. This domain
contains three highly conserved aromatic amino
acids that form an aromatic cage similar to the
one binding H3K9me3 in the chromodomain of
HP1ß. Mutations targeting the aromatic cage of
the Np95 tandem Tudor domain (Y188A and Y191A)
abolished specific H3 histone tail binding. These
multiple interactions of the multi-domain protein
Np95 with hemimethylated DNA and repressive
histone marks as well as with DNA and histone
methyltransferases integrate the two major
epigenetic silencing pathways.
INTRODUCTION
DNA methylation and histone modiﬁcations are crucially
involved in the regulation of gene expression, inheritance
of chromatin states, genome stability and diﬀerentiation
(1–3). Although the biochemical networks controlling
these epigenetic marks have been the subject of intensive
investigation, their interconnection is still not well
resolved in mammals. DNA methylation patterns are
established by de novo DNA methyltransferases Dnmt3a
and 3b, while Dnmt1 is largely responsible for maintaining
genomic methylation after DNA replication (4,5). Dnmt1
possesses an intrinsic preference for hemimethylated
DNA substrates (6,7) and associates with proliferating
cell nuclear antigen (PCNA) at replication sites in vivo
(8–10). The transient interaction of Dnmt1 with PCNA
enhances methylation eﬃciency but is not strictly
required to maintain genomic methylation in human and
mouse cells (11,12).
Recently, Np95 has emerged as a central regulatory
factor for DNA methylation and interacts with all three
Dnmts (13). Np95 localizes at replication foci and its
genetic ablation leads to genomic hypomethylation and
developmental arrest (14–19). Np95 and its SET- and
Ring- associated (SRA) domain were shown to bind
hemimethylated DNA with higher aﬃnity than corre-
sponding symmetrically methylated or unmethylated
sequences both in vitro and in vivo (17,18,20–22). In
addition, crystal structures of the SRA domain com-
plexed with hemimethylated oligonucleotides revealed
ﬂipping of the 5-methylcytosine out of the DNA double
helix, a conﬁguration that would stabilize the SRA–DNA
interaction (20–22). Thus, recruitment of Dnmt1 to
hemimethylated CpG sites by Np95 has been proposed
as mechanism for the maintenance of genomic
methylation.
In addition to its role in controlling DNA methylation,
Np95 has been shown to take part in several other
chromatin transactions. Np95 or its human homolog
ICBP90/UHRF1 were reported to interact with the
histone deacetylase HDAC1 and the histone methyl-
transferase G9a and to mediate silencing of a viral
promoter, suggesting a role of Np95 in gene silencing
through histone modiﬁcation (13,23,24). Np95 binds
histone H3 and displays a Ring domain-mediated E3
ubiquitin ligase activity for core histones in vitro and
possibly histone H3 in vivo (25,26). The plant
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homeodomain (PHD) of Np95 has been linked to
decondensation of replicating pericentric heterochromatin
(PH), but it is still unclear which domains recognize
speciﬁc histone modiﬁcations (16,26,27).
In this study we systematically analyzed the binding
properties of Np95 and its individual domains to DNA
and histone tails in vitro and their binding kinetics in living
cells. Our data reveal a multi-functional modular structure




Expression construct for GFP–Dnmt1 and RFP–PCNA
were described previously (10,28,29). All Np95 constructs
were derived by PCR from corresponding myc- and
His6-tagged Np95 constructs (25). To obtain GFP–
and Cherry-fusion constructs the Dnmt1 cDNA in the
pCAG–GFP–Dnmt1-IRESblast construct (11) or the
pCAG–Cherry–Dnmt1–IRESblast was replaced by Np95
encoding PCR fragments. The GFP–Np95Tudor
expression construct was derived from the GFP–Np95
construct by overlap extension PCR (30). The GFP–
Tudor mutant (Y188A, Y191A) was derived from the
GFP–Np95 construct by PCR-based mutagenesis (31).
All constructs were veriﬁed by DNA sequencing.
Throughout this study enhanced GFP (eGFP) or
monomeric Cherry (mCherry) constructs were used and
for simplicity referred to as GFP– or Cherry-fusions.
Cell culture, transfection and immunoﬂuorescence staining
HEK293T cells and embryonic stem cells (ESCs) were
cultured and transfected as described (11), with the excep-
tion that FuGENE HD (Roche) was used for transfection
of ESCs. The dnmt1/ J1 ESCs used in this study are
homozygous for the c allele (4). For immunoﬂuorescence
staining, TKO ESCs were grown on cover slips, ﬁxed with
3.7% formaldehyde in PBS for 10min and permeabilized
with 0.5% Triton X-100 for 5min. After blocking with 3%
BSA in PBS for 1 h endogenous Np95 was detected with a
polyclonal rabbit anti-Np95 serum (32). The secondary
antibody was conjugated to Alexa Fluor 568 (Molecular
Probes). Nuclear counterstaining was performed with
DAPI and cells were mounted in Vectashield (Vector
Laboratories). Images were obtained using a TCS SP5
AOBS confocal laser scanning microscope (Leica) using
a 63x/1.4NA Plan-Apochromat oil immersion objective.
Fluorophores were excited with 405 and 561 nm lasers.
In vitro DNA binding assay
The in vitro DNA binding assay was performed as
described previously (33) with the following modiﬁcations.
Two diﬀerent double-stranded DNA probes were labeled
with distinct ﬂuorophores and used in direct competition
(see Supplementary Figures S3 and S6 for details).
DNA oligos were controlled for CG methylation state
by digestion with either a CG methylation-sensitive
(HpaII) or -insensitive (MspI) enzyme (Supplementary
Figure S4). For extract preparation 2mM MgCl2 and
1mg/ml DNaseI were included in the lysis buﬀer.
Extracts from 1-3 transfected 10 cm plates were diluted
to 500-1000 ml with immunoprecipitation (IP) buﬀer and
1 mg of GFP–Trap (34) (ChromoTek, Germany) per ﬁnal
assay condition was added. After washing and equilibra-
tion beads were resuspended in 500ml of binding buﬀer
(20mM Tris-HCl pH 7.5, 150mM NaCl, 0.5mM
EDTA, 1mM DTT, 100 ng/ml BSA). Two oligonucleotide
substrates were added to a ﬁnal concentration of 50 nM
each and incubated at room temperature (RT) for 60min
with constant mixing. Fluorescence intensity measure-
ments were performed with a Tecan Inﬁnite M1000
plate reader using the following excitation/emission wave-
lengths: 490±10 nm/511±10nm for GFP, 550±15nm/
580±15nm for ATTO550 and 650±10nm/670±10 nm
for ATTO647N. Values were adjusted using standard
curves obtained with ATTO-dye coupled oligonucleotide
primers and puriﬁed GFP. Binding activity was expressed
as the ratio between the ﬂuorescent signals of bound
DNA probe and GFP fusion protein bound to the
beads, so that the signals from bound probes are
normalized to the amount of GFP fusion. Furthermore,
values were normalized using a control set of DNA probes
having identical sequences but distinct ﬂuorescent labels
(see Supplementary Figures S3 and S6 for details).
Peptide pull-down assay
Peptides were purchased as TAMRA conjugates (PSL,
Germany) and are listed in Supplementary Figure S7.
The peptide pull-down assay was performed analogously
to the DNA binding assay described above. After one-step
puriﬁcation of GFP fusion proteins with the GFP–Trap
(ChromoTek, Germany), the beads were equilibrated in
1ml IP buﬀer and resuspended in 500 ml binding buﬀer
supplemented with 100 ng/ml of BSA. Peptides were
added to a ﬁnal concentration of 0.74mM and the
binding reaction was performed at RT for 15min to
60min with constant mixing. The beads were washed
twice with 1ml of IP buﬀer and resuspended in 100 ml of
the same. Wavelengths for excitation and measurement of
TAMRA were 490±5nm and 511±5nm, respectively.
Fluorescence intensity measurements were adjusted using
standard curves from TAMRA coupled peptide and
puriﬁed GFP.
Live cell microscopy and ﬂuorescence recovery after
photobleaching analysis
Live cell imaging and ﬂuorescence recovery after photo-
bleaching (FRAP) analysis were performed as described
previously (11). For presentation, we used linear contrast
enhancement on entire images.
Statistical analysis
Results were expressed as mean±SEM. The diﬀerence
between two mean values was analyzed by Student’s
t-test and was considered to be statistically signiﬁcant in
case of P< 0.05 and highly signiﬁcant with P< 0.001.
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Electrophoretic mobility shift and supershift assays
Un- and hemimethylated DNA substrates (1 pmol
UMB550 and HMB647N, respectively) were incubated
with 0.6 pmol puriﬁed GFP–Np95 and 0.4 pmol
GFP–antibody (mouse monoclonal antibody, Roche).
Samples were subjected to a 3.5% non-denaturing
PAGE and analyzed with a ﬂuorescence scanner
(Typhoon Trio scanner; GE Healthcare) to detect
ATTO550 (unmethylated substrate), ATTO647N
(hemimethylated substrate) and green ﬂuorescence
(GFP–Np95).
RESULTS AND DISCUSSION
Np95 binding kinetics is largely independent of DNA
methylation levels in vivo
Recent studies showed Np95 bound to hemimethylated
DNA, suggesting that the essential function of Np95 in
the maintenance of DNA methylation consists of
substrate recognition and recruitment of Dnmt1. To inves-
tigate the dynamics of these interactions in vivo we
transiently transfected wild-type (wt) J1 ESCs with expres-
sion constructs for Cherry-Np95 and GFP–Dnmt1 and
monitored their subcellular distribution using live-cell
microscopy (Figure 1A and B). Np95 showed a nuclear
distribution with a cell cycle-dependent enrichment at
replicating PH, similar to Dnmt1. Consistent with earlier
observations (8,12,14–16) we detected co-localization of
Np95 and Dnmt1 at sites of DNA replication. We
investigated the dynamics of Np95 binding by quantitative
ﬂuorescence recovery after photobleaching (FRAP)
analysis (Figure 1B). As chromocenters (aggregates of
PH) are not homogeneously distributed in the nucleus,
we chose to bleach half nuclei to ensure that the
bleached region contains a representative number of
potential binding sites. We observed a relatively fast and
full recovery of relative GFP–Dnmt1 ﬂuorescence inten-
sity (Figure 1B), reﬂecting a transient and dynamic inter-
action as described before (11). In contrast, Cherry-Np95
showed a considerably slower and only partial (80%)
recovery within the same observation period. These
results indicated a relatively stable binding of Np95 to
chromatin and revealed an immobile protein fraction of
about 20%. These in vivo binding properties would be
consistent with tight binding of Np95 to hemimethylated
CpG sites and ﬂipping of the methylated cytosines out of
the DNA double helix as shown in recent co-crystal struc-
tures of the SRA domain of Np95 (20–22).
To directly test the contribution of DNA methylation
and the interaction with Dnmt1 to protein mobility, we
compared the binding kinetics of GFP–Np95 in wt ESCs
and ESCs lacking either Dnmt1 or all three major DNA
methyltransferases Dnmt1, 3a and 3b (triple knockout,
TKO). Surprisingly, Np95 binding to chromatin was not
aﬀected by either drastic reduction (dnmt1/) or even
complete loss (TKO) of genomic methylation and
showed in both cases remarkably similar FRAP kinetics
compared to wt J1 ESCs (Figure 1C). Similar results were
obtained with a C-terminal GFP fusion (Np95-GFP;
Supplementary Figure S1), arguing against conforma-
tional or sterical impairments of the N-terminal fusion
protein that could aﬀect the binding kinetics. Also, both,
the levels of endogenous Np95 and its degree of accumu-
lation at chromocenters were highly variable in TKO cells,
with chromocenter accumulation clearly visible in some
cells (Supplementary Figure S2). These results show that
DNA methylation and the three DNA methyltransferases
do not have a major eﬀect on the overall binding kinetics
of Np95 in living cells.
The SRA domain of Np95 is necessary and suﬃcient for
DNA binding in vitro
Next, we investigated the DNA binding activity of Np95
and the contribution of distinct Np95 domains by
generating a systematic set of individual domains and
deletion constructs fused to GFP (Figure 2A). To
directly compare the in vitro binding aﬃnity of Np95
regarding diﬀerent methylation states, we synthesized
double-stranded DNA-binding substrates with either one
or three un- or hemimethylated CpG sites and labeled
them with two distinct ﬂuorophores (Supplementary
Figure S3). DNA probes were controlled for CG
methylation state by digestion with either a CG
methylation-sensitive (HpaII) or -insensitive (MspI)
enzyme (Supplementary Figure S4). Performing conven-
tional electrophoretic mobility shift and supershift assays
we conﬁrmed the DNA binding activity of Np95 and
detected a preference for hemimethylated DNA substrates
(Figure 2B and Supplementary Figure S5).
As a second line of evidence and to quantify binding
preferences, we applied our recently developed non-
radioactive DNA binding assay (33) and tested
GFP–fused wt Np95 as well as a systematic set of individ-
ual domains and deletion constructs for their DNA-
binding properties in vitro (Figure 2C and Supplementary
Figure S6). This assay allows fast comparison of diﬀerent
potential binding substrates in direct competition as
well as the simultaneous quantiﬁcation of GFP–labeled
protein to calculate relative binding activity. The diﬀerent
GFP–Np95 fusion constructs were expressed in HEK293T
cells, puriﬁed with the GFP–Trap (34) and incubated with
the ﬂuorescently labeled DNA substrates. GFP–fusion
protein and bound DNA substrates were quantiﬁed with
a ﬂuorescence plate reader (Figure 2C and Supplementary
Figure S6). Furthermore, results were corrected for any
bias due to incorporation of diﬀerent ﬂuorescent labels
(Supplementary Figures. S3 and S6). Under these assay
conditions we observed an up to 2-fold preference
(factor 1.6–1.9) of Np95 for DNA substrates containing
one or three hemimethylated CpG sites (Supplementary
Figure S6). Deletion of the SRA domain completely abol-
ished the DNA-binding activity of Np95, whereas deletion
of either the PHD or the Tudor domain had no eﬀect
(Figure 2C). Consistently, the isolated PHD and Tudor
domains did not bind to DNA, while the SRA domain
alone showed similar binding strength and sequence pref-
erence as full-length Np95. Together, these results clearly
demonstrate that the SRA domain of Np95 preferentially
binds to hemimethylated CpG sites, although this
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Figure 1. Binding kinetics of Dnmt1 and Np95 in living cells. (A) Schematic representation of Np95 and Dnmt1 ﬂuorescent fusions. Ubl,
ubiquitin-like domain; Tudor, tandem Tudor domain; PHD, plant homeodomain; SRA, SET- and Ring-associated domain; Ring domain; PBD,
PCNA-binding domain; TS, targeting sequence; ZnF, zinc-ﬁnger; BAH, bromo adjacent homology domain; (KG)7, lysine-glycine repeat. (B) Dnmt1
and Np95 display diﬀerent kinetics. Representative images from FRAP experiments on wt J1 ESCs transiently co-transfected with Cherry-Np95 and
GFP–Dnmt1 constructs. Images show co-localization at chromocenters before (Pre) and at the indicated time points after (Pb) bleaching half of the
nucleus. Bleached areas are outlined. Corresponding FRAP curves are shown on the right. Bars, 5 mm. (C) FRAP kinetics of GFP–Np95 in J1 ESCs
with diﬀerent genetic backgrounds [wt, dnmt1–/– and dnmt1–/–, 3a–/–, 3b–/– (TKO)]. Kinetics of GFP–Dnmt1 is shown for comparison. Mobile and
immobile fractions are indicated on the right. Values represent mean±SEM.
Nucleic Acids Research, 2010, Vol. 38, No. 6 1799
 at Universitatsbibliothek M






preference is only about 2-fold with puriﬁed proteins and
substrates in vitro.
The SRA domain dominates binding kinetics but not
localization of Np95
Next, we investigated the role of distinct Np95 domains
in nuclear interactions in vivo. To this aim, we expressed
the same GFP–Np95 constructs in np95/ ESCs and
tested their binding kinetics with FRAP experiments
(Figure 2D). Importantly, GFP–Np95 showed similar
FRAP kinetics in Np95 deﬁcient, wt or Dnmt-deﬁcient
ESCs (Figures 1C and 2D). Among all domains tested,
only the SRA domain showed similar kinetics as
full-length Np95, including the relatively slow recovery
and an immobile fraction of about 20%, while the
Tudor and PHD domain displayed the same high
mobility as GFP. Also, FRAP curves of the corresponding
deletion constructs indicated that the Tudor and the PHD
domains have only a minor contribution to in vivo binding
kinetics, while deletion of the SRA domain drastically
increased the mobility of Np95. These data indicate that
the SRA domain dominates the binding kinetics of Np95
in vivo. Curiously, the addition of the PHD to the SRA
domain (GFP–PHD-SRA) resulted in intermediate
kinetics and loss of the immobile fraction. This eﬀect
was, however, not observed in the context of the
full-length protein, suggesting that nuclear interactions
of Np95 are controlled by a complex interplay among
its domains. To directly study the role of the SRA
domain in controlling the subcellular localization of
Np95 we co-transfected np95/ ESCs with expression
constructs for Cherry-Np95 and either GFP–SRA or
GFP–Np95SRA (Figure 2E). This direct comparison
showed that the isolated SRA domain does not co-localize
with full-length Np95 at PH. Together, these results
indicate that the SRA domain of Np95 is necessary and
suﬃcient for DNA binding in vitro and also dominates the
binding kinetics in vivo, but is per se not suﬃcient for
proper subnuclear localization. The fact that the
Np95SRA construct co-localized with Np95 suggests
that other domains than the SRA control the subcellular
targeting of Np95.
Np95 binds to histone H3 via a tandem Tudor domain
Database searches showed that the sequence between the
Ubl and PHD domains of Np95 is highly conserved in
vertebrates and displays structural similarity to the
family of Tudor domains [(35); PDB 3db4; Figure 3A
and B]. The crystal structure revealed that the Tudor
domain is composed of two subdomains (tandem Tudor)
forming a hydrophobic pocket that accommodates a
histone H3 N-terminal tail trimethylated at K9
(H3K9me3) (PDB 3db3; Figure 3C). This hydrophobic-
binding pocket is created by three highly conserved
amino acids (Phe152, Tyr188, Tyr191) forming an
aromatic cage (Figure 3A and C). Interestingly, a very
similar hydrophobic cage structure has been described
for the chromodomain of the heterochromatin protein
1ß (HP1ß) (Supplementary Figure S7) that is known to
bind trimethylated lysine 9 of histone H3 and associates
with PH (36).
To further investigate the histone tail-binding properties
of Np95, we mutated two amino acids of the aromatic
cage (Y188A, Y191A) and tested the isolated tandem
Tudor domain and corresponding mutant in comparison
with Np95 using a peptide binding assay. GFP–Np95,
GFP–Tudor and GFP–Tudor (Y188A, Y191A) were
expressed in HEK293T cells, puriﬁed with the GFP–
Trap and incubated with TAMRA-labeled histone tail
peptides. The ﬂuorescence intensity of GFP fusion
proteins and bound peptides was quantiﬁed and the
relative binding activity calculated (Figure 3D and
Supplementary Figure S7). The tandem Tudor domain
showed a highly signiﬁcant preference for the trimethy-
lated (H3K9me3) peptide, while this eﬀect was less pro-
nounced in the full-length Np95. Interestingly, acetylation
of K9 (H3K9ac), a modiﬁcation largely underrepresented
in silent chromatin, prevented binding of the tandem
Tudor domain. Remarkably, point mutations targeting
aromatic cage residues within the tandem Tudor domain
completely abolished speciﬁc binding to N-terminal
histone H3 peptides.
Consistent with these binding data the tandem Tudor
domain also showed a weak enrichment at PH, while the
PHD domain, previously proposed as potential histone
H3-binding motif (26), did neither bind to H3K9
peptides in vitro nor to PH in vivo (Supplementary
Figure S8). These results indicate that the tandem Tudor
domain of Np95 features a peptide binding pocket with
structural and functional striking similarity to HP1ß and
confers selective binding to histone modiﬁcation states
associated with silent chromatin.
These multiple interactions of Np95 with heterochro-
matin components correlate well with functional data.
The depletion of Np95 in mouse cells resulted in increased
transcription of major satellite repeats (16). Also, an inter-
action of Np95 with G9a was described and both were
found to be essential for transcriptional regulation (24)
and epigenetic silencing of transgenes (13).
In summary, we showed that the SRA domain is neces-
sary and suﬃcient for DNA binding of Np95 in vitro.
Photobleaching experiments further indicated that the
SRA domain also dominates the binding kinetics of
Np95 in living cells which was however largely indepen-
dent of the DNA methylation level. These results suggest
that the SRA domain may also bind to unmethylated
DNA or undergo additional, still unidentiﬁed interactions
in vivo. While the essential role of Np95 in the mainte-
nance of DNA methylation is well established, it is still
unclear how a relatively weak preference for hemimethy-
lated DNA can be suﬃcient to maintain DNA methyla-
tion patterns over many cell division cycles for an entire
life time. We suggest that the multiple interactions of
the multi-domain protein Np95 with hemimethylated
DNA and H3K9 methylated histone tails as well as with
histone (G9a) and DNA (Dnmt1, 3a and 3b) methyl-
transferases may add up to the necessary speciﬁcity
in vivo. Clearly, these multiple interactions place Np95 at
the center of various epigenetic silencing mechanisms and
likely mediate epigenetic crosstalk.
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Figure 2. In vitro DNA binding and in vivo mobility of Np95 domains. (A) Schematic representation of the analyzed GFP–Np95 fusion constructs.
(B) Electrophoretic mobility shift and supershift assay. GFP–Np95 binding to hemimethylated DNA substrates is shown by the shifted
GFP–Np95:DNA complex. The addition of a GFP–antibody supershifted the GFP–Np95:DNA complex (supershift assay with unmethylated
DNA substrates in direct competition with hemimethylated DNA substrates is shown in Supplementary Figure S6). (C) In vitro DNA-binding
properties of Np95 constructs. Binding assays were performed using ﬂuorescently labeled double stranded oligonucleotide probes containing one
central hemimethylated CpG site. Shown are ﬂuorescence intensity ratios of bound probe/bound GFP fusion. Values represent means and SD of
three to six independent experiments. GFP was used as control. Further control experiments with either one or three central CpG sites and
alternating ﬂuorescent labels are shown in Supplementary Figure S3. (D) Kinetics of Np95 constructs in living np95–/– ESCs determined by half
nucleus FRAP analysis. GFP is shown as reference. Curves represent mean values from 6 to 15 nuclei. SEM (0.001–0.005) is not shown for clarity of
illustration. (E) Confocal mid-sections of living np95–/– ESCs transiently expressing the indicated Np95 fusion constructs (left and mid-panels).
Merged images are displayed on the right. Bar, 5 mm.
Nucleic Acids Research, 2010, Vol. 38, No. 6 1801
 at Universitatsbibliothek M









































































































































Figure 3. Structure and H3 N-terminal tail binding of the tandem Tudor domain. (A) Schematic drawing of the multi-domain architecture of Np95
(top) and alignment of tandem Tudor domains from vertebrate Np95 homologs (bottom). Arrows show the end and start positions of the crystallized
tandem Tudor domain shown in (B). Residues forming the aromatic cage shown in (C) are indicated by arrowheads. Absolutely conserved residues of
the tandem Tudor domain are black shaded, while positions showing conservative substitutions are boxed with residues in bold face.
Secondary-structure elements were generated with EsPript (37) using the crystal structure of human UHRF1 (PDB 3db3 and 3db4) and are
shown above the amino acid sequence: a-helices (g), b-strands, strict alpha turns (TT) and strict beta turns (TTT). Accession numbers: Homo
sapiens Q96T88.1; Pan troglodytes XP_001139916.1; Bos Taurus AAI51672.1; Mus musculus Q8VDF2.2; Rattus norvergicus Q7TPK1.2; Dario rerio
NP_998242.1; Xenopus laevis ABY28114.1, Gallus gallus XP_418269.2. (B) Side view of the tandem Tudor domain as a cartoon model (left) and as
surface representation (right) in complex with a histone H3 N-terminal tail peptide trimethylated at lysine 9 (green stick model; only Arg8-Lys9-Ser10
of the H3 peptide are resolved). The image was generated with PyMOL (38). (C) An aromatic cage is formed by Phe152, Tyr188 and Tyr191 and
accommodates the trimethylated lysine 9 of H3 (H3K9me3). (D) Histone H3 N-terminal tail binding speciﬁcity of GFP–Np95, GFP–Tudor and
GFP–Tudor (Y188A Y191A) in vitro. Shown are ﬂuorescence intensity ratios of bound probe/bound GFP fusion. GFP was used as negative control.
Shown are means±SEM from four to ten independent experiments and two-sample t-tests were performed that do or do not assume equal
variances, respectively. Statistical signiﬁcance compared to the binding ratio of H3K9me3 is indicated: *P< 0.05, **P< 0.001.
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Supplementary Figure 1. Nuclear localization, FRAP kinetics and DNA binding specificity 
for an Np95 construct C-terminally fused to GFP (Np95-GFP, respectively). (A) Schematic 
drawing of Np95-GFP. Abbreviations are as in Fig. 1. (B) Representative images from FRAP 
experiments for Np95-GFP transiently expressed in wt, dnmt1-/- and TKO J1 ESCs as indicated 
on the left. Images show confocal mid-sections of nuclei before (Pre) and at the indicated time 
points after bleaching (Pb) half of the nucleus. Bleached areas are outlined. Arrowheads mark 
pericentric heterochromatin. Bars, 5 µm. (C) FRAP kinetics of Np95-GFP in J1 ESCs with 
different genetic backgrounds as shown in B and Fig. 1C. Kinetics of GFP-Dnmt1 is shown for 
comparison. Mobile and immobile fractions are indicated on the right. Values represent mean ± 
SEM. Note that the kinetics are similar to those shown for GFP-Np95 in Fig. 1C and that there is 
no significant difference in cells with different genetic backgrounds.  
 
  




Supplementary Figure 2. Variable expression levels and localization of Np95 in TKO cells. 
TKO cells were stained with DAPI (A, B and C) and an anti-Np95 antibody (A’, B’ and C’). 
A-A’ and B-B’ show examples of cells with very low and high Np95 levels, respectively. In B’ 
accumulation of endogenous Np95 at chromocenters is evident. C and C’ show a field containing 
cells with very different Np95 levels and degrees of Np95 accumulation at chromocenters. Scale 
bars are 3 µm (A-B’) and 10 µm (C and C’). 
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Supplementary Figure 3. Oligo design for the in vitro DNA binding assay (A) DNA 
oligonucleotides used for the preparation of double stranded probes for in vitro DNA binding 
assays. M: 5-methyl-cytosine. (B) Description of double stranded probes used for in vitro DNA 
binding assays. Name, status of the central CpG site, fluorescent label, as well as DNA 
oligonucleotides and nature of the dCTP used in the primer extension reaction are specified. By 
using a control set of two probes with identical sequence but different fluorescent labels we 
observed effects due to probe preparation and/or unspecific binding of ATTO dyes (data not 










Supplementary Figure 4. Quality control of un- and hemi-methylated DNA substrates 
Unmethylated and hemimethylated DNA substrates (UMB550 and HMB647N, respectively) 
were digested with MspI or HpaII and analyzed by 15 % non-denaturing PAGE for CG 
methylation. DNA substrates were detected via their fluorescent ATTO label using the Typhoon 
Trio scanner. Note that the unmethylated DNA substrate is digested by both MspI and HpaII, 
whereas the hemimethylated substrate is cut by MspI, but not by the methylation sensitive HpaII. 
Sequences of the double stranded probes before (42mer) and after cut (21mer) as well as the 
unextended primer are displayed above. Enzyme recognition motifs are boxed and asterisks 
represent fluorescent ATTO label.  




Supplementary Figure 5. Electrophoretic mobility shift and supershift assays with 
GFP-Np95. Un- and hemimethylated DNA substrates (1 pmol UMB550 and HMB647N, 
respectively) were incubated with 0.6 pmol purified GFP-Np95 and 0.4 pmol GFP-antibody. 
Samples were subjected to a 3.5 % non-denaturing PAGE and analyzed by the Typhoon Trio 
scanner to detect ATTO550 (unmethylated substrate), ATTO647N (hemimethylated substrate) 
and green fluorescence (GFP). Note that the DNA:GFP-Np95:GFP-antibody complex is shifting 
higher than the DNA:GFP-Np95 complex (arrows).  
 
 




Supplementary Figure 6. DNA binding specificity of GFP-Np95 
The sequence specific DNA binding activity of Np95 was tested with an in vitro binding assays 
using GFP-Np95 with un- and hemimethylated substrates in direct competition. The DNA 
substrates included either one (left) or three (right) CG sites. Note that regardless of the attached 
fluorescent label (indicated by asterisks) and number of CG sites the hemimethylated DNA 
substrates are preferentially bound (1.6- to 1.9-fold). Shown are the means ± SEM from two 










Supplementary Figure 7. Histone tail binding of Np95 and HP1ß (A) Amino acid sequences 
of TAMRA-labeled histone tail peptides used for the peptide binding assay. (B) Histone H3 and 
H4-tail binding specificity of GFP-Np95 in vitro. Ratios of bound TAMRA-labeled peptide over 
bound GFP fusion were determined and normalized to the ratio of H3K4/9un peptide over 
GFP-Np95. GFP was used as negative control. Shown are means ± SEM from six independent 
experiments. (C) Structural comparison of the H3K9me3-binding aromatic cages formed by the 
tandem Tudor domain of Np95 (left) and the chromodomain of HP1ß (right, PDB 1kne). In these 
structures, only Arg8-Lys9-Ser10 and Lys9-Ser10 from histone H3 are resolved peptides, 
respectively (green stick models). The image was generated with PyMOL (1).  
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Supplementary Figure 8. Histone tail binding and subcellular distribution of PHD and 
Tudor domain of Np95 (A) Histone H3 N-terminal tail binding specificity of GFP-Tudor, 
GFP-PHD and GFP in vitro. Shown are fluorescence intensity ratios of bound probe / bound 
GFP fusion. GFP was used as negative control. Shown are means ± SEM from four to six 
independent experiments. Only the tandem Tudor domain shows preferential binding of H3K9 
trimethylated histone tails. (B) Schematic representation of the analyzed Np95 constructs. All 
constructs were N-terminal GFP fusions (left panel). Confocal mid sections of living np95-/- 
ESCs transiently expressing the indicated Np95 fusion constructs and RFP-PCNA as S phase 
marker (left and mid panels). Merged images are displayed on the right. Bars, 5 µm. Only the 











































strand during DNA  replication,  thereby maintaining  an  important epigenetic mark. Crucial  for  this 
process  is  not  only Dnmt1’s  intrinsic  preference  for  hemimethylated  substrates,  but  also  various 
interactions  of  Dnmt1  with  different  cellular  structures  and  cofactors  at  different  cell‐cycle  and 




et  al.,  2003).  This  theoretical  model  was  based  on  sequence  comparison  with  prokaryotic 
methyltransferases, which contain the same conserved motifs that are necessary for the catalysis of 
the methyl  transfer  reaction. However, an  inhibitor designed on  the basis of  this homology model 
and directed against the catalytic center of Dnmt1 was only functional for the prokaryotic enzymes 
(RG108, unpublished data). Moreover, it is well established that the C‐terminal domain of Dnmt1 by 
itself  is  catalytically  inactive,  and  needs  interaction  with  the  N‐terminal  part  of  the  enzyme  for 
allosteric  activation,  thus  involving  structural  changes.  These  data  indicate  significant  structural 
differences between prokaryotic DNA methyltransferases and the catalytic domain of Dnmt1. Of the 
N‐terminal  two  thirds of  the enzyme, only an X‐ray structure of  the TS domain has been  reported 





Dnmt1  as  GFP  fusion  and  ATTO  labeled  DNA  substrates,  we  prepared  Dnmt1:DNA  complexes, 




covalently binds  two DNA substrates at  the same  time. This surprising observation clearly  requires 









It  was  suggested  that  Dnmt1  forms  a  stable  dimer  in  head‐to‐head  orientation  via  a  bipartite 
interaction surface located within the TS domain (Fellinger et al., 2009). However, nothing is known 
about  the  affinity of  this  interaction  and both  single molecule  spectroscopy methods used  in  this 
study require highly diluted samples. To find out whether Dnmt1 forms a monomer or a dimer at the 
concentration range of our experimental conditions (1‐10 nM), we used GFP‐Dnmt1 and performed a 







GFP  and  GFP‐Dnmt1 were  expressed  in  HEK293T  cells  and  one‐step  purified  via  the  GFP  tag  as 
described before ((Frauer and Leonhardt, 2009), chapter 2.3, supplementary methods). Briefly, cells 
were lysed and incubated with agarose beads that are functionalized with the His‐tagged GFP binding 




beads  ((Frauer  and  Leonhardt,  2009),  chapter  2.1).  Furthermore,  we  established  a  protocol  for 
preparation  and  purification  of  covalent  Dnmt1:DNA  complexes.  We  prepared  DNA  trapping 
substrates  containing  the mechanism‐based  inhibitor  5‐aza‐cytosine  at  a  central  hemimethylated 
CpG site as described (Frauer and Leonhardt, 2009), chapter 2.1). The DNA substrates were 42 base 
pairs  in  length and  labeled with ATTO550 or ATTO700. Upon  incubation of  immobilized GFP‐Dnmt1 
with  trapping DNA substrates  in  the presence of  the cofactor S‐adenosine‐L‐methionine  (AdoMet), 
an  irreversible  covalent  bond  is  formed  between  enzyme  and DNA,  involving  the  cysteine  of  the 
catalytic  PC  motif  (C1229)  and  the  5‐aza‐cytosine  of  the  CpG  site,  respectively.  The  covalent 
Dnmt1:DNA complexes were subsequently eluted  from the beads as described above.  Importantly, 










the  single molecule  level,  revealing  that  the molecular  brightness  of GFP  in  complex with GBP  is 
improved by a factor of 1.4. The molecular brightness of GFP‐Dnmt1 is very similar to this value both 






Figure 9.  (A) Working principle of  fluorescence  intensity distribution analysis  (FIDA). A  fluorescence  intensity 
trace of a fluorophore in solution is recorded with a carefully chosen bin size (left). Subsequently, a histogram 
of the number of photons within each time bin is calculated (right). These data can be fitted in order to retrieve 
the molecular brightness of  the  fluorophore.  (B)  Summary of  FIDA  for GFP  and GFP‐Dnmt1.  The molecular 
brightness  of GBP:GFP  and GBP:GFP‐Dnmt1  complexes was  normalized  to  that  of GFP. Note  that  the GFP 




To provide a  second  line of evidence  for  the monomeric  state of Dnmt1, we performed a  control 











contains  different  fluorescent  species  that  can  be  unambiguously  detected  and  identified  using 








that  is  not  zero.  But,  confirming  the  results  of  FIDA,  we  could  not  detect  any  cross‐correlation 
between  the  two  fluorophores,  excluding  the  formation  of  stable  GFP‐Dnmt1:RFP‐Dnmt1  dimers 
under these experimental conditions (Figure 10). Notably, the concentration of the co‐purified fusion 
















prepared  covalent  complexes  by  incubating  Dnmt1  simultaneously with  DNA  trapping  substrates 





Figure  11.  FCCS  analysis  of  HPLC‐purified  GFP‐Dnmt1:DNA  complexes.  GFP‐Dnmt1  was  simultaneously 
incubated  with  two  differently  labeled  DNA  trapping  substrates  (ATTO550  or  ATTO700,  respectively).  As 
revealed by FCCS analysis, cross‐correlation is present for GFP‐Dnmt1 with ATTO550‐DNA (A), GFP‐Dnmt1 with 
ATTO700‐DNA  (B), and ATTO550‐DNA with ATTO700‐DNA  (C). Autocorrelation  curves are  shown  for  relative 
amplitude comparison. Stars in the complex model indicate 5‐aza‐cytosine. 
 
Since we  know  that  Dnmt1  can  form  covalent  complexes with  DNA  substrates  containing  5‐aza‐
cytosine  at  a  CpG  site,  we  expected  a  significant  fraction  of  co‐diffusing  ATTO550/GFP  and 
ATTO700/GFP. Accordingly, we observed a clear cross‐correlation between GFP and both ATTO dyes 
(Figure  11A  and  11B,  respectively).  Additionally  and  very  surprisingly,  we  also  observed  cross‐
correlation  between  ATTO550  and  ATTO700  (Figure  11C),  suggesting  that  both  ATTO550  and 










to approximately 100 nM, which  is at  least one order of magnitude higher  than  the concentration 
range of our singe molecule experiments (Frauer and Leonhardt, 2009)).  
Thus, in order to exclude the possibility that covalent complexes of GFP‐Dnmt1 with the single DNA 
substrates  aggregate  subsequent  to  the  enzymatic  reaction,  we  first  prepared  both  GFP‐







Figure  12.  Cross‐correlation  between  the  two  DNA  labels  is  not  due  to  aggregation  subsequent  to  the 










column  (Figure  13A,  grey  curve).  This  sample  shows  a  peak  for  absorbance  at  280  nm  (aromatic 
amino  acids)  between  fractions  A12  and  B12, which  corresponds  to  an  elution  volume  of  about 
















Figure  13.  HPLC  and  FCCS  analysis  confirmed  that  GFP‐Dnmt1  forms  a  complex with  two  DNA  substrates 
simultaneously.  (A) GFP‐Dnmt1 was expressed  in HEK293T cells, one‐step purified via  the GFP nanotrap and 
subsequently incubated with two DNA trapping substrates having identical sequences but different fluorescent 
labels  (ATTO5500 or ATTO700,  respectively). Samples of GFP‐Dnmt1 and  the GFP‐Dnmt1:DNA complex were 
analyzed  by  size‐exclusion  chromatography,  detecting  absorbance  at  280,  488  and  700  nm.  Aliquots  of 
fractions A9‐B8 were subjected to 6 % SDS‐PAGE and Coomassie staining. (B) FCCS analysis was performed for 
fractions  A10‐B9,  and  cross‐correlation  amplitudes  for  GFP/ATTO550  (GY),  GFP/ATTO700  (GR)  and 






of  the  Dnmt1:DNA  sample  supports  this  hypothesis  (Figure  13B).  When  normalizing  the  cross‐
correlation amplitudes by the autocorrelation curve of GFP and plotting these values for the different 
elution  fractions,  the highest  cross‐correlation values of all possible  fluorophore  combinations are 
observed  for  the  fractions  corresponding  to  the  shoulder. However,  significantly,  cross‐correlation 
















Figure  14.  FCCS  analysis  of  HPLC‐purified  covalent  GFP‐Dnmt1:DNA  complexes  revealed  that  two  DNA 
substrates can bind covalently to GFP‐Dnmt1 at the same time. GFP‐Dnmt1 was simultaneously incubated with 
two  different  DNA  trapping  substrates  labeled with  either  ATTO550  or  ATTO700  (TT),  or, with  a  trapping 
substrate labeled with ATTO550 and a canonical binding substrate labeled with ATTO700 (BT). Significant cross‐
correlation between the two different DNA  labels was observed exclusively  in the first case.  Importantly, this 
cross‐correlation was  resistant  to denaturation of  the  complex  and not observed  for  a  catalytically  inactive 
mutant of Dnmt1 (Table 15). Stars in the complex models indicate 5‐aza‐cytosine. 
 
As mentioned  above, we  don’t  expect  non‐covalent DNA  binding  of Dnmt1  in  the  concentration 
range  used  for  our  single molecule  spectroscopy  studies.  To  test,  if  both  DNA molecules  in  the 
Dnmt1:DNA complex with 1:2 stoichiometry are indeed bound covalently or if one of them is bound 
non‐covalently, we  incubated  purified  GFP‐Dnmt1  either with  two  differentially  labeled  trapping 





substrates  have  the  identical  sequence  to  trapping  substrates  with  the  exception  of  having  a 




between ATTO  label  and GFP was  exclusively  observed  for  trapping  substrates,  suggesting  cross‐
correlation only in the case of covalent complex formation between Dnmt1 and DNA. Moreover, the 
observed  cross‐correlation  was  in  all  cases  resistant  to  denaturation  with  SDS  (Table  15),  again 
supporting  the hypothesis of covalent bond  formation.  In  stark contrast, when  likewise  incubating 
the  respective  DNA  substrates with  the  catalytic  site mutant  Dnmt1C1229W, which was  previously 
reported  to be catalytically  inactive  (Schermelleh et al., 2005), we did not detect cross‐correlation 
between  GFP  and  any  ATTO  label  (Table  15).  Together,  these  results  strongly  indicate  that  the 
complex formation between Dnmt1 and the two DNA substrates is indeed covalent. 
 
Table  15.  Summary of  FCCS  analyses  for  complexes of GFP‐Dnmt1 or  catalytically  inactive GFP‐Dnmt1C1229W 
with DNA  upon  incubation with  either  differentially  labeled  binding  and  trapping  substrates  (HMB550  and 
HMT700, respectively) or differentially labeled trapping substrates (HMT500 and HMT700, respectively). Cross‐
correlation between different pairs of fluorophores (CC pairs) was determined before and after denaturation 
with SDS. ‘+’  indicates that cross‐correlation  is clearly detected;  ‘‐‘ indicates that cross‐correlation  is zero; ‘(‐)’ 
indicates that the deviation of cross‐correlation from zero is so low, that it is probably due to aggregation. 
 
Protein  DNA substrate  CC pair  CC ‐ SDS  CC + SDS 
GFP‐Dnmt1  HMB550/HMT700  550/GFP  ‐  ‐ 
700/GFP  +  + 
550/700  ‐  ‐ 
GFP‐Dnmt1  HMT550/HMT700  550/GFP  +  + 
700/GFP  +  + 
550/700  +  + 
GFP‐Dnmt1C1229W  HMB550/HMT700  550/GFP  (‐)  ‐ 
700/GFP  (‐)  ‐ 
550/700  (‐)  ‐ 















GFP‐Dnmt1  including  a  TEV  site  in  the  linker  region was  purified  and  cut with  TEV  protease  resulting  in  a 











(amino  acid motif:  ENLYFQG) within  the  linker  region  between GFP  and Dnmt1. We  purified  this 
protein  as described  above making use of GBP  and GFP  tag,  and  subsequently used purified  TEV 
protease (TEVase) to cut the fusion protein at the respective recognition sequence. After establishing 














by Dnmt1. Thus, other methods should be applied  in order  to  further  investigate  the possibility of 
Dnmt1 dimerization. However, regardless of the question whether Dnmt1  is present as a monomer 
or  a  dimer,  its  state  is  not  changed  by  complex  formation  with  DNA  substrates  (Figure  13A). 
Moreover, we provide evidence that a single Dnmt1 molecule might be able to covalently bind two 
DNA  substrates at  the  same  time  (Figure 11 and 14). This  finding  is very  surprising and has  to be 
carefully confirmed and further investigated (see chapter 3.2.4 for a more extensive discussion). 
In  conclusion,  we  provide  evidence  for  the  possibility  that  monomeric  Dnmt1  binds  two  DNA 
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During mammalian development one single cell, the zygote, gives rise to a complete organism 
consisting of many different cell types. These cell types are genetically identical; however they differ 
dramatically in structure and function. In fact, each cell type expresses a very specific set of genes, 
whereas expression of other genes is stably repressed. Cellular differentiation during development is 
regulated by a complex network of transcriptional regulators leading to differential gene expression. 
In addition, transcriptional regulation is functionally linked with and controlled by DNA methylation 
and other epigenetic mechanisms such as histone modification, the Polycomb/Trithorax system and 
RNA-mediated processes. In mammals, DNA methylation (the covalent attachment of methyl groups) 
takes place at the C5 position of cytosine residues mostly at CpG dinucleotides, and is catalyzed by a 
family of DNA methyltransferases. The methylation state of gene regulatory sequences, including 
promoters and enhancers, changes throughout development and methylation often correlates with a 
transcriptionally silent state. These DNA methylation marks are recognized by methyl-CpG binding 
proteins and translated into repressive chromatin states by recruitment of histone modifying 
enzymes and chromatin remodeling factors. In this chapter, we review the current literature of how 
methylation marks are set and maintained, and how DNA methylation regulates gene expression 
during cellular differentiation and development. We also discuss new insights into the complex 







Although  the  sequence  of mammalian Dnmt1  is  known  since  two  decades  and  its  impact  in  the 
regulation of gene expression has been extensively studied and demonstrated, the exact mechanistic 
basis of Dnmt1’s maintenance function remains to be elucidated.  
In  this  PhD  work,  I  developed  new  powerful  tools  to  study  DNA methyltransferase  activity  and 
binding  specificity  of  Dnmt1  and  other  proteins  involved  in  epigenetic  gene  regulation.  Applying 
these methods,  I provide further  insights  into the regulation of Dnmt1 activity. The data show that 
Dnmt1  recognizes  its  substrate not at  the  initial DNA binding but at  the  step of covalent  complex 
formation, further elucidate the functional role of the Dnmt1 CXXC domain, and provide evidence for 
a more complex role of Uhrf1 in regulating maintenance methylation than merely recruiting Dnmt1 
to  hemimethylated  sites.  Furthermore,  I  established  and  applied  protocols  to  study  Dnmt1 










In  the  past,  a  variety  of  biochemical  assays  have  been  developed  for  measuring  DNA 
methyltransferase activity. However, all  these methods depend on  the use of radioactively  labeled 
cofactor AdoMet, expensive and demanding equipment and/or multiple‐step protocols.  In chapter 
2.1,  we  present  a  simple,  non‐radioactive  and  versatile  assay  for  characterization  of  DNA 
methyltransferase activity and DNA binding (Frauer and Leonhardt, 2009). We used fusion constructs 
of green fluorescent protein  (GFP) and a GFP binding nanobody coupled to agarose beads for one‐
step purification  (GFP‐Trap®, ChromoTek GmbH,  (Rothbauer et  al., 2007),  see  also  chapter 3.1.2). 
Subsequently, we  incubated  the  immobilized GFP  fusion  proteins with  fluorescently  labeled DNA 
substrates.  After  removal  of  unbound  substrate,  the  absolute  amounts  and molar  ratios  of  GFP 
fusion proteins and bound DNA substrates were determined by fluorescence spectroscopy. The assay 
measures methyltransferase  activity  as  irreversible  covalent  complex  formation with  fluorescently 
labeled DNA  substrates containing  the mechanism‐based  inhibitor 5‐aza‐cytosine. As  introduced  in 




substrates  (binding  substrates). However,  in  contrast  to binding  substrates,  the  covalent  complex 
formation of  trapping  substrates with Dnmt1  is  irreversible and  the enzyme  is covalently  trapped. 
Thus, by  comparing  immobilization of binding  and  trapping  substrates upon  incubation with DNA 
methyltransferases, we can discriminate enzymatic activity‐dependent trapping from canonical DNA 
binding  allowing  us  to  test  and  screen  for  active methyltransferases.  Furthermore,  we  carefully 
selected  fluorophores with distinct excitation and emission spectra and are now able  to  test up  to 
four fluorescent substrates in direct competition (chapter 2.3). This allows us to precisely determine 
DNA  substrate  specificity of DNA methyltransferases  for  two distinct  steps of  the methyl  transfer 
reaction, i.e. DNA binding and covalent complex formation.  
Using this assay, we gained further insights into Dnmt1’s preference for hemimethylated sites, which 
is  the basis of  its maintenance activity. As  introduced  in  chapter 1.2.3,  the  substrate  specificity of 
Dnmt1  is well  established: DNA  substrates  containing hemimethylated CpG  sites  are preferred  to 
unmethylated  substrates  (Bestor  and  Ingram,  1983;  Jeltsch,  2006).  However,  reports  on  the 
mechanism  of  substrate  recognition  as  well  as  on  the  Dnmt1  domains  involved  are  conflicting 
(Bacolla et al., 2001; Flynn et al., 1996). With our new assay, we have the unique opportunity to test 






fluorescent  labels, we  found  that  Dnmt1  binds  equally well  to  all  four  substrates  and  is  neither 
affected by  the  presence  nor by  the methylation  state of  the  CpG  site  (chapter  2.3, discussed  in 
3.2.1).  Furthermore,  we  show  for  the  first  time  that  Dnmt1  prefers  hemimethylated  over 
unmethylated  substrate  for  covalent  complex  formation,  an  early  step  of  the  methyl  transfer 
reaction  (chapter 2.1, discussed  in 3.2.1). The preference  factor of about 15‐fold  is  in  the  range of 
previously  published  experiments, which measured  the  net  product  of  the methylation  reaction 
(Jeltsch, 2006; Pradhan et al., 2008),  suggesting  that  substrate  recognition  takes place at an early 
stage  of  the  reaction.  It  is  important  to  stress  that  the  factor  we  determined  is  not  exactly 
comparable  to  the  factors  produced  by  assays  measuring  enzymatic  activity  as  the  number  of 
transferred  methyl  groups  and  with  non‐competitive  assay  designs.  With  our  assay,  we  can 
specifically  determine  sequence  preferences  at  the  step  of  covalent  complex  formation  with 
different substrates in direct competition, which is so far unique for all published methods. The new 
assay therefore represents an important technical advance in comparison to other methods. 
Regarding  the question of which parts of Dnmt1 are essential  for  substrate  specificity, we  started 









small molecule  inhibitor screenings or, using  the 5‐aza‐cytosine containing  trapping substrates,  for 
identification  of  active  DNA  methyltransferases  in  cell  extracts  by  a  combination  of  SDS‐PAGE, 
Western  blot  and mass  spectrometry  analyses.  Finally, we  further  applied  the  newly  established 
toolbox  for  DNA  substrate  preparation  via  primer  extension  and  developed  another  assay  for 
characterization of the methyl‐CpG binding protein MeCP2 (see below, chapter 3.1.3). 
In conclusion, we are convinced  that  further use of this assay will be very valuable  for deciphering 








When developing  the assay, we observed an  interesting  feature of  the GFP‐binding protein  (GBP) 
(Kirchhofer  et  al.,  2009).  GBP  is  a  camelid‐derived  single‐domain  antibody  (nanobody)  and 
constitutes  the active part of  the GFP‐Trap®  (ChromoTek GmbH). We surprisingly  found  that upon 
binding,  the  GBP modulates  the  conformation  and  spectral  properties  of  the  green  fluorescent 
protein  (GFP),  i. e. the GBP bound GFP showed enhanced fluorescence  intensity and a blue‐shifted 
emission spectrum (Figure 17, see also chapter 2.1 and 2.2). We confirmed the enhancement effect 
also by  single molecule  spectroscopy  (see chapter 2.5).  Initially, we  investigated  this phenomenon 
using  an  enhanced  variant  of GFP  (eGFP), which was  also  used  for  the  generation  of GFP  fusion 
constructs.  Afterwards,  also  other  GFP  variants  were  tested.  Notably,  we  found  that  the 
enhancement effect differs between different GFP variants. In fact, the enhancement effect for wild‐





Figure  17.  GBP modulates  spectral  properties  of  eGFP.  (A)  The  fluorescence  intensity  of  eGFP  (1  µM)  is 
enhanced  by  addition  of  increasing  amount  of GBP  up  to  around  1.4  times,  if  exciting  at  490  ±  5  nm  and 
detecting the emission at 511 ± 5 nm. (B) At equimolar concentration, the GBP shifts the emission maximum of 
eGFP upon excitation at 490 nm  to a  lower wavelength, more precisely  from 511 nm  to 508 nm. Error bars 
represent the standard deviation of three independent experiments. 
 
GFP  is  a  barrel‐shaped  protein with  a  central  p‐hydroxybenzylidene‐imidazolinone  chromophore, 
which results from oxidative backbone cyclization involving residues Ser65, Tyr66 and Gly67 (Adams 
et  al.,  2000;  Chalfie  et  al.,  1994; Ormo  et  al.,  1996).  The  enhanced  form  of GFP  (eGFP)  shows  a 
characteristic dual‐peak excitation spectrum with maxima at 395 nm and 490 nm, while excitation at 
both wavelengths results in emission that peaks at 511 nm. The dual excitation peak results from the 







which  is  characterized  by  increased  absorption  efficiency  and  explains  the  resulting  increase  of 
fluorescence  emission. Wild‐type GFP  is  even more  sensitive  to  this  enhancement  effect  by GBP 
binding, since  the chromophore of a predominant  fraction of molecules  is originally present  in  the 
neutral state. In contrast, eGFP already favors the anion state if unbound and thus one could argue 
that  the  GBP mimics  the mutational  effect  on  GFP.  Our  spectral  analysis  indicates  that  for  GBP 
complexes with eGFP (GBP:eGFP) exclusively the anion state of the chromophore remains. Thus, it is 
possible  that  the  GBP:eGFP  complex  corresponds  to  the  fluorophore  state with  optimal  spectral 
properties and maximal molecular brightness. Notably, other GFP binding nanobodies showed either 
no or a quenching effect,  in the second case by stabilization of the neutral chromophore state. We 
also  established  a  protocol  for  fluorescence  intensity  scans  in  living  cells  and  confirmed  that 
modulation of spectral GFP properties upon GBP binding takes also place in vivo.  
The described nanobody‐mediated enhancement of GFP  fluorescence could be applied  to  improve 






Using  the  established  assay, we  can  now  easily  test DNA  binding  activity  and  specificity  of  other 
chromatin  associated  proteins.  As  introduced  in  chapter  1.1.5.2, MeCP2  is  a methyl‐CpG  binding 
protein  that  translates  DNA  methylation  marks  into  repressive  chromatin  states  by  binding  to 
methylated  CpG  sites  via  its  MBD  and  recruitment  of  histone  deacetylases,  histone 
methyltransferases and nucleosome remodeling factors via the TRD domain (Hendrich and Tweedie, 
2003; Jones et al., 1998; Nan et al., 2007) as well as by interaction with the heterochromatin binding 
protein  HP1  (Agarwal  et  al.,  2007).  MeCP2  has  been  shown  to  cause  large‐scale  chromatin 
reorganization  and  to  particularly  induce  chromatin  compaction  and  clustering  of  pericentric 
heterochromatin  via  its MBD  domain  (Brero  et  al.,  2005; Georgel  et  al.,  2003). Mutations  in  the 
MECP2 gene have been involved in human neurological disorders (e.g. the Rett syndrome (Guy et al., 
2001)). The mechanism of MeCP2 induced chromatin compaction and clustering remains elusive. 
In  order  to  gain  further  insights  into MeCP2  regulation  and  function we  tested  its  DNA  binding 
specificity and  those of single MeCP2 domains  (Figure 18),  in collaboration with  the group of Prof. 
Cardoso (TU Darmstadt). We used DNA substrates with unmethylated and fully methylated CpG sites. 





hydroxymethylated  cytosine  (Kriaucionis  and  Heintz,  2009), we  also  tested  binding  of MeCP2  to 
hydroxymethylated DNA. We could show  that MeCP2 preferentially binds  to  fully methylated DNA 
and with equally  lower affinity  to unmethylated and  fully hydroxyl‐methylated DNA  substrate. We 
identified  the MBD domain and  the TRD domain  to be  responsible  for  this binding  specificity. The 
MBD domain binds exclusively  to methylated DNA and  the  ID‐TRD domain,  comprising  the  region 
between TRD and MBD  (interdomain,  ID) and  the TRD domain, binds  to DNA  independent of  the 
methylation state of the CpG site and with a similar affinity as the MBD to methylated DNA. Notably, 
both the N‐terminal part (amino acids 1‐55) as well as the C‐terminal part (amino acids 311‐492) of 
MeCP2 do not  show  any binding  activity.  These  results  are  consistent with  fluorescence  recovery 
after photobleaching (FRAP) studies showing that the three domains, MBD, ID and TRD, contribute to 
chromatin  binding  in  vivo  (Kumar  et  al.,  2008).  Furthermore,  FRAP  analyses  of MBD  and  ID‐TRD 
domains  in wild‐type  embryonic  stem  cells  as well  as  dnmt1/3a/3b‐/‐  triple  knock‐out  embryonic 
stem  cells  recently  revealed  that  the  mobility  of  the  MBD  is  dependent  on  the  genomic  DNA 
methylation level whereas the ID‐TRD domain is not (our unpublished data, Andrea Rottach). Clearly, 






fusions  with  GFP  or  YFP  were  purified  from  insect  cells  via  the  GFP‐Trap®  after  baculovirus‐mediated 
expression  and  incubated with  unmethylated  (UMB),  fully  hydroxymethylated  (FhMB)  and  fully methylated 
DNA binding  substrates  (FMB)  in direct  competition. After  removal of unbound  substrate,  the  fluorescence 
intensity  of  immobilized  GFP/YFP  fusions  and  fluorescent  DNA  substrates  was measured  and  the  ratio  of 
DNA/protein bound was calculated. (B) The fractions of the single bound DNA substrates were normalized to 










fusions  and  fluorescently  labeled DNA  substrates  ((Frauer  and  Leonhardt, 2009),  chapter 2.1), we 
developed and applied another assay  to address  the mechanism of  the MeCP2‐induced chromatin 
clustering  in vitro. This  ‘sandwich assay’ allows us  to  test whether a protein  is able  to  induce DNA 
clustering,  simulated by binding  to at  least  two DNA molecules with high affinity and at  the  same 
time  (Figure  19A).  The workflow  of  the  assay  is  as  follows.  First,  two  differentially  fluorescently 
labeled  DNA  substrates  are  prepared,  one  of  them  biotinylated,  and  the  GFP  fusion  protein  is 
expressed  in and purified from human embryonic kidney (HEK 293T) cells using the GBP coupled to 
Ni‐NTA agarose (chapter 2.3). Second, Strep‐Tactin® agarose beads (IBA) are functionalized with the 
biotinylated  fluorescent  DNA  substrate.  Third,  these  functionalized  beads  are  simultaneously 
incubated with both the purified GFP fusion as well as the second fluorescent DNA substrate. After 
removal of unbound  substrate,  the  ratio of  second  to  first DNA  is  calculated  from  the  respective 
fluorescence  intensities and  serves as a measure  for  the DNA cluster efficiency. When performing 
this assay for MeCP2, we detect, as a proof of principle, a significantly higher 2nd/1st DNA ratio than 
























MBD and  ID‐TRD domain  could be necessary  for  the  clustering effect. These hypotheses  can now 
easily be tested by varying the methylation state of the two DNA substrates in combination with the 
use of single domains or a combination of MeCP2 domains in the sandwich assay.  
Furthermore, there  is recent evidence that MeCP2  is poly(ADP‐ribosyl)ated by PARP1 and that  this 
post‐translational  modification  reduces  clustering  of  pericentric  heterochromatin  in  vivo 
(unpublished data, Cardoso group). To further test the role of poly(ADP‐ribosyl)ation, the sandwich 
assay could be applied  to MeCP2 purified  from  insect cells, since proteins expressed  in  these cells 
have  been  shown  to  be  highly  poly(ADP‐ribosyl)ated.  Additionally,  MeCP2  mutants  could  be 











3.2.1 HOW DNMT1 RECOGNIZES  ITS  SUBSTRATE 
Dnmt1 methylates DNA at the C5 position of cytosine residues within CpG dinucleotides and prefers 
hemimethylated  substrates,  which  are  typically  occurring  at  the  replication  fork  after  semi‐
conservative  DNA  replication.  This  led  early  to  the  identification  of  Dnmt1  as  the maintenance 
enzyme. Still,  the domains  involved and  the precise  step of  the methyl  transfer  reaction at which 








transfer  reaction  to be  responsible  for  substrate discrimination  (Flynn et  al., 1996). However, our 
data contradict two studies claiming that Dnmt1 preferentially binds to hemimethylated substrates 
(Araujo et al., 2001; Bacolla et al., 2001). We speculate that these differences might result from the 
use  of  different DNA  substrates. One  study  uses  a  (CGG∙CCG)12  triplet  repeat,  naturally  occurring 
within  the  5’‐untranslated  region  of  the  FMR1  gene  and  involved  in  the  etiology  of  the  fragile  X 
syndrome  (Fu  et  al.,  1991;  Verkerk  et  al.,  1991).  This  neurological  disorder  is  genomically 
characterized by expansion and de novo methylation of  this particular DNA  sequence as well as a 
proximal CpG island, finally leading to silencing of the FMR1 gene (Merenstein et al., 1996; Steyaert 
et  al.,  1996).  The  other  report  is  based  on  the  use  of  modified  non‐canonical  hairpin  DNA 
oligonucleotides, which have previously been shown to serve as Dnmt1 inhibitors (Bigey et al., 1999). 
In contrast  to  these studies, we are using canonical 42 base pair  long DNA substrates containing a 
single central CpG site. Interestingly, the two publications suggest different parts of the enzyme to be 
responsible  for  the differential  substrate binding. Whereas  the  first  study proposes  that  a Dnmt1 
mutant lacking the first 501 amino acids still preferentially binds to hemimethylated DNA substrates 




Apart  from  these  two  reports, our  results, which  indicate  that  substrate discrimination by Dnmt1 
occurs not until  covalent  complex  formation, are very  surprising. Usually, enzymes  recognize  their 





this  mechanism  of  substrate  recognition  is  also  the  most  economic  one,  since  it  allows  the 
discrimination of substrate from non‐substrate  in only one step and upon first  interaction between 
enzyme and potential substrate. In contrast, substrate recognition by Dnmt1 requires the succession 
of both DNA binding and presumably even base  flipping before  substrate discrimination occurs  in 
that  a  covalent  complex  is  preferentially  formed  with  hemimethylated  substrate,  which  is 
subsequently  subjected  to  methylation.  The  energy  costs  for  this  substrate  discrimination  are 
remarkable and  the question arises why Dnmt1 does not  recognize  its  target at  the  initial binding 
step  and  at  considerably  lower  energetic  costs.  One  could  argue  that  it  is  hard  to  recognize 
hemimethylated  CpG  sites  by  non‐covalent  binding  to  the major  groove  of  DNA  and  that  base 
flipping  might  be  required  for  hemimethylated  substrate  recognition.  However,  it  has  been 
demonstrated  for methyl‐CpG‐binding  proteins  that  recognition  of  fully methylated  CpG  sites  is 
possible without flipping the cytosine base out of the double helix (Ho et al., 2008; Ohki et al., 2001). 
Notably,  it has also been suggested  that Dnmt1 slides along the DNA helix  in order to processively 




of hemimethylated DNA.  For  this  sequence  specificity, both,  the N‐terminal domain  (Pradhan and 
Roberts,  2000)  as well  as  the  linker  region  (Bestor,  1992)  have  been  proposed  to  be  required  in 
addition  to  the  C‐terminal  domain.  We  have  recently  shown  that  linker  cleavage  as  well  as 
modification  of  linker  length  and  charge  does  not  affect  Dnmt1  activity  or  substrate  preference 
(unpublished data, Weihua Qin), excluding a role of the linker in substrate recognition. Moreover, it 
is  still  unknown  which  part  of  the  N‐terminal  domain  is  needed  for  substrate  specificity.  It  is 
important to realize that the question of the exact target recognition domain of Dnmt1 is difficult to 
address  separately  from  the question of  the domains needed  for enzyme activity at all,  since  the 
catalytic  domain  of Dnmt1  is  not  active  by  itself.  Thus,  the  intrinsic  sequence  preference  of  the 
catalytic  center  can  not  be  directly  tested.  Interestingly,  human  Dnmt1∆1‐580  still  preferentially 
methylates  hemimethylated  over  unmethylated  DNA  substrate  (Pradhan  and  Esteve,  2003).  This 
suggests  that  at  least  the  first  half  of  the  N‐terminal  domain  can  be  excluded  from  the  task  of 













activation  potential might  indeed  be  important  for methylation  spreading,  it  could  also  lead  to 
accidental mismethylation of unmethylated sites at the replication fork. It has been shown that the 
allosteric  activation  activity  is  more  pronounced  on  unmethylated  double  stranded  than  on 
unmethylated  single  stranded DNA  substrates  (Tollefsbol  and Hutchison,  1997). Nevertheless,  the 
observed de novo activity of Dnmt1  in vitro, even  in  the absence of allosteric activator,  raises  the 
question of how Dnmt1 can  reliably  fulfill  its maintenance  function  in vivo, and whether  there are 
other factors involved in repression of de novo methylation activity. In fact, we could recently show 
that,  in  contrast  to  dnmt1‐/‐  embryonic  stem  cells  with  hypomethylated  but  not  unmethylated 
genome, in which transient or stable expression of Dnmt1 restores methylation pattern to the wild‐
type  level,  dnmt1/3a/3b‐/‐  TKO  embryonic  stem  cells  rescued  with  Dnmt1  show  no  genomic 
methylation  (our  unpublished  data, Daniela Meilinger).  This  suggests  that  there might  be  indeed 




for maintenance methylation,  interaction with  PCNA  increases Dnmt1  activity  in  vivo  by  two  fold 
(Schermelleh et al., 2007). Similarly, Uhrf1 has been recently suggested to recruit Dnmt1 to sites of 
replication. But  in stark contrast  to PCNA, Uhrf1 has been shown  to not only  facilitate or enhance 
maintenance methylation but to be essential. In this work, we addressed the mechanisms by which 





results  in  an  inactive  enzyme  (Pradhan  and  Esteve,  2003).  Interestingly,  this  latter  truncation 




Based  on  a  homology model  (chapter  2.3,  collaboration  with  Johannes  Söding)  we  designed  an 
isolated Dnmt1 CXXC domain construct and characterized its DNA binding properties with the newly 







preferentially  binds  to  unmethylated DNA  as  it was  previously  demonstrated  for  numerous  CXXC 
domains of other mammalian proteins (chapter 2.3). These include the histone H3K4 methylase MLL 
(Allen  et  al.,  2006;  Ayton  et  al.,  2004;  Birke  et  al.,  2002),  the  transcriptional  activator  CGBP  as 









possible mechanism  of  substrate  discrimination,  in  that  the  CXXC  domain  could  act  as  negative 
regulatory  element  by  blocking  enzymatic  activity  upon  unmethylated  DNA  binding.  To  test  this 
hypothesis, we used  the homology model of  the CXXC domain  for constructing a deletion mutant, 
with  the aim of not affecting surrounding protein  structure and maximizing native protein  folding. 
We methodically tested and compared the functionality of wild‐type Dnmt1 and deletion mutant in 
vitro  and  in  vivo.  Surprisingly, we  found  that  the  CXXC  domain  is  dispensable  for  Dnmt1’s  DNA 
binding specificity in vitro and binding kinetics in vivo. Moreover, intramolecular interaction of N‐ and 
C‐terminal domain, substrate specific covalent complex formation and methyl transfer activity were 
not  affected  by  the  CXXC  deletion.  As  ultimate  proof  of  functionality, we  show  that  the  genetic 
complementation  of  dnmt1‐/‐  embryonic  stem  cells  with  the  deletion  construct  rescues  DNA 
methylation  levels and patterns as efficiently and accurate as  the complementation with  the wild‐
type enzyme. In summary, both in vitro and in vivo approaches show that the CXXC domain of Dnmt1 
is  dispensable  for  DNA  binding,  allosteric  activation,  methyltransferase  activity  and  substrate 
specificity.  
These  results  are  in  stark  contrast  to  a  study  claiming  that  the CXXC domain of human Dnmt1  is 
necessary for enzymatic activity  (Pradhan et al., 2008). This study proposed that deletion of amino 
acids  648‐690  in  human  Dnmt1  results  in  significant  reduction  of  enzymatic  activity  on 
hemimethylated  substrates  and  equally  poor  activity  on  unmethylated  substrates  in  vitro. 
Furthermore, overexpression of the Dnmt1∆CXXC deletion construct in HEK293‐A7 cells led to 25 % 










mouse  and  human  Dnmt1  sequences,  this  slightly  different  deletion  could  indeed  disrupt  a 
structurally well‐defined antiparallel β‐sheet, which remains unaffected by our deletion and might be 





methylation  levels  and  patterns  in  mouse  embryonic  stem  cells  lacking  Dnmt1  but  genetically 
complemented  with  the  deletion  construct  ultimately  demonstrates  that  the  CXXC  domain  is 









of Dnmt1 has  a  regulatory  function  in  specific  cell  types or  at  specific developmental  stages  that 
might  involve both DNA binding and protein‐protein  interaction. As a  first attempt  to address  this 
hypothesis, we plan pull‐down experiments with Dnmt1, the single CXXC domain as well as with the 





Recently, Tet1 has been  identified  to oxidize 5‐methylcytosine  to 5‐hydroxymethylcytosine  in DNA 
(Tahiliani et al., 2009), a mechanism suggested to be involved in active DNA demethylation (chapter 
1.1.6).  Interestingly, Tet1 contains a very similar CXXC domain  to  that of Dnmt1 and no  functional 
data were yet available for the CXXC domain of Tet1. In order to address the question whether the 












of  Tet1  is  closely  related  to  CXXC  domains  that  have  been  shown  to  mediate  protein‐protein 
interactions (Andersson et al., 2009; Hino et al., 2001; London et al., 2004), suggesting that the Tet1 
CXXC  domain  might  be  involved  in  interactions  with  other  proteins  rather  than  recognition  of 
methylated DNA substrates. To  test  for  these hypothetical protein‐protein  interactions of  the Tet1 
CXXC domain, pull‐down assays could be performed in combination with mass spectrometry analysis. 
3.2.3 THE  ROLE  OF  UHRF1  IN  MAINTENANCE  METHYLATION  AND  REGULATION  OF 
DNMT1 
As  introduced  in  chapters 1.1.5.2  and 1.3.4, Uhrf1 has  recently  emerged  as  essential  cofactor  for 
maintenance methylation. Uhrf1 binds  to DNA with hemimethylated CpG sites via  its SRA domain, 










photobleaching  (FRAP)  studies  in  embryonic  stem  cells  with  different  genetic  backgrounds  we 
characterized the various interactions mediated by Uhrf1 and the single Uhrf1 domains (chapter 2.4). 
We  found  that Uhrf1 binds  to DNA  substrates  containing hemimethylated CpG  sites only with  an 










might  thus  be  additionally  controlled  by  other  domains.  Interestingly, we  could  show  that Uhrf1 
preferentially binds trimethylated H3K9, a mark characteristic for silent chromatin. We show that this 
interaction  is mediated  by  the  tandem  Tudor  domain  of Uhrf1  via  an  aromatic  cage  (Jacobs  and 




hemimethylated  DNA,  trimethylated  H3K9  tails,  the  histone methyltransferase G9a  and  the  DNA 
methyltransferases Dnmt1, Dnmt3a and Dnmt3b add up to the necessary binding specificity of Uhrf1 
in vivo. For example, we could recently show that DNA binding enhances the specificity of Uhrf1 for 
trimethylated  H3K9  tails  (our  unpublished  data,  Garwin  Pichler).  Still,  there might  be  additional 
mechanisms  by which  Uhrf1  contributes  to  the maintenance  of  genomic methylation  levels  and 
patterns. 
In  fact,  overexpression  of  Uhrf1  induces  large‐scale  chromatin  rearrangements  and  particularly 
decondensation  of  pericentric  heterochromatin  via  its  PHD  domain  (Papait  et  al.,  2008).  This 
observation is independent from DNA methylation and raises the question whether Uhrf1 might play 




to  ‘naked’  DNA  (Robertson  et  al.,  2004).  Remarkably,  it  has  been  shown  that  Dnmt1  efficiently 
methylates nucleosomal DNA without dissociation of the histone octamer from the DNA (Gowher et 
al., 2005), which  is even possible  if  the DNA major groove  is oriented  towards  the histone surface 
(Okuwaki and Verreault, 2004). However, the ability of Dnmt1 to methylate nucleosomal substrates 
has  been  shown  to  be  highly  dependent  on  the  nature  of  the  DNA,  suggesting  that  particular 




The mechanism by which Uhrf1 might  induce nucleosomal  rearrangements and possibly  regulates 
chromatin  accessibility  to  Dnmt1  is  highly  speculative.  Uhrf1 was  shown  to  possess  E3  ubiquitin 
ligase activity via its Ring domain and to mediate ubiquitylation of histone H3 (Citterio et al., 2004). 
Interestingly, ubiquitylation of another histone H2b has been recently shown to recruit proteasomal 






In conclusion,  the mechanism by which Uhrf1  contributes  to maintenance methylation most  likely 
exceeds  the  previously  suggested  process  of merely  recruiting  Dnmt1  to  hemimethylated  target 
sites. Alternatively to Dnmt1 mistargeting, the failure of maintenance methylation resulting  in DNA 
hypomethylation in uhrf1‐/‐ embryonic stem cells might be a consequence of reduced accessibility of 










We  performed  fluorescence  intensity  distribution  analysis  (FIDA)  of  GFP‐Dnmt1  in  order  to 
determine  the  molecular  brightness  of  the  protein  species  in  comparison  to  monomeric  GFP. 




be not as  stable as  initially  suggested based on gel  filtration analysis. The methods  leading  to  the 
hypothesis of Dnmt1 dimerization, co‐immunoprecipitation and gel filtration analysis, do not always 
provide ultimate evidence for the multimerization state of proteins. In fact, co‐immunoprecipitation 
reveals  exclusively  qualitative  interaction  between  two  proteins  or  protein  domains.  It  is  also 
important to stress the point that potential dimerization of Dnmt1 via the TS domain, included in the 
N‐terminal  part  of Dnmt1,  competes with  the N‐C‐terminal  intramolecular  interaction, which  has 
been  suggested  to  allosterically  activate  Dnmt1  (Fatemi  et  al.,  2001;  Fellinger  et  al.,  2009). 
Interestingly,  co‐precipitation  of  RFP‐Dnmt1  with  GFP‐Dnmt1  was  inefficient  compared  to  co‐
precipitation  of  the  C‐terminal  with  the  N‐terminal  domain  of  Dnmt1  fused  to  RFP  and  GFP, 
respectively  (our  unpublished  data,  Karin  Fellinger).  This  suggests  that  the  intramolecular  N‐C‐
terminal interaction is favored over the N‐terminal self‐interaction of Dnmt1 and again supports the 
hypothesis  of  no  stable  dimer  formation. Moreover,  determination  of  the molecular weight  of  a 
protein by gel filtration has been shown to occasionally have some pitfalls. It has been reported that, 
although the gel filtration behavior of proteins generally relates well to their molecular weight, some 











However,  regardless of  the question whether Dnmt1  is present as monomer or dimer, we suggest 
that this state is not changed upon complex formation with DNA substrates based on both FIDA and 
gel filtration analyses (chapter 2.5). Surprisingly, fluorescence cross‐correlation spectroscopy (FCCS) 
of  Dnmt1  complexes  with  two  differentially  labeled  trapping  substrates  provides  evidence  for 
covalent complex formation of one Dnmt1 molecule with two DNA substrates at the same time. This 
finding  is unexpected and has to be carefully confirmed and further  investigated. We propose that 
one of  these  covalent attachment  sites  is  the  cysteine C1229 of  the PC motif within  the  catalytic 
domain of Dnmt1. Mutation of this cysteine residue to tryptophan resulted in a catalytically inactive 
mutant, with which  any enzymatic‐activity dependent  trapping  is  abolished  as  confirmed by  FCCS 
analysis  (Schermelleh  et  al.,  2005).  Consistently,  our  results  suggest  that  not  only  one  but  both 
covalent attachment sites are affected by this mutation. This observation indicates that the cysteine 
C1229  is not only  required  for covalent complex  formation at position 1229  itself, but also  for  the 
second  site,  clearly  complicating  the  localization  of  a  potential  second  site  of  covalent  complex 
formation.  If  it  is  true  that  two  DNA molecules  are  covalently  and  irreversibly  bound  by  Dnmt1 




















Although Dnmt1 prefers  hemimethylated over  unmethylated DNA  substrates,  it  still possesses de 
novo  activity  in  vitro.  Thus,  the  question  remains  how Dnmt1  can  reliably  fulfill  its maintenance 
function  in  vivo  and  the  involvement  of  other  factors, which  repress  de  novo  activity  of  Dnmt1 
and/or direct Dnmt1 activity to hemimethylated target sites, seems therefore obvious.  Indeed,  it  is 
well established  that  the N‐terminal domain of Dnmt1 plays a key  role  in enzymatic  regulation by 
mediating interactions with a variety of proteins that have been shown to control Dnmt1 activity in 
vivo. In this regard, PCNA and Uhrf1 have been both suggested to interact with Dnmt1 and to recruit 
it  to  sites  of  replication  and  hemimethylated  CpG  dinucleotides,  respectively.  Besides  PCNA  and 
Uhrf1, Dnmt1 has been shown to also  interact with many additional proteins, some of which have 
been likewise suggested to be required for maintenance of DNA methylation ((Lehnertz et al., 2003; 
Wang et al., 2009),  see also chapter 1.1.5.3).  In addition  to  these cofactors  that positively control 
Dnmt1 activity, we recently found evidence for the existence of factors that block Dnmt1 activity in 
vivo and/or remove  incorrectly positioned methylation marks.  In fact, we could show that genomic 
complementation  of  dnmt1/3a/3b‐/‐  triple  knock‐out  embryonic  stem  cells  with  Dnmt1  does  not 
increase genomic DNA methylation  levels, which are undetectable  in  these  cells  (our unpublished 






precisely,  the  fidelity of methylation  inheritance of plasmid DNA  in mouse  cells was  suggested  to 
reach only about 95 % per replication cycle and per CpG site (Wigler et al., 1981). These data strongly 
indicate that DNA methylation patterns may not be preserved by an exact copy process during semi‐




that  maintenance  of  an  average  methylation  level  per  CpG  site  might  be  sufficient  for  stable 
inheritance  of  this  epigenetic  mark,  and  that  the  precise  methylation  patterns  are  less  crucial. 






Thus,  for  faithful maintenance of DNA methylation patterns, especially  in post‐mitotic  tissues but 
also  in mitotic cells over hundreds of cell division cycles, there might be mechanisms  in addition to 
regulated maintenance methylation by Dnmt1. On  the one hand, de novo methylation by Dnmt3s 
could  recover  positions  that  were  missed  by  Dnmt1  and  on  the  other  hand,  demethylation  of 
positions  accidentally  de  novo  methylated  by  Dnmt1  could  occur  (see  also  chapter  1.1.6).  The 
advantage of  a  complex  interplay of  these mechanisms over  a  simple  and  exact  copy  process by 
Dnmt1  is  not  obvious.  Still,  such  a  flexible  system  could  facilitate  error  correction.  Indeed,  the 
scenario  of  an  almost  but  not  completely  perfect  maintenance  enzyme  in  the  absence  of  any 
proofreading mechanism was alarming, since only occasional mismethylation could then rapidly lead 
to an  increase  in methylation  levels over  time and dramatic changes  in methylation patterns.  It  is 
tempting  to  speculate  that  these hypothetic  correction mechanisms  could  also  induce  changes  in 
methylation  patterns  upon  internal  (e.g.  other  epigenetic)  or  external  cellular  signals.  Thus,  the 
general question  remains whether DNA methylation patterns  are  static or dynamic,  although  still 
rather  stable.  There  is  convincing  evidence  that  active  DNA  demethylation mechanisms  exist  in 
mammalian  cells  during  embryonic  and  germ  line  development  (discussed  in  chapter  1.1.6).  It  is 
therefore  possible  that  at  least  some  of  these  proposed  mechanisms  also  occur,  maybe  even 
sequence  specifically,  in  somatic  cells.  Clearly,  investigation  of  the  stability  and  dynamics  of DNA 
methylation patterns, the precise molecular characterization of Dnmt1’s maintenance function and 
elucidation  of DNA  demethylation mechanisms  are major  tasks  of  future  research  in  the  field  of 
epigenetics. 
3.3.2 ON THE ROLE OF UHRF1 IN MAINTENANCE METHYLATION 
The  impact  of  Uhrf1  on maintenance methylation  has  been  clearly  demonstrated,  however  the 
mechanism by which Uhrf1 controls Dnmt1 activity remains subject of speculation. Significantly, lack 





factor  of  two.  This  specific  DNA  binding  activity  of  Uhrf1 might  indeed  facilitate  recruitment  of 
Dnmt1 to hemimethylated sites. However, two factors argue for another role of Uhrf1 than simply 
directing Dnmt1  to  target  sites. First,  the preference  for Uhrf1 binding  to hemimethylated DNA  is 
very weak and only approximately one tenth of the intrinsic preference of Dnmt1 for methylation of 
hemimethylated DNA. Second,  the cellular expression  levels of Dnmt1 are very high. This  indicates 
that a two‐fold loss in binding affinity for hemimethylated CpG sites might be easily compensated by 









within  the DNA  double  helix. While DNA  binding with  concomitant  base  flipping  is  a mechanism 
usually  employed  by  DNA‐modifying  enzymes,  e.g.  DNA  methyltransferases  and  thymine  DNA 
glycosylases, this is a very surprising characteristic of Uhrf1. The DNA modifying enzymes presumably 
use this base flipping to avoid sterical constraints and to provide the correct molecular environment 






which  recognizes  its  target  sequence  without  flipping  the  cytosine  out  of  the  double  helix. 
Alternatively,  it  could  be  that  Uhrf1  possesses  a  so  far  unknown  catalytic  function  on  DNA,  but 
clearly, this hypothesis is highly speculative. 
One strategy to further elucidate Uhrf1 function in regulation of Dnmt1 would be to bridge the gap 
between well‐controlled  but  insufficiently  realistic  in  vitro  experiments  and  realistic  but  less‐well 
controlled in vivo experiments. On the one hand, in vitro DNA binding assays and methyltransferase 
activity  assays  are usually performed on  ‘naked’ DNA with purified proteins, which  represents  an 
extreme  simplification  of  the  in  vivo  situation.  DNA  within  the  nucleus  is  densely  packed  into 
nucleosomes and higher order chromatin structures and also, Uhrf1 and Dnmt1 dynamically interact 
with numerous  cellular proteins. On  the other hand,  in  vivo  experiments  (e.g.  FRAP  and  trapping 
assays in living cells (Schermelleh et al., 2005)) using transiently or stably expressed GFP fusions are 
often  difficult  to  interpret,  since  the  complex  cellular  interaction  networks  could  affect  the 
specifically addressed function of a protein. 
Thus,  to bridge  this gap we propose  to  test Uhrf1 and Dnmt1 DNA binding  specificities as well as 
specific Dnmt1 activity using  fluorescently  labeled unmethylated and hemimethylated nucleosomal 
substrates  in  our  assay. One  challenge  for  these  experiments  is  certainly  the  preparation  of  long 
hemimethylated  DNA  sequences.  However,  recently,  a  structure‐guided  rational  protein  design 
approach combined with random mutagenesis and selection has been reported, which resulted in an 
M.HhaI  mutant  that  specifically  methylates  GCG  sites.  This  specificity  results  in  generation  of 












With  the  goal  to  reconstruct  a  three‐dimensional  structure  of  Dnmt1,  we  established  the 
overexpression  of  Dnmt1,  Dnmt1  mutants  and  Dnmt1  domains  in  insect  cells  using  baculoviral 
expression  vectors  and  successfully  developed  a  purification  protocol  including  Ni‐,  desalting‐, 
heparin‐, and gel filtration columns. Currently, we are optimizing sample preparation conditions for 
cryo‐electron  microscopy.  In  a  first  attempt,  we  plan  to  use  Dnmt1  in  complex  with  trapping 
substrates for freezing the reaction at the covalent complex formation step. By this approach, we are 
aiming to obtain a homogeneous protein sample with a defined and stable conformation. 
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